Document:

EX-10.8

 Exhibit 10.8 

EXECUTION VERSION 

COLLABORATION AGREEMENT 
 between

 ARIAD Pharmaceuticals, Inc. 

and 
 Otsuka Pharmaceutical Co.,
Ltd 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

 TABLE OF CONTENTS 

 

							
	 ARTICLE 1 – DEFINITIONS
		 	2	 
	 ARTICLE 2 – GRANT OF LICENSES
		 	15	 
	 ARTICLE 3 – RESERVED TERRITORIES AND NON-COMPETITION
		 	17	 
	 ARTICLE 4 – DEVELOPMENT AND COMMERCIALIZATION COMMITTEES
		 	21	 
	 ARTICLE 5 – DEVELOPMENT
		 	25	 
	 ARTICLE 6 – EXCHANGE OF KNOW-HOW AND IMPROVEMENTS
		 	29	 
	 ARTICLE 7 – PRICING AND REIMBURSEMENT
		 	30	 
	 ARTICLE 8 – REGULATORY MATTERS
		 	31	 
	 ARTICLE 9 – PHARMACOVIGILANCE
		 	35	 
	 ARTICLE 10 – FORECASTS AND ORDERING
		 	36	 
	 ARTICLE 11 – SHIPMENT AND DELIVERY
		 	39	 
	 ARTICLE 12 – MANUFACTURE AND FINAL MANUFACTURING OF THE PRODUCT
		 	42	 
	 ARTICLE 13 – QUALITY ASSURANCE
		 	44	 
	 ARTICLE 14 – RECALLS AND PRODUCT WITHDRAWAL
		 	47	 
	 ARTICLE 15 – MARKETING AND DISTRIBUTION OF THE PRODUCT
		 	48	 
	 ARTICLE 16 – CO-PROMOTION
		 	53	 
	 ARTICLE 17 – MEDICAL AFFAIRS ACTIVITIES
		 	55	 
	 ARTICLE 18 – PRODUCT TRADEMARKS
		 	55	 
	 ARTICLE 19 – CONSIDERATION AND PAYMENTS
		 	57	 
	 ARTICLE 20 – REPRESENTATIONS AND WARRANTIES
		 	64	 
	 ARTICLE 21 – COMPLIANCE WITH LAW; DATA PRIVACY; ANTI-BRIBERY AND ANTI-CORRUPTION
		 	68	 
	 ARTICLE 22 – INDEMNIFICATION, LIMITATIONS OF LIABILITY AND INSURANCE
		 	70	 
	 ARTICLE 23 – THE PATENTS
		 	74	 
	 ARTICLE 24 – CONFIDENTIALITY
		 	80	 
	 ARTICLE 25 – TERM
		 	82	 
	 ARTICLE 26 – TERMINATION
		 	82	 
	 ARTICLE 27 – STANDSTILL
		 	88	 
	 ARTICLE 28 – FORCE MAJEURE
		 	88	 
	 ARTICLE 29 – LAW TO GOVERN AND JURISDICTION
		 	89	 
	 ARTICLE 30 – DISPUTE RESOLUTION
		 	89	 
		
	APPENDICES				
		
	 APPENDIX 1 – PATENTS
				
	 APPENDIX 2 – PRE-APPROVED SUBLICENSEES
				
	 APPENDIX 3 – TRADEMARKS
				
	 APPENDIX 4 – PRESS RELEASE
				

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

 THIS COLLABORATION AGREEMENT (“Agreement”) is effective as of December 22, 2014
(hereinafter called “Effective Date”), between ARIAD Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 26 Landsdowne Street, Cambridge, Massachusetts 02139-4234, USA (“ARIAD”) and
Otsuka Pharmaceutical Co., Ltd, a corporation organised and existing under the law of Japan with a principal place of business at Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-Ku, Tokyo 108-8242, Japan (“Otsuka”). 

RECITALS 
  

	a.	ARIAD develops, Manufactures, licenses and markets pharmaceutical compounds and products and has rights to certain patents and know-how that are used to make, have made, develop, register, market, distribute and sell,
directly or indirectly, the Compound and pharmaceutical preparations containing said Compound as an active pharmaceutical ingredient. As of the Effective Date, such pharmaceutical preparations have been commercialized in certain countries under the
brand name IclusigTM. 

  

	b.	ARIAD owns or has rights under certain know-how relating to the Compound and Product, and certain patents directed to the Compound and Product in the Territory. 

 

	c.	Otsuka is an international pharmaceutical company with its headquarters in Japan, having particular expertise, experience, skills, infrastructure and appropriately qualified personnel, to effectively develop, package
and Commercialize the Product in the Field throughout the Territory in accordance with the terms and conditions of this Agreement. 

  

	d.	Prior to entering into discussions with ARIAD, Otsuka possessed no confidential technology or information of its own relating to the Compound and/or the Product. ARIAD and Otsuka entered into a Confidential Disclosure
Agreement on May 14, 2014 (the “CDA”) by means of which ARIAD disclosed to Otsuka confidential information and data relating to the Compound and the Product. 

 

	e.	Otsuka wishes to purchase the Product in bulk form from ARIAD and to acquire a license to package, label, promote, advertise, distribute and sell the Product in the Territory and the right to serve as the marketing
authorization holder in the Territory, and to perform certain development activities, and ARIAD wishes to supply the Product in bulk form to Otsuka and to grant such license, all as further set forth herein. 

 

	f.	The Parties agree that this preamble constitutes an integral part of this Agreement and that all capitalized terms used in this preamble shall have the respective meanings given above or in Article 1 or elsewhere in
this Agreement. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 1 

 NOW, THEREFORE, in consideration of the above premises and the mutual promises set forth below, the Parties
hereby agree as follows: 
 ARTICLE 1 – DEFINITIONS 

Capitalized terms used in this Agreement shall have the meanings specified below or elsewhere herein. 

 

	1.1	“Acquiring Party” has the meaning set forth in Section 3.2.5. 

  

	1.2	“Adverse Ruling” has the meaning set forth in Section 26.1. 

  

	1.3	“Affiliate” means any corporation or business entity that, whether now or in the future, controls, is controlled by or is under common control with a Party. For the purposes of this definition, the
terms “controls”, “controlled by” and “under common control with” as used with respect to any Party, means (i) to possess (directly or indirectly) the power to direct the management or affairs of a corporation or
other business entity, whether through ownership of voting securities or other equity rights or by contract relating to voting rights or corporate governance or otherwise, or (ii) to own, directly or indirectly, more than fifty percent
(50%) of the outstanding voting securities or other ownership interest of such corporation or other business entity. 

  

	1.4	“Alliance Manager” has the meaning set forth in Section 4.5. 

  

	1.5	“Anti-Corruption Laws” means all Applicable Laws for the prevention of fraud, kickbacks, bribery, corruption, racketeering, money laundering or terrorism, including the FCPA, each, as amended from time
to time. 

  

	1.6	“Applicable Laws” means the applicable provisions of any and all national, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, and ordinances, and any and all
directives, and orders or administrative decisions of any governmental agency or authority (including Regulatory Authorities) having jurisdiction over or related to the subject matter in question, including Regulatory Requirements, Regulatory Laws,
Export Control Laws, and the FCPA and other Anti-Corruption Laws, which are applicable to the subject matter of this Agreement. 

  

	1.7	“Assigned Otsuka Improvements” has the meaning set forth in Section 5.7. 

  

	1.8	“Baseline” has the meaning set forth in Section 16.5. 

  

	1.9	“BMS” means Bristol-Myers Squibb Company. 

  

	1.10	“BMS Agreement” has the meaning set forth in Section 3.2.4. 

  

	1.11	“Breaching Party” has the meaning set forth in Section 26.1. 

  

	1.12	“Bulk Product” has the meaning set forth in Section 10.2. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 2 

	1.13	“Bulk Tablet Cost” means, per unit (tablet) of Bulk Product, an amount equal to [***] US dollars ($[***]). 

  

	1.14	“Business Day” means a day other than a Saturday or Sunday or any public holiday in the United States or Japan or any other day on which banks are required or authorized by applicable law to be closed
in the United States or Japan. For the avoidance of doubt, any reference in this Agreement to “days” in the lower case means calendar days. 

  

	1.15	“CDA” has the meaning set forth in the recitals above. 

  

	1.16	“Certificate of Analysis” has the meaning set forth in Section 13.1.2. 

  

	1.17	“Certificate of Conformance” has the meaning set forth in Section 13.1.3. 

  

	1.18	“cGMP” means all applicable current good manufacturing practices as adopted by the authorities of the country where such manufacture takes place, including current good manufacturing standards,
practices and procedures promulgated by the FDA and set forth in 21 C.F.R. Parts 210 and 211 and standards relating to manufacturing practices for active pharmaceutical ingredients, intermediates, bulk products or finished pharmaceutical products.

  

	1.19	“Claim Notice” has the meaning set forth in Section 22.4.1. 

  

	1.20	“CNDA” means a Chinese new drug application, or an amendment or supplement thereof, filed with the CFDA (China Food and Drug Administration) pursuant to the Drug Registration Regulation (SFDA Order 28).

  

	1.21	“Commercialization Plan” has the meaning set forth in Section 15.2. 

  

	1.22	“Commercialize” means all activities directed to importing (into, or within, the Territory), exporting (within the Territory), storing, marketing, promoting, selling, offering for sale and distributing
the Product in the Territory. “Commercializes,” “Commercialized,” “Commercialization” and other forms of the word “Commercialize” shall have the correlative meaning. For clarity, “Commercialize”
excludes Manufacture and Final Manufacturing. 

  

	1.23	“Competitive Product” means [***]. 

  

	1.24	“Compliance Event” has the meaning set forth in Section 21.7. 

  

	1.25	“Composition Patent” means any patent in the Territory granted from a national stage application of International Published Patent Application [***] (a “national stage patent of [***]”), or a
divisional or continuation of such national stage patent of [***]. For clarity, national stage patents of [***] or divisionals or continuations thereof, in the Territory, include the following: 

 

	 	(i)	[***], granted in Japan on [***];

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 3 

	 	(ii)	[***], granted in China on [***]; 

  

	 	(iii)	[***], granted in South Korea on [***];

  

	 	(iv)	any patent granted from pending Japanese Patent Application [***]; 

  

	 	(v)	any patent granted from pending Chinese Patent Application [***]; 

  

	 	(vi)	any other patent granted from a continuation or divisional application of (iv) or (v); and 

  

	 	(vii)	if, but only if, [***] is added to the Territory pursuant to Section 3.1, [***], granted in [***] on [***]. 

  

	1.26	“Compound” means the active pharmaceutical ingredient known as ponatinib, as a free base or as a salt, as a solvate or not, and if in solid form, regardless of the specific form, whether
amorphous or crystalline, including without limitation, crystalline ponatinib monohydrochloride. 

  

	1.27	“Confidential Information” has the meaning set forth in Section 24.1. 

  

	1.28	“Control” (including any variations such as “Controlled” and “Controlling”) means, with respect to any item of Know-how, Regulatory Documentation, material, patent, or
other Intellectual Property Right, the possession of the right, whether directly or indirectly, and whether by ownership, license or otherwise (other than by operation of the license grants under this Agreement), to grant a license, sublicense or
other right (including the right to reference Regulatory Documentation) to or under such Know-how, Regulatory Documentation, material, patent, or other Intellectual Property Right as provided for herein without violating the terms of any
then-existing agreement with any Third Party; provided, that Intellectual Property Rights of an acquirer of a Party or its Affiliates in existence prior to the acquisition date, or developed after the acquisition date solely by such acquirer without
use of or reference to such Party’s preexisting Know-how, Regulatory Documentation, material, patent, or other Intellectual Property Right and without contribution from employees of a Party or its Affiliates other than the acquirer, shall not
be deemed to be “Controlled” by such Party or Affiliate. 

  

	1.29	“Co-Promotion Agreement” has the meaning set forth in Section 16.3. 

  

	1.30	“Co-Promotion Fee” has the meaning set forth in Section 16.5. 

  

	1.31	“Co-Promotion Notice” has the meaning set forth in Section 16.1. 

  

	1.32	“Co-Promotion Option” has the meaning set forth in Section 16.1. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 4 

	1.33	“Customer” means any entity or person that is authorized to purchase and dispense or sell the Product in the Territory under Applicable Law. 

 

	1.34	“Data Protection Laws” has the meaning set forth in Section 21.6. 

  

	1.35	“Debarred” has the meaning set forth in Section 15.5.3. 

  

	1.36	“Default Notice” has the meaning set forth in Section 26.1. 

  

	1.37	“Defending Party” has the meaning set forth in Section 23.5.1. 

  

	1.38	“Delivery” has the meaning set forth in Section 11.2. 

  

	1.39	“Destination Terminal” has the meaning set forth in Section 11.2. 

  

	1.40	“Development Plan” has the meaning set forth in Section 5.1.1. 

  

	1.41	“Disqualified” has the meaning set forth in Section 15.5.3. 

  

	1.42	“Escalation Notice” has the meaning set forth in Section 4.6.1(b). 

  

	1.43	“Excluded” has the meaning set forth in Section 15.5.3. 

  

	1.44	“Excluded Claim” has the meaning set forth in Section 30.3.6. 

  

	1.45	“Export Control Laws” means all applicable U.S. laws and regulations relating to (a) economic and trade sanctions and embargoes imposed by the Office of Foreign Assets Control of the U.S.
Department of Treasury or (b) the export or re-export of commodities, technologies, or services, including the Export Administration Act of 1979, 24 U.S.C. §§ 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C.
§§ 1701-1706, the International Traffic in Arms Regulations, 22 C.F.R. parts 120-130, the Trading with the Enemy Act, 50 U.S.C. §§ 1 et. seq., the Arms Export Control Act, 22 U.S.C. §§ 2778 and 2779, and the
International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986 (as amended). 

  

	1.46	“FCPA” means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et. seq.) as amended. 

  

	1.47	“FDA” means the U.S. Food and Drug Administration. 

  

	1.48	“Field” means oncology. 

  

	1.49	“Final Manufacturing” means all activities required to prepare the Product (which, for clarity, is to be supplied by ARIAD to Otsuka as finished drug product in bulk packaging except as set forth in
Section 10.2) for commercial sale in the Territory, including primary and secondary packaging and labeling with the approved packaging and label for the country in the Territory in which it is to be sold; stability or other testing; quality
control; and release of the Product for sale in the Territory. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 5 

	1.50	“First Commercial Sale” means the first sale to a Third Party of Product for use or consumption by an end-user in the Field in a given country in the Territory after Registration has been obtained in
such country. A First Commercial Sale shall not include a sale of Product for use in clinical trials, for research or for other non-commercial uses, or supply of Product without charge as part of a Named Patient Program or similar program.

  

	1.51	“Forecast” has the meaning set forth in Section 10.4. 

  

	1.52	“Full Royalty Term” means, on a country-by-country basis within the Territory, the period from the date of First Commercial Sale in a country until the later of (i) [***] (ii) [***] or
(iii) [***] ([***])[***] after the date of First Commercial Sale in such country. 

  

	1.53	“Global Product Profile” has the meaning set forth in Section 15.3.3. 

  

	1.54	“Global Study” has the meaning set forth in Section 5.5.1. 

  

	1.55	“Global Third Party License” has the meaning set forth in Section 23.6.3(a). 

  

	1.56	“Government Official” means (a) any officer or employee of a government or any department, agency or instrumentality of a government; (b) any person acting in an official capacity for or on
behalf of a government or any department, agency, or instrumentality of a government; (c) any officer or employee of a company or business owned or controlled by a government; (d) any officer or employee or person acting in an official
capacity for or on behalf of a public international organization or any department, agency, or instrumentality of such public international organization such as the World Bank or United Nations; (e) any political party or official thereof;
and/or (f) any candidate for political office. 

  

	1.57	“Healthcare Professional” means any member of the medical, pharmacy or nursing professions or any other person who in the course of his or her professional activities may prescribe, administer or
dispense to an end-user a medicinal product. 

  

	1.58	“ICDR” has the meaning set forth in Section 30.3.1. 

  

	1.59	“Improvements” means all improvements, modifications or developments relating to the Compound and/or to the Product in the Field other than as described in the US NDA or the marketing authorization for
the Product approved in the European Economic Area as of the Effective Date. 

  

	1.60	“Incremental Sales” has the meaning set forth in Section 16.5. 

  

	1.61	“Indemnified Party” has the meaning set forth in Section 22.4.1. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 6 

	1.62	“Indemnifying Party” has the meaning set forth in Section 22.4.1. 

  

	1.63	“Industry Guidelines” means voluntary industry codes or guidelines to which a Party has publically stated it adheres as of the Effective Date, or subsequently during the Term, including, with respect to
Otsuka, the Code of Practice and the “Transparency Guideline for the Relation between Corporate Activities and Medical Institutions” as promulgated by the Japan Pharmaceutical Manufacturers Association, and the Fair Competition Code as
promulgated by the Fair Trade Council of the Ethical Pharmaceutical Drugs Marketing Industry (as such codes or guidelines are revised from time to time by their promulgating organization). 

 

	1.64	“Initial Fee” has the meaning set forth in Section 19.1. 

  

	1.65	“Inspected Party” has the meaning set forth in Section 13.7.1. 

  

	1.66	“Inspecting Party” has the meaning set forth in Section 13.7.1. 

  

	1.67	“Intellectual Property Rights” means all rights in, to and under patents, trademarks, copyrights, databases, data, trade secrets and confidential information, and all other intellectual or industrial
property and other proprietary rights throughout the world. 

  

	1.68	“JDCC” has the meaning set forth in Section 4.1. 

  

	1.69	“JNDA” means a Japanese new drug application, or an amendment thereof filed with the MHLW through PMDA under Article 14 of the Pharmaceuticals and Medical Devices Act of Japan (Law No. 145 of 1960,
as amended). 

  

	1.70	“Know-how” means valuable, secret and substantial information regarding the Product, including documentation, processes, data and other information on file with any competent Regulatory Authority in
support of a Marketing Authorization, which may be necessary, useful or advisable to enable Otsuka to research, develop, Commercialize or conduct Final Manufacturing of the Product in the Field in the Territory, Controlled by ARIAD or its Affiliates
as of the Effective Date or at any time during the Term. Know-how includes all unpatented Assigned Otsuka Improvements owned by ARIAD as provided in Section 5.7 and unpatented Intellectual Property Rights licensed to ARIAD pursuant to a Global
Third Party License. 

  

	1.71	“Knowledge” shall mean, with respect to a fact or matter, that the applicable Party’s senior-most executive management employee directly responsible for such fact or matter is actually aware of
such fact or matter after making reasonable inquiry with respect to such fact or matter of the persons directly reporting to him or her. “Known” has a correlative meaning. 

 

	1.72	“Latent Defect” means a Non-Conformance that is not discoverable or actually discovered upon reasonable visual inspection performed pursuant to Section 11.5.1, but that is discovered at a later
time (e.g., a failure to comply with the shelf-life set forth in the Specification that is identified as a result of long-term stability studies conducted by ARIAD or its Affiliates or a Third Party authorized by ARIAD or its Affiliates).

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 7 

	1.73	“Launch Quantities” has the meaning set forth in Section 10.3. 

  

	1.74	“Local Currencies” means the currency used in each of the respective countries in the Territory. 

  

	1.75	“Losses” has the meaning set forth in Section 22.1. 

  

	1.76	“MAH” means the marketing authorization holder for the Product in each country in the Territory. 

  

	1.77	“Manufacture” means the manufacturing of the Product up to and including finished drug product in bulk packaging, and all activities related to such manufacturing of Product, or any ingredient thereof,
either directly or through a contract manufacturer, including in-process and semi-finished Product testing, ongoing stability tests and regulatory activities related to any of the foregoing. “Manufactured” or “Manufacturing” and
other forms of the word “Manufacture” shall have correlative meaning. For the avoidance of doubt, “Manufacture” shall not include Final Manufacturing of the Product for sale in the Territory. 

 

	1.78	“Manufacturing Process” has the meaning set forth in Section 12.3. 

  

	1.79	“Marketing Authorization” means a marketing authorization for the Product granted in a country in the Territory, including for Japan, an approved JNDA, and for China, an approved CNDA.

  

	1.80	“MHLW” means the Japanese Ministry of Health, Labour and Welfare. 

  

	1.81	“Named Patient Program” means a compassionate use, named patient use, or similar program for the supply of the Product in the Field in the Territory prior to obtainment of Registrations, to the extent
permitted by and in accordance with Applicable Laws. 

  

	1.82	“Net Sales” means, with respect to a Product, the amount invoiced by Otsuka or its Sublicensees for such Product, less the following deductions (to the extent such amounts are included in the amount
invoiced for such Product): 

  

	 	(a)	[***], [***], [***] and/or other [***] actually allowed and taken directly with respect to such sales; 

  

	 	(b)	[***] (including [***], [***] to [***] and [***], [***] or [***] for [***],[***],[***],[***] and similar types of [***]); 

  

	 	(c)	[***], [***], [***], [***] or other [***] and paid with respect to the [***],[***],[***] or [***] of such Product (excluding [***], [***] or [***] based on [***]); 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 8 

	 	(d)	the amount of [***] and amounts [***] or [***] by reason of [***], [***], [***] amounts, [***] or [***] of [***], or because of [***]; 

 

	 	(e)	charges for [***] and [***] directly related to the [***] of Product [***], to the extent not already deducted or excluded from the gross amount invoiced; and 

 

	 	(f)	[***] that are not [***] by Otsuka or its Sublicensees (i.e., [***]) after Otsuka or its Sublicensee (as the case may be) has made commercially reasonable efforts to [***] the same, provided that, such deduction shall
be taken only in the [***] in which such [***] are no longer [***]. 

  

	 	(g)	Notwithstanding the foregoing, no [***], [***], [***], [***], [***], or any similar amount, however designated, that is given or associated with the purchase by the Third Party of any product or service in addition to
the Products shall be [***] to the Product. 

 Such amounts shall be determined from the books and records of Otsuka and its
Sublicensees maintained in accordance with generally accepted accounting principles, consistently applied throughout such party’s organization. 

In the case of any sale of such Product for consideration other than (or in addition to) cash, such as barter or countertrade, Net Sales shall
be calculated on the [***] of the [***] consideration received. 
 In the case of any sale of a Product that contains Compound and one or
more other active ingredients in a single dosage form (“Combination Product”), the Net Sales in a country in the Territory for purposes of determining payments based on Net Sales hereunder shall be calculated by [***] the [***] of
such Combination Product in such country during the applicable reporting period by the [***], [***] where: [***] is the [***] of the [***] received by Otsuka or its Sublicensees when [***] in [***] in such country and [***] is the [***] by Otsuka or
its Sublicensees of the other [***] included in the [***] when [***] in [***] in such country, in each case during the applicable reporting period or, if sales of both the Product and the other active ingredient(s) did not occur in such period, then
in the most recent reporting period in which sales of both occurred. In the event that such [***] cannot be determined for both the [***] and all other [***] included in such [***], Net Sales in a country in the Territory for purposes of determining
payments based on Net Sales hereunder shall be calculated by [***] the [***] of the Combination Product in such country during the applicable reporting period (using the above provisions) by the [***] of [***] where [***] is the [***] if
determinable as set forth above, and if not determinable, the [***] of the Product and [***] is the [***] if determinable as set forth above, and if not determinable, then the [***] of all other [***] included in the [***], as such [***] are
determined by the Parties in good faith. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 9 

 If such Product is sold to any Third Party together with other products or services, the price of
such Product, solely for purposes of the calculation of Net Sales, shall be deemed to be [***] than the [***] at which such Product would be [***] in a [***] transaction to a Third Party [***]. 

For avoidance of doubt, in the case of any sale of such Product between or among Otsuka or its Sublicensees for resale, Net Sales shall be
calculated as [***] only on the value charged or invoiced on the [***] thereafter to [***]. 
  

	1.83	“New Formulation” means any formulation of Product other than the Tablet Formulation. For clarity, any Combination Product shall be a New Formulation. 

 

	1.84	“New Indication” means any indication in the Field, excluding the first indication approved in Japan under a JNDA approval obtained using data from the Ongoing Study, but including any additional
indication that the Parties mutually agree (through the JDCC) to develop under any Development Plan and any indication developed separately by ARIAD pursuant to Section 5.5.3. For clarity, an earlier line of treatment (e.g., first-line when
only second-line has been approved) shall be a New Indication. 

  

	1.85	“NHI List Price” means the price for the Product (in its various Presentations), as adjusted by the MHLW from time to time, specified in the Japanese National Health Insurance Drug Price List, which
comprises a list of drug prices to be reimbursed to hospitals, pharmacies and other health-insurance medical service providers under the Japanese national health insurance programs. 

 

	1.86	“Non-Breaching Party” has the meaning set forth in Section 26.1. 

  

	1.87	“Non-Conformance” means a failure of the Product supplied hereunder to comply with (i) any of the Product warranties set forth in Section 20.1.6(a), (b) or (c) with respect to Bulk
Product, and/or (ii) any of the Product warranties set forth in Section 20.1.7(a), (b) or (c) with respect to Secondary Packaged Product. For clarity, a Latent Defect is an instance of Non-Conformance. The adjective
“Non-Conforming” shall have the correlative meaning. “Non-Conformance” does not include damage caused to Products caused by actions of or on behalf of Otsuka following Delivery by ARIAD to Otsuka, including Final
Manufacturing. 

  

	1.88	“Notified Party” has the meaning set forth in Section 21.7. 

  

	1.89	“Notifying Party” has the meaning set forth in Section 21.7. 

  

	1.90	“Objection Notice” has the meaning set forth in Section 11.5.2. 

  

	1.91	“Ongoing Study” means [***] clinical trial of Product in Japan that was started prior to the Effective Date and is scheduled to be completed after the Effective Date. 

 

	1.92	“Option Exercise Period” has the meaning set forth in Section 16.1. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 10 

	1.93	“Otsuka Iclusig Staff” means all personnel of Otsuka or its Sublicensees who are routinely involved in the further development, Final Manufacturing, or Commercialization of the Product, including:
(i) the marketing and promotion of the Product, (ii) seeking and maintaining Registrations for the Product, or (iii) the performance of the Pharmacovigilance Agreement and/or the Quality Agreements. 

 

	1.94	“Otsuka Improvements” has the meaning set forth in Section 5.7. 

  

	1.95	“Parties” means ARIAD and Otsuka and “Party” means either of them as the context indicates. 

  

	1.96	“Patents” means (a) all patents and patent applications in the Territory that are Controlled by ARIAD or its Affiliates as of the Effective Date and at any time during the Term that (i) are
necessary or useful (or, with respect to patent applications, would be necessary or useful if such patent applications were to issue as patents) for the research, development, Commercialization or Final Manufacturing of Product in the Field in the
Territory, including as listed in Appendix 1 hereto, or (ii) claim or cover any Assigned Otsuka Improvements owned by ARIAD as provided in Section 5.7 or (iii) are licensed to ARIAD pursuant to a Global Third Party License;
(b) all patents in the Territory issuing from the applications in subclause (a); (c) any additions, divisions, continuations, continuations-in-part, counterparts, amendments, amalgamations, reissues and re-examinations of such applications
or patents in the Territory; (d) any confirmation, importation and registration patents thereof in the Territory; and (e) any extensions and renewals of all such patents and patent applications in the Territory in whatever legal form and
by whatever legal title they are granted. 

  

	1.97	“Payment” has the meaning set forth in Section 19.8. 

  

	1.98	“Pharmacovigilance Agreement” has the meaning set forth in Section 9.4. 

  

	1.99	“PMDA” means the Japanese Pharmaceutical and Medical Devices Agency, or any successor agency thereto. 

  

	1.100	“Preexisting Named Patients” has the meaning set forth in Section 3.5. 

  

	1.101	“Presentation” means each stock-keeping unit of Product differentiated by dosage strength, bottle count, packaging presentation, and/or country-specific labeling for the Product for which Marketing
Authorization has been received in a country in the Territory (e.g., a 60 count bottle of 15mg tablets labeled for a specific country in the Territory). 

  

	1.102	“Price Cut” has the meaning set forth in Section 19.5.3. 

  

	1.103	 “Pricing and Reimbursement Approval” means any official, final, binding and non-appealable determination of the reimbursable price of
the Product in accordance with Applicable Laws and approval by relevant Regulatory Authorities pertaining to the 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 11 

	 	
reimbursement of the Product, as applicable in each country in the Territory in which a Regulatory Authority approves or determines the price and/or reimbursement of pharmaceutical products. For
clarity, Pricing and Reimbursement Approval for Japan means the NHI List Price. 

  

	1.104	“Proceeding” means any (i) Third Party private action, claim or lawsuit, and any (ii) governmental, judicial, administrative or adversarial proceeding, hearing, probe or inquiry brought by any
Third Party public entity, including whistleblower complaints. Proceedings shall not include any action, claim or lawsuit brought by one Party or its Affiliates against the other Party or its Affiliates. 

 

	1.105	“Product” means any pharmaceutical product containing Compound as an active chemical entity, alone or in combination with one or more other active ingredients, in any and all forms, presentations,
dosages, and formulations. 

  

	1.106	“Product-Related Inspection” has the meaning set forth in Section 12.6. 

  

	1.107	“Product Withdrawal” means removal of Product from the market in any country in the Territory on grounds of public health or safety resulting in discontinuation of all or substantially all distribution
of Product in such country in the Territory. Product Withdrawal does not include a Recall. 

  

	1.108	“Protected Personal Information” has the meaning set forth in Section 21.6. 

  

	1.109	“Quality Agreement” means a written agreement to be entered into by the Parties relating to quality assurance for the Product, as set forth in Section 12.5. 

 

	1.110	“Raw Materials” means any raw materials, components, or other ingredients required for the Manufacture of the Product. 

 

	1.111	“Recall” means a recall or retrieval of Product on grounds of Non-Compliance, public health or safety which is limited as to lot(s) or batch(es) of Product in the Territory. 

 

	1.112	“Reconciliation Payment” has the meaning set forth in Section 19.5.2. 

  

	1.113	“Reduced Royalty Term” has the meaning set forth in Section 19.3.2. 

  

	1.114	“Reference Sample” has the meaning set forth in Section 13.4. 

  

	1.115	“Registrations” means (a) Marketing Authorizations, (b) Pricing and Reimbursement Approval, (c) receipt of any license required to import Product(s) into each country in the Territory,
and (d) any other official license or approval which is legally required to Commercialize the Product in each country of the Territory (e.g., wholesale licenses). 

 

	1.116	“Regulatory Authority” means the MHLW or any other government agencies that are the competent authorities for the issuance of the Registrations, or any part of them, in each country of the Territory
throughout the Term. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 12 

	1.117	“Regulatory Documentation” means all letters, correspondence and other documents and information submitted to Regulatory Authorities or received from Regulatory Authorities in writing, including in
electronic format. 

  

	1.118	“Regulatory Laws” means all laws, and all orders, determinations, regulations, licenses and directions made or issued under such laws, in respect of the Marketing Authorization, Registrations, Final
Manufacturing and Commercialization of the Product in each country of the Territory. 

  

	1.119	“Regulatory Requirements” means all licenses, registrations, mandatory standards, conditions, manufacturing principles, directions, orders and determinations in force from time to time set out in the
Regulatory Laws and all other Applicable Laws that apply to the manufacture (including Manufacture and Final Manufacturing), supply, packaging, labeling and/or Commercialization of medicinal products in each country in the Territory.

  

	1.120	“Royalty Term” means, with respect to a country in the Territory, the Full Royalty Term and the Reduced Royalty Term, collectively. 

 

	1.121	“Safety Information” has the meaning set forth in Section 9.5. 

  

	1.122	“SEC” means the U.S. Securities and Exchange Commission or any successor agency. 

  

	1.123	“Secondary Packaged Product” has the meaning set forth in Section 10.2. 

  

	1.124	“Sell-Off Period” has the meaning set forth in Section 26.7.5. 

  

	1.125	“Senior Officer” means, (i) with respect to ARIAD, its Chief Executive Officer and (ii) with respect to Otsuka, its President. 

 

	1.126	“Specifications” means the specifications for the Product (in bulk product form, or, as applicable, in the form of Secondary Packaged Product) as defined by ARIAD and incorporated into the Quality
Agreements, together with changes to such specifications made at the request of a Regulatory Authority in the Territory or in accordance with Section 12.3. 

  

	1.127	“Sprycel” means the product containing the compound known as Dasatinib. 

  

	1.128	“Sublicensee” means (a) each Affiliate of Otsuka and Third Party listed in Appendix 2 hereto, which listed Affiliates and Third Parties have been pre-approved by ARIAD to fulfill any of
Otsuka’s obligations under this Agreement, and (b) any other Affiliate of Otsuka or Third Party approved by ARIAD in accordance with Section 2.1.2. 

 

	1.129	“Subcontractor” means a Third Party appointed by Otsuka, subject to Section 2.5, to perform activities under this Agreement on behalf of Otsuka in any part of the Territory. For clarity, a
Subcontractor does not include a Sublicensee. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 13 

	1.130	“Supply Agreement” has the meaning set forth in Section 10.1. 

  

	1.131	“Tablet Formulation” means the Product containing the Compound as its sole active pharmaceutical ingredient in the solid, oral tablet form as Manufactured by ARIAD or any Affiliate or Third Party
contract manufacturer of ARIAD as of the Effective Date (i.e., the 15mg and 45mg dosage strengths) or at any time during the Term (e.g., the 30mg dosage strength). For clarity, the Tablet Formulation excludes [***]. 

 

	1.132	“Taxes” has the meaning set forth in Section 19.8. The terms “Taxable” and “Tax” have correlative meanings. 

 

	1.133	“[***] Price” has the meaning set forth in Section 19.5.1. 

  

	1.134	“Term” means the period beginning on the Effective Date and ending, subject to any earlier termination of this Agreement in accordance with the provisions hereof, on the later of (x) the
date of expiration of the last-to-expire Royalty Term in the Territory, or (y) the last sale by Otsuka or its Sublicensees of a Product in the Territory under any of the Trademarks or any Registration for the Product obtained under this
Agreement. 

  

	1.135	“Terminated Product” has the meaning set forth in Section 26.7.3. 

  

	1.136	“Terminated Country” has the meaning set forth in Section 26.7.3. 

  

	1.137	“Territory” means Indonesia, Japan, Malaysia, People’s Republic of China (including Hong Kong, and referred to herein as “China”), Philippines, Singapore, South Korea, Taiwan,
Thailand, and Vietnam. If, but only if, the Parties enter into an amendment as provided in Section 3.1, the Territory shall also include [***]. 

  

	1.138	“Territory-Only Third Party License” has the meaning set forth in Section 23.6.2(a). 

  

	1.139	“Territory Product Profile” has the meaning set forth in Section 15.3.3. 

  

	1.140	“Third Party” means any Person other than ARIAD, Otsuka and their respective Affiliates. For purposes of this definition, “Person” means any (i) natural person, (ii) partnership,
company, corporation or other form of business organization or legal entity, and (iii) any governmental or administrative entity. 

  

	1.141	“Third Party Infringement Claim” has the meaning set forth in Section 23.5.1. 

  

	1.142	“Third Party License” has the meaning set forth in Section 23.5.6. 

  

	1.143	“Third Party Research Project” has the meaning set forth in Section 5.9. 

  

	1.144	[***] 

  

	1.145	“Tie-Breaking Decisions” has the meaning set forth in Section 4.6.2. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 14 

	1.146	“Trademark Guidelines” has the meaning set forth in Section 15.3.4. 

  

	1.147	“Trademarks” means any trademark owned by or licensed to ARIAD or its Affiliate under which the Product shall be Commercialized by Otsuka within the Field in the Territory, as it shall be determined and
indicated in due course by ARIAD to Otsuka, whether registered in the Territory or not (including any trademarks, service marks, names or logos that include any corporate name or logo of ARIAD). As of the Effective Date, the Trademarks are those set
forth in Appendix 3. 

  

	1.148	“Transaction” has the meaning set forth in Section 3.2.5. 

  

	1.149	“Transfer Price” has the meaning set forth in Section 19.4. 

  

	1.150	“US NDA” means a new drug application filed with the US Food and Drug Administration (FDA). 

ARTICLE 2 – GRANT OF LICENSES 
  

	2.1	Grant of licenses.  

  

	 	2.1.1	Subject to the terms and conditions of this Agreement, including any reservation of ARIAD’s rights expressly set forth herein, ARIAD hereby grants to Otsuka, and Otsuka hereby accepts: 

 

	 	(a)	an exclusive license under the Patents, the Know-how, the Trademarks and any other Intellectual Property Rights of ARIAD and its Affiliates in and to the Compound or Product to perform Final Manufacturing of Product and
to Commercialize Product in the Field in the Territory during the Term, in each case in accordance with the terms of this Agreement. 

  

	 	(b)	a co-exclusive license (with ARIAD and its Affiliates and their respective contractors) under the Patents, the Know-how, the Trademarks and any other Intellectual Property Rights of ARIAD and its Affiliates in and to
the Compound or the Product to conduct research and development of the Compound and the Product in the Territory as expressly set forth in this Agreement. 

  

	 	(c)	For clarity, the licenses set forth in Sections 2.1.1(a) and (b) do not include the right to Manufacture the Product for clinical or commercial use (unless, and only to the extent, the Parties mutually agree
through the JDCC or pursuant to Section 4.6.1(c)(iii) to develop Product in one or more New Formulation(s) and the Parties agree that Otsuka shall be responsible for the Manufacture of Product in such agreed New Formulation(s)).

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 15 

	 	(d)	If a joint venture between ARIAD and one or more Third Parties qualifies as an Affiliate of ARIAD under this Agreement, then the Intellectual Property Rights owned by such Third Party and such joint venture are excluded
from the license granted to Otsuka pursuant to this Section 2.1.1, provided, that, for clarity any Intellectual Property Rights licensed, transferred or assigned from ARIAD to such joint venture shall be included within the scope of the license
granted to Otsuka pursuant to this Section 2.1.1, and provided, further that any Intellectual Property Rights of such joint venture relating to Improvements that are developed with the use of or reference to the Intellectual Property Rights
licensed, transferred or assigned from ARIAD to such joint venture shall be included within the scope of the license granted to Otsuka pursuant to this Section 2.1.1. 

 

	 	2.1.2	The licenses set forth in Section 2.1.1 shall be sublicenseable by Otsuka without ARIAD’s consent to its Sublicensees listed in Appendix 2 hereto. The licenses set forth in Section 2.1.1 shall otherwise
be sublicenseable by Otsuka only with ARIAD’s prior written consent. Any such permitted sublicenses shall not be further sublicenseable or assignable without ARIAD’s prior written consent. Otsuka shall be liable for all acts or omissions
of its Sublicensees. Any act or omission by any Sublicensee that would constitute a breach of this Agreement if done, or omitted to be done, by Otsuka, shall be deemed to be a breach of this Agreement by Otsuka. 

 

	 	2.1.3	The licenses set forth in Section 2.1.1 shall be non-transferable and non-assignable except as expressly set forth in Section 31.8.1. 

 

	2.2	ARIAD agrees that, subject to ARIAD’s rights under Section 3.5 with respect to Preexisting Named Patients, it shall not appoint any Third Party in the Territory to Commercialize or conduct the Final
Manufacturing of the Product in the Field or otherwise in contravention of the licenses set forth in Section 2.1.1. Otsuka acknowledges that ARIAD has, or may have, other licensing or distribution arrangements for the Product outside the
Territory. 

  

	2.3	Otsuka acknowledges that ARIAD grants the licenses and rights to Otsuka set forth in this Article 2 in reliance upon the particular expertise, experience, skills, infrastructure and qualified personnel of Otsuka in
respect of the Commercialization of pharmaceutical products in the Territory. 

  

	2.4	 In consideration of the licenses and appointment granted to Otsuka by ARIAD under Section 2.1, and in order to maintain at all times the highest
quality for the Product and to ensure a scientifically proper and safe exploitation of the Know-how and Patents and in order to maintain and to protect the goodwill of the Trademarks, throughout the Term, Otsuka agrees that it and its Sublicensees
and its Affiliates shall not, directly or indirectly, purchase Product from any person other than ARIAD or a source approved in writing by ARIAD, whether for clinical or commercial use (other than a contract

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 16 

	 	
manufacturer in connection with the Final Manufacturing of Product in the Territory or, if applicable, Otsuka’s Manufacture of New Formulation(s), if any, as permitted under this Agreement).

  

	2.5	Other than agreements with (i) its Sublicensees, (ii) Customers entered into in the normal course of business of selling the Product, (iii) Third Party contract manufacturers for the Final Manufacturing
in the Territory, or (iv) contracted medical representatives, and subject further to Section 2.1.2, Otsuka shall not enter into any agreement with Third Parties with respect to Otsuka’s pharmacovigilance or quality assurance
obligations relating to the Product, or subcontracting or sublicensing rights to Commercialize the Product in a country in the Territory, except as may be expressly permitted by ARIAD hereunder or otherwise by prior approval in writing from ARIAD.
Otsuka may subcontract other activities under this Agreement, provided that Otsuka has given ARIAD prior written notice identifying the activity and the Subcontractor. 

ARTICLE 3 – RESERVED TERRITORIES AND NON-COMPETITION 
  

	3.1	Development of the Product for and commercialization of the Product in all countries other than those in the Territory are reserved exclusively to ARIAD or its Affiliates, or to Third Parties appointed by ARIAD or its
Affiliates, as the case may be. Notwithstanding the foregoing, at Otsuka’s request made within [***] ([***])[***] after the Effective Date, the Parties shall discuss expanding the Territory under this Agreement to include [***] (provided that
ARIAD is not prohibited from engaging in such discussions with Otsuka as a result of any agreement with, exclusive negotiation restriction, or other legally binding exclusivity obligations to a Third Party), and if mutually agreed by the Parties
within [***] ([***])[***] of Otsuka’s request (or such longer period as the Parties may agree upon) (each in its sole discretion and with no obligation for either Party to agree), the Parties shall execute an amendment to this Agreement to
include [***] in the definition of the Territory under this Agreement (with all other terms and provisions of this Agreement remaining unchanged). In consideration of the licenses granted to Otsuka by ARIAD under Section 2.1, Otsuka shall
refrain from selling the Product to Customers located outside the Territory. Without limiting the foregoing, Otsuka shall refrain from the following activities solely with respect to the Product: 

 

	 	(a)	sales or marketing visits or details outside of the Territory; 

  

	 	(b)	direct mail, including the sending of unsolicited e-mails, to persons or entities located outside of the Territory; 

  

	 	(c)	advertising in media, on the Internet or other promotions, where such advertising or promotion is specifically targeted at potential purchasers outside the Territory; 

 

	 	(d)	 online advertisements addressed to potential purchasers outside the Territory and other efforts specifically designed to be found by potential
purchasers 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 17 

	 	
outside the Territory, including the use of outside-the-Territory based banners on Third Party websites and paying a search engine or online advertisement provider to have advertisements or
higher search rankings displayed specifically to potential purchasers outside the Territory; and 

  

	 	(e)	advertising or promotion in any form, or translation of Otsuka’s website into a language other than an official language of any country forming part of the Territory, that in each case Otsuka would not reasonably
carry out but for the likelihood that it will reach potential customers in countries outside the Territory. 

  

	3.2	Competitive Product. 

  

	 	3.2.1	As of the Effective Date, and thereafter during the Term, neither Party nor its Affiliates shall develop, register, file for registration, manufacture, purchase, sell, promote, distribute, commercialize or otherwise
exploit any Competitive Product in the Territory nor enable or authorize any Third Party to do so; provided that, subject to Section 3.2.4, Otsuka shall be permitted to [***] for a maximum of [***] ([***]) [***] after the Effective Date.

  

	 	3.2.2	Without limiting Section 3.2.1, in the event of early termination of this Agreement by ARIAD pursuant to Section 26.1, 26.2, 26.4.2, 26.4.3, 26.4.4, or 26.5, for a [***] ([***]) [***] period after such
termination, Otsuka and its Affiliates shall not develop, register, manufacture, purchase, sell, promote, distribute, commercialize or otherwise exploit any Competitive Product in the Territory nor enable or authorize any Third Party to do so.

  

	 	3.2.3	Without limiting Section 3.2.1, in the event of early termination of this Agreement by Otsuka pursuant to Section 26.1 or 26.2, for a [***] ([***]) [***] period after such termination ARIAD and its Affiliates
shall not, directly or indirectly, commercialize or otherwise exploit any Competitive Product in the Territory, nor enable or authorize any Third Party to do so. 

  

	 	3.2.4	Within [***] ([***]) [***] after Effective Date, Otsuka shall give notice to Bristol-Myers K.K. (“BMKK”) under the Japan co-commercialization agreement between Otsuka and BMKK dated on or about January 1, 2011
(the “BMS Agreement”) that Otsuka shall cease promoting and shall terminate its right to promote Sprycel in Japan, with such termination taking effect within [***] ([***]) [***] after the Effective Date. [***]. 

 

	 	3.2.5	 Notwithstanding Section 3.2.1, 3.2.2 or 3.2.3, if a Party (the “Acquiring Party”) or any of its Affiliates, either as a result
of a merger, acquisition, change of control or similar transaction (including an acquisition of assets) (the “Transaction”) acquires or is acquired by or otherwise merges with an entity that owns, has a license to, or a right to
distribute, a Competitive Product that would otherwise result in a violation of Section 3.2.1, 3.2.2 or 3.2.3, then the Acquiring Party shall (i) promptly, and in any event no later than [***] ([***]) [***] following the date of the
Transaction, notify the other Party in writing of the Transaction and the Competitive Product, and (ii) in order to avoid termination of this Agreement as provided below, 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 18 

	 	
divest, or cause its relevant Affiliate to divest, all rights (including distribution rights) to the Competitive Product in accordance with this Section 3.2.5. The Acquiring Party shall
promptly, and in any event no later than [***] ([***]) [***] following the date of the Transaction, notify the other Party whether or not it (or its Affiliate) intends to undertake good faith efforts to divest the Competitive Product. If the
Acquiring Party notifies the other Party that it (or its Affiliate) does not intend to undertake good faith efforts to divest the Competitive Product in a particular country in the Territory, then the other Party may terminate this Agreement on a
country-by-country basis with respect to such country by written notice to the Acquiring Party, such termination to be effective [***] ([***]) [***] after the Acquiring Party’s receipt of notice of termination from the other Party, provided,
that any termination pursuant to this Section 3.2.5 with respect to Japan shall give the terminating Party the right to simultaneously terminate this Agreement with respect to the entire Territory. If the Acquiring Party notifies the other
Party that it or its Affiliate, as the case may be, intends to undertake good faith efforts to divest the Competitive Product, such divestiture shall be completed within [***] ([***]) [***] after the date of the Transaction and shall occur by
(1) a termination of or an outright sale or assignment to a Third Party of all of the Acquiring Party’s or its Affiliate’s rights and interest in and to the Competitive Product (including all rights under any contract, such as a
license or distribution agreement) or (2) an outlicense arrangement under which the Acquiring Party and its Affiliates have no ongoing involvement in the development or commercialization of the Competitive Product and derive no material ongoing
financial return following the effective date of divestiture and no financial benefit tied to sales or success of the divested Competitive Product. Should such divestiture not have occurred with respect to any country in the Territory within such
[***] ([***]) [***] period, and provided that the Acquiring Party has been using good faith efforts to divest the owned Competitive Product in such country during such [***] ([***]) [***] period, then the Acquiring Party shall have the right to
discontinue (and cause its Affiliates to discontinue) developing or commercializing the Competitive Product (i.e., withdraw the Competitive Product IND or Marketing Authorization and, to the extent applicable, cease all promotion, marketing and
other commercialization activities with respect to the Competitive Product) in such country and if such discontinuation shall not have occurred within [***] ([***]) [***] of the expiration of the original [***] ([***]) [***] period then the other
Party may terminate this Agreement with respect to such country after such total [***] ([***]) [***] period by written notice to the Acquiring Party, such termination to be effective [***] ([***]) [***] after the Acquiring Party’s receipt of
notice of termination from the other Party, provided, that any termination pursuant to this Section 3.2.5 with respect to Japan shall give the terminating Party the right to simultaneously terminate this Agreement with respect to the
entire Territory. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 19 

	 	3.2.6	For the avoidance of doubt, if a Third Party contractor of a Party or of its Affiliate (including a Sublicensee or Subcontractor) independently (not with the authorization of such Party or Affiliate) develops,
registers, files for registration, manufactures, purchases, sells, promotes, distributes, commercializes or otherwise exploits a Competitive Product in the Territory, such Party shall not be or be deemed to be in breach of this Section 3.2 by
virtue of such Third Party’s independent activities. Further for the avoidance of doubt, the terms of this Section 3.2 shall not preclude either Party or its Affiliates from conducting research relating to Competitive Products.

  

	3.3	Nothing in this Agreement shall be construed as giving Otsuka any right to use or otherwise exploit the Know-how, the Patents, the Trademarks, ARIAD’s other Intellectual Property Rights in the Product and/or any
other information received hereunder for purposes other than to perform Otsuka’s obligations and exercise its rights under this Agreement, including for purposes of meeting its responsibilities as the MAH in the Territory, solely in accordance
with the terms and conditions of this Agreement. Except as expressly set forth in this Agreement, neither Party grants to the other Party any right or license to any of its Intellectual Property Rights. 

 

	3.4	The Parties acknowledge and agree that the restrictions imposed on and accepted by Otsuka in this Article 3 are restrictions that ARIAD has independently and unilaterally determined are necessary in order to protect
ARIAD’s Intellectual Property Rights and ensure Otsuka is able to effectively commit and apply its skills, resources, networks and qualified personnel so that Otsuka may comply with and perform its obligations under this Agreement.

  

	3.5	Otsuka acknowledges that, as of the Effective Date, ARIAD, directly or through an Affiliate or Third Party contractor, is supplying Product labeled for the US, EEA or Australia to certain patients in the Territory (the
“Preexisting Named Patients”) under one or more non-chargeable Named Patient Programs. Otsuka acknowledges that ARIAD may (or shall if required by Applicable Law) continue to supply Product to such Preexisting Named Patients in the
Territory in accordance with the Applicable Laws of each country in the Territory in which Product is being dispensed to such Preexisting Named Patients. For clarity, Otsuka shall not have any obligation to supply Product to such Preexisting Named
Patients unless agreed upon by the Parties and it is the expectation of each Party that, to the extent permitted by Applicable Law, the Preexisting Named Patients will stop receiving Product under Named Patient Programs upon receipt of Marketing
Authorization for Product in the country in the Territory in which Product is being dispensed to them, and will transition to commercially-supplied Product. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 20 

 ARTICLE 4 – DEVELOPMENT AND COMMERCIALIZATION COMMITTEES 

 

	4.1	Joint Development & Commercialization Committee. The Parties shall, within [***] ([***]) [***] of the Effective Date, establish a Joint Development & Commercialization Committee
(the “JDCC”), comprised of [***] ([***]) representatives of ARIAD and [***] ([***]) representatives of Otsuka, at least one of whom from each Party, who shall serve as co-chair, shall have experience and seniority sufficient to
enable him or her to make decisions on behalf of the Party he or she represents concerning issues within the remit of the JDCC.  

  

	4.2	Development-Related Responsibilities. The JDCC shall be responsible for: (i) confirming and preparing annual (or, if needed, more frequent) updates and revisions to the Development Plan for the Territory
prepared jointly by the Parties pursuant to Section 5.1; (ii) monitoring activities and progress under the Development Plan; (iii) overseeing the maintenance of all Marketing Authorizations in the Territory, including the performance
of post-approval commitments in the Territory; (iv) overseeing the sharing of regulatory correspondence and other regulatory information, and overseeing planning and submissions for Marketing Authorizations in the Territory that are filed after
the Effective Date; (v) subject to Article 5, overseeing further medical and development work for the Product in the Territory, including development of the Product for any New Indication or in any New Formulation as may be mutually agreed by
the Parties; (vi) subject to Article 5, overseeing clinical trials, investigator-initiated trials, post-hoc data analyses, and sponsored research arrangements for the Territory; (vii) overseeing pharmacovigilance activities for the
Territory; (viii) overseeing medical affairs activities for the Territory; (ix) developing a publication strategy in the Territory and review procedures for such publications; (x) attempting to resolve disagreements escalated by any
subcommittees or project teams; and (xi) assuming such other responsibilities as are set forth in this Agreement, or as mutually agreed in writing by duly authorized representatives of the Parties from time to time. 

 

	4.3	Commercialization-related Responsibilities. The JDCC shall be responsible for: (i) reviewing and discussing the Commercialization Plan, and updates thereto, prepared by Otsuka as set forth in
Section 15.2; (ii) monitoring actual Commercialization activities and progress in accomplishing the Commercialization Plan in the Territory; (iii) overseeing and evaluating geographic expansion, market access plans (including any
proposed submissions of health economics and outcomes studies or analyses), and plans and strategies for obtaining Pricing and Reimbursement Approval (as applicable) in the Territory, including in light of ARIAD’s global positioning of the
Product and pricing and reimbursement strategies and tactics outside of the Territory; (iv) ensuring a process is in place for the review and discussion by the Parties of Otsuka’s core promotional and sales training materials;
(v) discussing whether and under what terms to initiate any Named Patient Programs in any country in the Territory (in addition to those described in Section 3.5), which, if implemented, shall be governed by the Pharmacovigilance
Agreement, the Quality Agreements and any applicable terms of this Agreement; (vi) attempting to resolve disagreements escalated by any subcommittees or project teams; and (vi) assuming such other responsibilities as are set forth in this
Agreement, or as mutually agreed in writing by duly authorized representatives of the Parties from time to time. [***]. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 21 

	4.4	Committee Administration. 

  

	 	4.4.1	Subcommittees. The JDCC may form subcommittees or project teams as it deems appropriate to fulfill its responsibilities. The parties intend to establish joint pharmacovigilance (PV) and supply chain subcommittees
or project teams as soon as practicable after the Effective Date in order to facilitate discussions and coordination of the Parties’ efforts and activities relating to Product PV and manufacture, supply and quality assurance (including
Manufacture and Final Manufacturing) under this Agreement. If a subcommittee or project team cannot reach agreement on any matter within its remit, such matter shall be submitted to the JDCC for discussion and resolution prior to any further dispute
resolution action being taken. 

  

	 	4.4.2	Changes to Representatives. A Party may change any one or more of its representatives to the JDCC or to a subcommittee or project team at any time upon written notice to the other Party. The number of
representatives appointed by each Party to the JDCC or to a subcommittee or project team may be modified by mutual agreement of the Parties; provided, that at all times the number of representatives from each Party shall be equal.

  

	 	4.4.3	Schedule and Minutes. The representatives of the JDCC shall mutually agree on the schedule for meetings, provided that there shall be at least [***] ([***]) meeting per [***]. Either Party may schedule an
emergency meeting of the JDCC upon reasonable advance written notice to the other Party. A representative of the Party hosting a meeting of the JDCC shall serve as secretary of that meeting. The secretary of the meeting shall prepare and distribute
to all members of the JDCC: (a) agenda items at least [***] ([***]) [***] in advance of the applicable meeting and (b) draft minutes of the meeting within [***] ([***]) [***] following the meeting to allow adequate review and comment. Such
minutes shall provide a description in reasonable detail of the discussions held at the meeting and a list of any actions, decisions or determinations approved by the JDCC. Minutes of the JDCC meeting shall be approved or disapproved, and revised as
necessary, within [***] ([***]) [***] after their initial circulation in draft form. Minutes for any subcommittees shall be prepared in the same manner and in accordance with the same timelines. The final minutes of any subcommittee shall be
provided to the JDCC. The final minutes of the JDCC shall be provided to the Alliance Managers. 

  

	 	4.4.4	 Location and Attendance. The location of JDCC meetings shall alternate between ARIAD’s principal place of business and Otsuka’s
principal place of business, or as otherwise agreed by the Parties. The JDCC may also meet by means of telephone conference call or videoconference, provided 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 22 

	 	
that at least [***] ([***]) meeting per [***] shall be held in person. Each Party shall use reasonable efforts to cause its representatives to attend JDCC meetings. If a Party’s
representative to the JDCC or any subcommittee is unable to attend a meeting, such Party may designate an alternate to attend such meeting in place of the absent representative. In addition, each Party may, at its discretion, invite non-voting
employees, and, with the consent of the other Party, consultants or scientific advisors, to attend the meetings of a Committee. 

  

	4.5	Alliance Managers. Each Party shall appoint a business representative who possesses a general understanding of the relevant technical, business and legal issues to act as its Alliance Manager (each, an
“Alliance Manager”). The Alliance Managers shall be responsible for creating and maintaining collaborative, efficient and responsive communication within and between the Parties, and for day-to-day management of operational
matters other than matters within the remit of the JDCC. The Alliance Managers shall have no authority to modify this Agreement or waive any non-compliance with its terms. Alliance Managers may attend JDCC and subcommittee meetings as observers.

  

	4.6	Decision Making Process.  

  

	 	4.6.1	Each Party shall have one vote on the JDCC. Each co-chair shall be responsible for casting his or her Party’s vote. If such co-chair is unable to attend a JDCC meeting, he or she may act through a substitute who is
a member of the JDCC by notice to the other Party. Any decision of the JDCC shall require unanimous agreement of the Parties (through the affirmative vote of both Parties’ co-chairs of the JDCC). If the JDCC fails to unanimously agree on any
matter within the JDCC’s responsibilities within [***] ([***]) [***], or such other period as the JDCC co-chairs may agree upon, after the JDCC has met and attempted to agree on such matter, then such matter shall first be presented to the
Alliance Managers for resolution, and if the dispute is not resolved within [***] ([***]) [***]after such referral to the Alliance Managers, then: 

  

	 	(a)	with respect to (i) all matters relating to [***], and (ii) other responsibilities of the JDCC relating to [***], Otsuka shall have final decision-making authority and the decision of Otsuka’s co-chair of
the JDCC with respect to such matters shall be final and binding on the Parties; provided, however, that (A) decisions with respect to [***], and (B) any [***] matter [***], may be referred by ARIAD to the Senior Officers as provided in
the following paragraph, and Otsuka’s co-chair of the JDCC shall not have the final decision-making authority with respect to such matter; 

  

	 	(b)	 with respect to all matters that are within the JDCC’s responsibilities other than those relating to [***], including with respect to the

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 23 

	 	
responsibilities of the JDCC set forth in Section 4.2, either Party may, by written notice to the other Party (“Escalation Notice”), refer such matter to the Senior Officers
for resolution. In addition, ARIAD may provide an Escalation Notice regarding (i) decisions with respect to [***], and (ii) any [***] matter [***]. The Senior Officers shall use good faith efforts to resolve any matter referred to them as
soon as practicable. Any final decision that the Senior Officers mutually agree to in writing shall be conclusive and binding on the Parties; and 

  

	 	(c)	If the Senior Officers are unable to resolve any matter set forth in an Escalation Notice within [***] ([***]) [***]after the applicable Party receives such Escalation Notice (or such longer period as the Senior
Officers may agree upon), then (i) with respect to [***], ARIAD shall have final decision-making authority and the decision of ARIAD’s Senior Officer with respect to such matters shall be final and binding on the Parties, (ii) with
respect to [***], Otsuka shall have final decision-making authority, and the decision of Otsuka’s Senior Officer with respect to [***] shall be final and binding on the Parties, provided that such decision by Otsuka is [***], and (iii) all
other matters set forth in an Escalation Notice that are not resolved by the Senior Officers shall be subject to the mutual agreement of both Parties and shall not be subject to arbitration or any other form of external dispute resolution and,
unless and until such mutual agreement is reached, the status quo shall be maintained, except as set forth in the final sentence of this Section 4.6.1(c). For clarity, neither Party shall have final decision-making authority with respect to the
following, which shall be subject to the mutual agreement of both Parties and shall not be subject to arbitration or any other form of external dispute resolution: (x) [***]; and (y) [***]. Notwithstanding the foregoing, disagreements of
the JDCC regarding [***] that are not resolved by the Senior Officers as provided in this Section 4.6.1 shall be resolved by expedited arbitration as provided in Section 30.4. 

 

	 	4.6.2	A Party’s right to exercise final decision-making authority pursuant to Section 4.6.1 (“Tie-Breaking Decisions”) shall be subject to the following limitations: all Tie-Breaking Decisions shall
be subject to all Applicable Laws; no Tie-Breaking Decision shall amend or breach any term or condition of this Agreement or diminish the rights or increase the obligations of either Party under this Agreement; and the Party with final
decision-making authority shall make all Tie-Breaking Decisions only after giving reasonable consideration to the other Party’s comments (through its JDCC members or Senior Officer, as applicable) on such matters. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 24 

 ARTICLE 5 – DEVELOPMENT 

 

	5.1	Development Plan. 

  

	 	5.1.1	ARIAD and Otsuka shall use good faith efforts to agree, through the JDCC, upon a development plan with respect to the development and Registration of the Product in the Territory (once approved by the JDCC the
“Development Plan”). The Development Plan shall be updated by the JDCC at least [***]. The Development Plan shall include country-specific timelines and activities. The Development Plan shall, as applicable, clearly identify any
allocation of responsibility between the Parties for the development activities described therein. Disputes over the content of the Development Plan shall be resolved in accordance with Section 4.6, and shall not be subject to arbitration or
any other form of external dispute resolution except as provided in the last sentence of Section 4.6.1(c). 

  

	 	5.1.2	The JDCC shall approve the initial Development Plan within [***] ([***]) [***] after the Effective Date. The initial Development Plan shall address the development and Registration of the Product in all countries of the
Territory other than [***], and at a minimum, shall provide that, contingent on ARIAD delivering all required data and other information to Otsuka on a timely basis, Otsuka or its Sublicensee shall, on a country-by-country basis in the Territory
excluding [***] (i) file an application for Marketing Authorization in each such country that does not require additional clinical trials within [***] ([***]) [***]of the Effective Date, or (ii) file an investigational new drug application
for conducting clinical trials of the Product within [***] ([***]) [***]of the Effective Date in each such country that requires such additional clinical trials to support an application for Marketing Authorization.  

 

	5.2	Development Efforts.  

  

	 	5.2.1	The Parties shall use commercially reasonable efforts to further develop the Product broadly in Philadelphia chromosome-positive (Ph+) leukemias, including as a first-line therapy for CML, in Japan. Within [***] ([***])
[***] after the receipt of the first Marketing Authorization for the Product in Japan, the Parties shall meet to discuss the strategy and priorities for further development of the Product in Japan. The JDCC shall update the Development Plan
accordingly when specific activities to meet those objectives have been agreed upon by the JDCC. 

  

	 	5.2.2	Otsuka shall use commercially reasonable efforts to develop the Product for any New Indication and in any New Formulation, if and to the extent mutually agreed by the Parties on a country-by-country basis in the
Territory, and the JDCC shall update the Development Plan to incorporate such agreed activities. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 25 

	5.3	ARIAD shall continue to conduct the Ongoing Study and shall bear [***] percent ([***]%) of the costs of the Ongoing Study until completion of such trial, including [***] costs associated with obtaining clinical supplies
of the Product for the Ongoing Study. For clarity, (i) ARIAD shall continue to control the conduct of the Ongoing Study and shall continue to be listed as the sponsor of such trial until completion of such trial; (ii) any extension or
expansion of the Ongoing Study whether or not required by PMDA, including, without limitation, additional patients beyond the number of patients enrolled as of the Effective Date or any addition to the activities specified therein, shall not be part
of the Ongoing Study and Otsuka shall be responsible for [***] percent ([***]%) of the cost thereof pursuant to Section 5.4; and (iii) ARIAD, through the JDCC, may agree, but shall not be required to agree, to take responsibility for, or
pay the costs of, activities under the Development Plan in excess of the activities and costs required in connection with the Ongoing Study. 

  

	5.4	Otsuka shall bear [***] percent ([***]%) of (i) the costs of any commitments made to Regulatory Authorities as a condition of, or following, the grant of Marketing Authorization in the Territory, and (ii) the
costs of any clinical trials conducted in and solely for the benefit of the Territory, including any extension or expansion of the Ongoing Study as described in Section 5.3 and any clinical trials conducted in connection with development of the
Product for any New Indication or in any New Formulation solely in and for the benefit of the Territory, if and to the extent mutually agreed by the Parties on a country-by-country basis in the Territory, in each case of (i) and (ii), excluding
costs in connection with the Ongoing Study and other costs for which ARIAD is responsible as described in Section 5.3. For clarity, this Section 5.4 pertains to clinical trials conducted solely in and for the benefit of the Territory, and
does not apply to clinical trials that are conducted in the Territory as part of global clinical trials, the costs of which shall be borne by the Parties as and to the extent provided in Section 5.5. 

 

	5.5	Global Studies. 

  

	 	5.5.1	If, after the Effective Date, ARIAD is interested in undertaking any global development of the Product for any New Indication or in any New Formulation (i.e., any global clinical trial of the Product that includes
clinical trial sites in (x) the US and/or the European Economic Area and (y) Japan and the data from which, if such trial is successful, could be used to obtain marketing authorization for the Product in the US, the European Economic Area
and Japan under a protocol that PMDA has indicated is sufficient to support an application for Marketing Authorization in Japan, or, with respect to a New Formulation, any non-clinical study or research for the benefit of the US, the European
Economic Area and Japan (each a “Global Study”)), ARIAD shall inform Otsuka of such interest and shall provide Otsuka with information and plans relating to such Global Study, including budgets for out-of-pocket costs and, as
applicable, proposed protocols and clinical trial designs. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 26 

	 	5.5.2	If Otsuka, in its sole discretion, agrees to participate in the funding of any such Global Study with respect to a New Indication or a New Formulation, Otsuka shall coordinate, [***], the clinical trials under such
Global Study conducted at clinical trial sites in Japan and shall pay directly, or reimburse to ARIAD, on a [***], [***] percent ([***]%) of ARIAD’s global out-of-pocket costs paid to Third Parties (or accrued in accordance with GAAP and
subsequently paid to Third Parties) for the conduct of such Global Study. For clarity, ARIAD shall be the sponsor of such clinical trials in Japan. 

  

	 	5.5.3	If Otsuka elects not to participate in the funding of any such Global Study with respect to a New Indication or a New Formulation as described in Section 5.5.1, ARIAD may, at its option and at its sole expense,
conduct such Global Study; provided, however, that if ARIAD proceeds with such Global Study, ARIAD shall submit to Otsuka, at least [***] each [***], a written report that summarizes the then-current development status, the results achieved,
the problems being encountered, out-of-pocket costs incurred and other pertinent information relating to the Global Study with respect to such New Indication or New Formulation, as applicable. If Otsuka initially declines to participate in the
funding of such Global Study with respect to a New Indication or a New Formulation, Otsuka shall subsequently have the right to use the data from such Global Study to seek marketing authorization for the Product in the Territory for such New
Indication or New Formulation or for any other purpose in the Territory, provided that Otsuka reimburses ARIAD [***] percent ([***]%) of ARIAD’s out-of-pocket costs previously paid to Third Parties for the conduct of such Global Study to date,
and Otsuka continues to pay directly, or reimburse to ARIAD, on a [***], [***] percent ([***]%) of ARIAD’s out-of-pocket costs paid to Third Parties (or accrued in accordance with GAAP and subsequently paid to Third Parties) for the conduct of
such Global Study. 

  

	5.6	Each Party hereby acknowledges and agrees that: 

  

	 	5.6.1	further development of the Product will not necessarily result in the extension or variation of the Marketing Authorization of the Tablet Formulation of Product in any dosage strength; 

 

	 	5.6.2	other than the Ongoing Study, nothing in this Agreement shall require ARIAD to perform any additional testing or additional development activities with respect to the Product, except as expressly set forth in the
Development Plan; and 

  

	 	5.6.3	 neither Party makes any warranty, and nothing in this Agreement may or shall be construed as a warranty by either Party, that the Product will obtain
Registrations in any or all of the countries in the Territory and neither Party 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 27 

	 	
shall have claims against the other Party arising out of any delay or refusal by Regulatory Authorities to issue Registrations or to issue Registrations that are acceptable to the Parties.

  

	5.7	ARIAD shall own any data, information and other Know-how, and any Improvements, resulting from development activities for the Product conducted by ARIAD or its contractors or other activities of ARIAD for the Product
conducted outside the Development Plan, and Otsuka shall have the right to use any and all such data, information and other Know-how and Improvements solely to the extent necessary or useful for the research, development, Final Manufacturing and/or
Commercialization of the Product in the Territory in accordance with the terms and conditions of this Agreement. Otsuka shall promptly disclose to ARIAD all Improvements resulting from Product development activities conducted by Otsuka or its
Sublicensees or contractors pursuant to this Agreement (“Otsuka Improvements”). Otsuka agrees to assign and hereby assigns to ARIAD all of Otsuka’s right, title and interest in and to all Otsuka Improvements that solely and
directly relate to the Compound and/or the Product (the “Assigned Otsuka Improvements”), provided however that Otsuka shall have the right to use the Assigned Otsuka Improvements solely in connection with the rights granted to
Otsuka under Article 2, subject to the terms and conditions of this Agreement. Otsuka hereby grants ARIAD a worldwide, perpetual, irrevocable, royalty-free, exclusive, sublicensable license to use all Otsuka Improvements (other than Assigned Otsuka
Improvements) solely in connection with the research, development, manufacture or commercialization of the Compound and/or the Product, subject to Otsuka’s retained right to exercise its rights and perform its obligations under this Agreement.
Otsuka shall not incur any obligation to any Third Party that may prohibit or impair its ability to disclose and assign Assigned Otsuka Improvements to ARIAD. Otsuka shall refrain from filing any patent applications directed to Assigned Otsuka
Improvements and Otsuka shall assist ARIAD in filing and prosecuting any patent application directed to Assigned Otsuka Improvements that ARIAD may choose to undertake at its sole discretion, including by obtaining inventors’ statements and
signatures; provided that ARIAD shall bear the reasonable and direct out-of-pocket expenses incurred by Otsuka in the course of providing such assistance. ARIAD shall have unrestricted rights to disclose and license the Assigned Otsuka Improvements
to ARIAD’s Affiliates and distributors outside of the Territory. 

  

	5.8	Otsuka and its Affiliates shall not undertake or carry out as sponsor any research project, study or clinical trial relating to the Compound or the Product except as expressly set forth in the Development Plan.

  

	5.9	 Otsuka shall report to the JDCC any proposals by Otsuka or suggestions or proposals that it receives from Third Parties (including investigators) with
respect to Third Party research projects, studies and/or clinical trials relating to the Compound and/or the Product in the Territory, including investigator-initiated trials, that Otsuka wishes to support (each, a “Third Party Research
Project”). Any such Third Party Research Projects shall be reviewed as part of ARIAD’s global medical and clinical development strategy and may be supported by Otsuka only if approved in writing

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 28 

	 	
by ARIAD. In the event that ARIAD approves the support by Otsuka of a Third Party Research Project in writing, and the clinical trial or study under such Third Party Research Project will be
funded by Otsuka and conducted under a protocol designed by Otsuka, Otsuka shall perform or support such Third Party Research Project in accordance with a detailed plan to be agreed upon in advance with ARIAD, and all relevant protocols shall be
developed in consultation with, and approved in writing by, ARIAD prior to the conduct of such trial or study. Otsuka shall ensure that such approvals required of Third Party investigators are obtained by them for such Third Party Research Projects.
Data ownership or license rights for such Third Party Research Projects, publication rights, drug safety reporting and other terms shall be agreed between ARIAD and Otsuka (and by Otsuka with Third Parties, as necessary) prior to the commencement of
any such Third Party Research Project. For clarity, Otsuka shall not support, participate, or otherwise aid or advise any Third Party with respect to Third Party Research Projects, including projects, studies and/or clinical trials that are
initiated or sponsored by Third Parties, such as investigator-initiated trials, that have not been approved as set forth above; provided that, other than the requirement to obtain ARIAD’s approval, the above terms shall not apply to a Third
Party Research Project that is sponsored by a Third Party under the Third Party’s protocol without involvement by Otsuka in the design or conduct of such trial or study (e.g., an investigator-sponsored trial) and, for the avoidance of doubt,
Otsuka may, with ARIAD’s prior written approval, supply Product and support pharmacovigilance activities for such a Third Party-sponsored Third Party Research Project. For all Third Party Research Projects that are approved by ARIAD and for
which Otsuka will supply Product, ARIAD shall supply such Product to Otsuka at [***]. 

  

	5.10	Otsuka shall ensure that all necessary notifications are made and/or necessary consents are obtained under applicable data protection or privacy regulations in the Territory such that all personal information obtained
in the course of the conduct of development activities under this Agreement by Otsuka, its Affiliates or any Third Party subcontractor of Otsuka or its Affiliates can be lawfully transmitted to, and used by, ARIAD and its Affiliates for development
work relating to the Compound and/or the Product. 

  

	5.11	Otsuka shall include appropriate provisions in its contractual agreements with institutions, Healthcare Professionals and other relevant Third Parties to give effect to the rights granted to ARIAD in Section 5.7
and Section 5.10. 

 ARTICLE 6 – EXCHANGE OF KNOW-HOW AND IMPROVEMENTS 

 

	6.1	 Throughout the Term, ARIAD shall use commercially reasonable efforts to supply Otsuka free of charge with Know-how that is necessary or useful for
Otsuka to research, develop, Commercialize or conduct Final Manufacturing of the Product in the Territory in accordance with this Agreement, including access to Know-how and information that, prior to the Effective Date hereof, was made available to
Otsuka in read-only mode. Notwithstanding the foregoing, and without limiting any obligation of 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 29 

	 	
ARIAD under the Development Plan, nothing in this Agreement shall require ARIAD to develop additional Know-how or to obtain additional Know-how from Third Parties. Otsuka acknowledges that such
Know-how is the result of significant investment and efforts on the part of ARIAD and its Affiliates and may be highly confidential, strategically valuable and competitively sensitive in nature. 

 

	6.2	All Know-how, Improvements and/or other information and data relating to the Product and/or the Compound and disclosed to Otsuka by or on behalf of ARIAD or its Affiliates hereunder are at all times and shall after
expiration or termination of this Agreement for any reason remain ARIAD’s or its Affiliates’ sole and exclusive property. Except with respect to information and data arising from any Global Study that Otsuka elects not to fund pursuant to
Section 5.5.3, Otsuka shall have the right to use, cross-reference, file or incorporate by reference any information and data relating to the Product and/or the Compound for purposes of performing under this Agreement, including in order to
support any regulatory filings relating to the Product and in interactions with any Regulatory Authority in connection with the development and Registration of the Product in the Territory. 

 

	6.3	Throughout the Term, upon ARIAD’s reasonable request, Otsuka shall supply ARIAD in writing or by any other appropriate means, free of charge and without translation, with any and all information and data relating
to the Product and/or the Compound to the extent in Otsuka’s possession and Controlled by Otsuka or its Affiliates, including relevant market analyses and assessments of the competitive landscape for the Product, and, subject to Applicable
Laws, any patient or physician feedback relating to Product. ARIAD shall be free to use such information and data for the purpose of its business and to disclose the same to ARIAD’s Affiliates and ARIAD’s distributors outside of the
Territory, provided that no Confidential Information pertaining to Otsuka’s business shall be disclosed by ARIAD to such other distributors. 

ARTICLE 7 – PRICING AND REIMBURSEMENT 
  

	7.1	Otsuka shall use commercially reasonable efforts to obtain Pricing and Reimbursement Approval in each country of the Territory where applicable, on a country-by-country basis, as soon as reasonably possible. Otsuka
shall use commercially reasonable efforts to obtain the best reasonably possible reimbursement price for the Product in each country in the Territory in which Pricing and Reimbursement Approval is applicable, on a country-by-country basis, including
seeking Pricing and Reimbursement Approval that is [***] than the pricing and reimbursement approval of [***] and [***] in each such country (assuming those products have patent and/or regulatory exclusivity in such country at such time).

  

	7.2	 Subject to Section 4.6 and the discussions of the JDCC regarding plans and strategies for obtaining Pricing and Reimbursement Approval in the
Territory, Otsuka, or a Sublicensee that is the MAH in the applicable country, shall make all applications and submissions with respect to Pricing and Reimbursement Approvals to the applicable authorities in each country in the Territory where
applicable. The JDCC shall establish 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 30 

	 	
a Pricing and Reimbursement Approval project team that shall obtain and consider input from each of the Parties with respect to Pricing and Reimbursement Approval strategies and target
reimbursement pricing. The JDCC shall review and approve (subject to [***]) (x) the final form of application or other submission for Pricing and Reimbursement Approval, including the reimbursement price to be proposed to the applicable
Regulatory Authority, and (y) the decision to cease negotiations, as applicable, and accept the negotiated Pricing and Reimbursement Approval. Otsuka shall ensure that all applications and interactions with the Regulatory Authorities relating
to Pricing and Reimbursement Approval, where applicable, are compliant with all Applicable Laws and Industry Guidelines. ARIAD shall use commercially reasonable efforts to provide Otsuka with relevant documentation and data to support such
applications for Pricing and Reimbursement Approval for the Product. Otsuka shall keep ARIAD apprised of Otsuka’s progress with respect to all such applications and shall promptly provide ARIAD with a copy of all communications received from
any Regulatory Authority regarding such applications, with English translations. Otsuka shall provide ARIAD with copies of all proposed Pricing and Reimbursement Approval applications and submissions to Regulatory Authorities where applicable,
accompanied by translations into English if the original was not written in English, and shall incorporate the strategies for obtaining Pricing and Reimbursement Approvals in each applicable country in the Territory to the extent agreed upon by the
JDCC, subject to [***]. Otsuka also shall provide ARIAD with copies of the final submitted forms of all such Pricing and Reimbursement Approval applications and submissions in the applicable countries in the Territory and a translation into English
if the original was not written in English. 

  

	7.3	For clarity, Otsuka shall be solely responsible for determining the actual selling price to Customers in the Territory. 

ARTICLE 8 – REGULATORY MATTERS 
  

	8.1	Marketing Authorizations. 

  

	 	8.1.1	ARIAD shall prepare the initial JNDA for the Product, incorporating input and expertise from Otsuka through a joint project team or subcommittee to be appointed by the JDCC, which project team or subcommittee shall be
led by ARIAD. The JDCC shall approve the initial JNDA before submission (with [***] having final decision-making authority, including through the Escalation Notice process; provided that any disputes with respect to [***], shall be resolved as set
forth in Section 30.4). As soon as practicable after approval of such initial JNDA by the JDCC, but in any event after providing sufficient advance notice to the PMDA, Otsuka, at its sole expense, shall submit the JNDA to the MHLW through the
PMDA. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 31 

	 	8.1.2	Otsuka shall, at its sole expense, apply for all other Marketing Authorizations in accordance with the Development Plan, and upon issuance of each Marketing Authorization (including the JNDA), Otsuka shall be the MAH in
each country in the Territory and shall maintain such Marketing Authorizations in good standing at its sole expense, subject to ARIAD’s option to become the MAH in Japan as set forth in Section 8.6. In light of ARIAD’s conduct of the
Ongoing Study and as the marketing authorization holder for the Product in the US and the European Economic Area, ARIAD shall use commercially reasonable efforts to provide Otsuka with information, and access to ARIAD’s personnel, to support
Otsuka’s applications for Marketing Authorizations, including providing Otsuka with Certificates of a Pharmaceutical Product (CPP) and/or Certificates of Medicinal Products for the Product from the US FDA and/or the European Medicines Agency as
requested by Otsuka for the purpose of obtaining Marketing Authorizations in applicable countries in the Territory. Both Parties shall use appropriately qualified personnel for such activities, including personnel with local regulatory expertise. In
accordance with its responsibilities as the MAH in the Territory, Otsuka shall act as the authorized contact for the Regulatory Authorities in the Territory in connection with obtaining and maintaining Marketing Authorizations (subject to
ARIAD’s involvement as provided in Section 8.3), as well as in connection with the Final Manufacturing or Commercialization of the Product. For clarity, Otsuka is responsible for [***] and [***] for Marketing Authorizations in the
Territory, subject to ARIAD’s [***] as set forth in Section 8.6. 

  

	 	8.1.3	ARIAD shall be responsible for maintaining the Company Core Data Sheet (CCDS) / Company Core Safety Information (CCSI) for the Product. In the event that a change to the CCDS/CCSI necessitates a change to the local
labeling in the Territory, Otsuka shall be responsible for developing a proposed revised draft product label or package insert for each country in the Territory. ARIAD shall provide Otsuka with information and reasonable access to ARIAD’s
personnel, to support Otsuka’s changes to the Marketing Authorizations to modify the revised draft labeling. Otsuka shall promptly submit a change to applicable Marketing Authorizations in the Territory to modify the labeling.

  

	8.2	Subject to Section 4.6, the JDCC shall review and approve (a) the prescribing information, label and final packaging of the Product for the Territory to be submitted in connection with applications for
Marketing Authorizations, and shall subsequently review and approve any modifications thereto required by a Regulatory Authority or proposed by either Party, and (b) Otsuka’s proposals for, and the protocols of, all clinical or
observational studies, including post-marketing studies (other than protocols of Third Party Research Projects that are sponsored by a Third Party under the Third Party’s protocol without involvement by Otsuka in the design or conduct of such
trial or study as provided in Section 5.9). Otsuka shall prepare and submit the relevant documentation related to Marketing Authorizations (other than the initial JNDA) and other Registrations in compliance with Applicable Laws, following
review by the JDCC. For clarity, disputes regarding [***] are subject to resolution under Section 30.4. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 32 

	8.3	Otsuka shall prepare for and conduct meetings with the local Regulatory Authorities in consultation with ARIAD, and shall promptly: 

  

	 	(a)	notify ARIAD in advance of planned scheduled interactions with Regulatory Authorities relating to the Product and invite ARIAD to attend such interactions, at ARIAD’s cost, if permitted by the Regulatory Authority;

  

	 	(b)	notify ARIAD of spontaneous interactions with the Regulatory Authorities relating to the Product as soon as reasonably possible after the interaction; 

 

	 	(c)	prepare meeting minutes of such interactions with Regulatory Authorities and circulate the same to ARIAD, accompanied by a translation into English if the original minutes are not in English; and 

 

	 	(d)	address questions and requests from the Regulatory Authorities relating to the Product following consultation with ARIAD. 

Notwithstanding the foregoing, (i) ARIAD shall participate, at [***], (A) in meetings with the PMDA in order to
respond to PMDA questions relating to the initial JNDA (including questions relating to the Ongoing Study), and (B) at Otsuka’s reasonable request or ARIAD’s election if not requested by Otsuka, in meetings with the PMDA regarding CMC
matters, (ii) ARIAD shall promptly prepare all first drafts of answers to PMDA questions relating to the initial JNDA (including questions relating to the Ongoing Study), and (iii) upon Otsuka’s request, ARIAD shall prepare first
drafts of responses to questions and requests from other Regulatory Authorities; and all final drafts of responses to Regulatory Authority requests and questions relating to the Product shall be mutually agreed upon by the Parties through the JDCC.
In addition, ARIAD shall use commercially reasonable efforts to provide Otsuka with information, and access to ARIAD’s personnel, to support Otsuka’s preparation for and conduct of meetings with the local Regulatory Authorities relating to
the Product. For clarity, ARIAD shall take the lead and shall have primary responsibility (as between the Parties) for all regulatory matters relating to the activities conducted by ARIAD, including the Ongoing Study and CMC work for the Product.

  

	8.4	 Without limiting the foregoing, Otsuka shall (i) provide advance copies to ARIAD’s representatives on the JDCC of any proposed material
submission to, or material communication with, any Regulatory Authority to the extent they relate to the Marketing Authorization or otherwise to the Compound or Product, and shall consider in good faith, and accommodate when reasonably appropriate,
any requests by ARIAD to make any modification thereto, and (ii) keep ARIAD fully and promptly informed, throughout the Term, about all material communications received from the local Regulatory Authorities of the Territory concerning the
Product and/or the Compound, 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 33 

	 	
including providing ARIAD with a copy of all such material communications (without translation) no later than [***] after receipt by Otsuka and with a copy thereof translated into English as soon
as practicable thereafter. Without prejudice to full compliance by both Parties with any obligations established by Applicable Laws of each country in the Territory, any and all material communications to local Regulatory Authorities concerning the
Compound and/or a Product shall be submitted by Otsuka only after the relevant contents have been discussed with and approved by the JDCC; provided, however, that Otsuka shall not be required to delay any communication with or regulatory submission
to any applicable Regulatory Authority in a manner that affects Otsuka’s ability to comply with regulatory requirements or Applicable Laws. Otsuka shall provide English translation of all material documents relating to the Product to be
submitted by Otsuka or its Sublicensees to, or that are received by Otsuka or its Sublicensees from, Regulatory Authorities in a language other than English. On a semi-annual basis, Otsuka shall provide ARIAD with an itemized list of (a) all
written communications received from the local Regulatory Authorities in the Territory concerning the Product and/or the Compound during the prior [***] ([***]) [***]and (b) all documents and written communications relating to the Product
submitted by Otsuka or its Sublicensees to any Regulatory Authority in the Territory during the prior [***] ([***]) [***]. Upon the request of ARIAD, Otsuka shall provide ARIAD with untranslated copies of any such communications or documentation
itemized on such list. For clarity, (1) any communications with Regulatory Authorities or documents submitted to Regulatory Authorities that relate to Product quality shall not be governed by this Section 8.4 and shall be subject to
Section 12.5, and/or the Quality Agreements, and (2) any communications with Regulatory Authorities or documents and written communications submitted to Regulatory Authorities that relate to pharmacovigilance shall not be governed by this
Section 8.4 and shall be subject to Article 9 until the Pharmacovigilance Agreement becomes effective and thereafter shall be subject to the Pharmacovigilance Agreement. 

 

	8.5	If any material alterations, modifications or amendments of this Agreement or modification of the Product are required to comply with the request of any Regulatory Authority as prerequisites for the continuation of the
Marketing Authorization or the grant or the continuation of the Registration of the Product, or if the Marketing Authorization or Registrations are suspended or withdrawn by any said Regulatory Authority, each Party shall notify the other Party
immediately and the Parties shall use commercially reasonable efforts to agree upon a reasonable and mutually acceptable resolution thereof. 

  

	8.6	 ARIAD shall have the option to require that the Marketing Authorization for Japan be transferred to ARIAD or its Affiliate, [***]. Such option shall
be exercisable by ARIAD’s giving at least [***] ([***]) [***]prior written notice to Otsuka, to be given no [***] than the [***] of the [***] for the [***] and to take effect no [***] than the [***] of such [***]; provided that, at the time
ARIAD gives such written notice, ARIAD or its Affiliate shall have received a marketing authorization holder license or other form of approval from the PMDA to hold a marketing authorization in Japan in

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 34 

	 	
accordance with Applicable Laws and Regulatory Authority requirements, evidence of which license or approval shall be provided by ARIAD to Otsuka with ARIAD’s written notice. Upon receipt of
ARIAD’s option exercise notice, ARIAD shall initiate the transfer of the Japanese Marketing Authorization in accordance with the relevant procedures in Japan, and Otsuka shall cooperate with ARIAD to obtain such transfer as soon as reasonably
possible. On or after the date of the transfer of the Japanese Marketing Authorization to ARIAD, Otsuka shall [***], the [***] of the [***] for the Japanese Marketing Authorization, and ARIAD shall [***] Otsuka within [***] ([***]) [***]. The
Parties, through the JDCC, shall discuss and approve any changes to the label for the Product in Japan that are required or otherwise appropriate to reflect the change of MAH in Japan. Promptly upon ARIAD becoming the MAH for Japan, Otsuka shall
transfer all Japanese Regulatory Documentation to ARIAD that is necessary or useful for ARIAD’s performance of its obligations as the MAH for Japan. 

ARTICLE 9 – PHARMACOVIGILANCE 
  

	9.1	ARIAD shall own and manage the global safety database for the Product and ARIAD or its Affiliates shall be responsible for the timely reporting of all relevant adverse drug reactions/experiences, including those
associated with Product quality complaints, and aggregate safety data relating to the Compound, outside the Territory. The MAH in the Territory shall be responsible for the timely reporting of all relevant adverse drug reactions/experiences,
including those associated with Product quality complaints, and aggregate safety data relating to the Compound, in accordance with local pharmacovigilance legislation within the Territory. 

 

	9.2	ARIAD shall be responsible for global medical surveillance, risk management, global medical literature review and monitoring, and responses for the Compound to the appropriate Regulatory Authorities outside the
Territory. ARIAD shall be responsible for the interpretation, in light of ARIAD’s global pharmacovigilance data, of adverse events in the Territory of which ARIAD becomes aware, including adverse events reported to ARIAD by Otsuka. The MAH in
the Territory, in collaboration with ARIAD’s PV department, shall be responsible for local medical surveillance, risk management, medical literature review and monitoring within the Territory, and responses to the appropriate Regulatory
Authorities within the Territory. The MAH shall provide an English-translated copy of the final responses to Regulatory Authorities to ARIAD. 

  

	9.3	Otsuka shall implement and execute local Compound-specific risk management activities, in collaboration with ARIAD’s PV department, that are aligned with ARIAD’s global risk management strategies.

  

	9.4	 Further details of the Parties’ respective pharmacovigilance obligations and responsibilities (e.g., signal management, case processing and
reporting, aggregate reporting, risk management, health authority responses, safety data exchange, etc.) shall be set forth in a pharmacovigilance agreement that will be agreed to by the Parties (and

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 35 

	 	
their respective Affiliate(s), as appropriate) within [***] ([***]) [***] after the Effective Date (as it may be amended from time to time, the “Pharmacovigilance Agreement”). In
the event of a conflict between the terms of the Pharmacovigilance Agreement and the terms of this Agreement, the provisions of this Agreement shall govern; provided, however, that the Pharmacovigilance Agreement shall govern in respect of
pharmacovigilance, including safety and risk management, matters. In any event, no Named Patient Program (other than with respect to Preexisting Named Patients) or commercial launch or sale of the Product shall take place in the Territory until the
Parties have entered into the Pharmacovigilance Agreement. 

  

	9.5	Prior to executing the Pharmacovigilance Agreement, the Parties agree to work together in good faith to coordinate activities regarding pharmacovigilance with respect to the Product in accordance with this Article 9,
including by exchanging standard operating procedures and other information relevant to such pharmacovigilance activities as mutually agreed by the Parties. Without limiting the foregoing, prior to executing the Pharmacovigilance Agreement, in the
event Otsuka receives reports of adverse drug reactions/experiences or safety data relating to the Product (including Compound contained therein) (“Safety Information”) Otsuka shall send the Safety Information to ARIAD on source
documents, or other mutually agreed format, translated into English, via email or fax as soon as practicable, but, in any event, not later than [***] ([***]) [***] after it receives the Safety Information, and, in the event Otsuka receives any
information concerning any investigation, inquiry or other action by any Regulatory Authority concerning the safety of the Product, Otsuka shall send such information to ARIAD via email or fax as soon as possible, but in any event, no later than
[***] ([***]) [***] after Otsuka receives notice of such regulatory request, inquiry or other action. Otsuka shall not respond to any Regulatory Authority request or inquiry relating to the safety of the Product without discussing the issue with and
getting alignment with ARIAD. 

 Otsuka shall transmit Safety Information and Regulatory Authority inquiries concerning safety
of the Product to: 
 ARIAD Pharmaceuticals, Inc. 
  

			
	Address:		26 Landsdowne Street
			Cambridge, Massachusetts 02139-4234
	Tel:		+1 (617) 621-2200
	Fax:		+1 (888)-472-7962
	Email:		sae@ariad.com

 ARTICLE 10 – FORECASTS AND ORDERING 

 

	10.1	 As soon as practicable after the Effective Date, the Parties, through a project team or subcommittee of the JDCC, shall discuss the timeline and
activities required to commence the Final Manufacturing in the Territory. By [***], [***], the Parties or 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 36 

	 	
their Affiliates shall enter into a side letter agreement setting forth the Parties’ respective obligations regarding the Manufacture and supply of Bulk Product for Otsuka’s performance
qualification and process validation testing on the Product. In addition, within [***] ([***]) days after the Effective Date, the Parties or their Affiliates shall enter into one or more supply agreement(s) setting forth the Parties’ respective
obligations regarding the Manufacture and supply of Bulk Product for use in the Final Manufacturing of Product for clinical trials and for commercial sale and promotional sampling. At a later date, when applicable, the Parties or their Affiliates
shall enter into one or more supply agreement(s) setting forth the Parties’ respective obligations regarding the manufacture and supply of Secondary Packaged Product. Each such supply agreement (each a “Supply Agreement”) shall
contain reasonable and customary terms and conditions, including, e.g., specifications, changes to Manufacturing process or specifications, forecast, ordering, shipment and delivery, safety stock provisions, back-up facilities, failure to supply
(including appropriate remedies in the event of a failure to supply), audit and inspection, shortage allocation, acceptance and rejection, supply of Product for investigational use, including process validation and performance qualification testing,
as well as provisions consistent with this Article 10 and Article 11 of this Agreement. The Supply Agreements collectively shall govern ARIAD’s obligation to Manufacture or have Manufactured and supply or have supplied all of Otsuka’s and
its Sublicensees’ requirements of Bulk Product and Secondary Packaged Product for the Territory, including for clinical trials, promotional sampling and for commercial requirements. In the event of a conflict between the terms of a Supply
Agreement and the terms of this Agreement, the provisions of this Agreement shall govern; provided, however, that the Supply Agreement shall govern in respect of matters relating to the Manufacture and supply of Product and the Quality Agreements
shall govern in respect of matters relating to quality assurance for the Product. 

  

	10.2	ARIAD shall supply the Product to Otsuka in the Tablet Formulation, in finished drug product form, in bulk packaging (“Bulk Product”). In addition, at Otsuka’s request, ARIAD shall supply the
Product to Otsuka in secondary packaging and labeling, as then being finished, packaged and distributed by ARIAD in the US or the European Union (as requested by Otsuka) (“Secondary Packaged Product”) for Territory-specific labeling
and Commercialization in countries in the Territory other than Japan, South Korea and China, where Secondary Packaged Product is required or permitted by Applicable Law. The Parties shall enter into separate Supply Agreements and Quality Agreements
as deemed necessary by the JDCC for Secondary Packaged Products in each country in the Territory where such Secondary Packaged Product is to be supplied. In the event the Parties mutually agree through the JDCC to develop Product under this
Agreement in one or more New Formulation(s), the Parties shall discuss and agree upon which of them shall be responsible for the Manufacture and supply of bulk Product and for the Final Manufacturing of finished Product in such New
Formulation(s), but unless ARIAD otherwise agrees, ARIAD shall be responsible for the Manufacture and supply of bulk Product for [***], and Otsuka shall be responsible for the Final Manufacturing of finished Product in such New Formulation(s) for
[***]. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 37 

	10.3	Within the time period set forth in the Supply Agreement, Otsuka shall notify ARIAD in advance of the anticipated First Commercial Sale in each country of the Territory. Such notification shall include a preliminary
estimate of the quantity of the Product in each then-available dosage strength needed for commercial launch in the Territory. Otsuka may change the estimated date of the First Commercial Sale and the estimated quantity of the Product needed for such
commercial launch at any time by notifying ARIAD; provided, however, that Otsuka shall provide ARIAD with an estimate of the minimum amount of the Product that shall be necessary for the first commercial launch in the Territory (the “Launch
Quantities”), prior to the anticipated First Commercial Sale in the Territory, within the time period set forth in the applicable Supply Agreement. 

  

	10.4	In the [***] of each [***] in accordance with the Supply Agreement, Otsuka shall provide ARIAD with a written [***] ([***])-[***] rolling Forecast of its anticipated [***] requirements for the Product (expressed as the
number of tablets of each then-available dosage strength) in the Territory (each a “Forecast”). ARIAD shall use commercially reasonable efforts to ensure sufficient manufacturing capacity and Raw Materials to meet each Forecast.
Each Forecast is a non-binding estimate and shall not obligate Otsuka to purchase the volume of the Product set forth in it nor shall it oblige ARIAD to supply such volume; provided, however, that, beginning on the date of obtainment of the first
Pricing and Reimbursement Approval in the Territory and continuing for the remainder of the Term, that portion of the volume of the Product Forecasted for the binding period (number of months) set forth in the Supply Agreement (which shall be
consistent with the binding forecast requirements under ARIAD’s contract manufacturing agreement with [***] as of the Effective Date) which is approved by ARIAD shall be binding upon Otsuka and ARIAD. The binding portion of the Forecast shall
be deemed approved by ARIAD unless ARIAD provides written notice of disapproval to Otsuka within [***] ([***]) [***] of receipt of the Forecast. ARIAD shall not be obligated to Manufacture or supply Otsuka with quantities of the Product in excess of
the approved binding portion of the most recent Forecast. 

  

	10.5	 Otsuka shall order the Product by submitting written purchase orders, in such form as the Parties shall agree from time to time, to ARIAD specifying
the quantities of each dosage strength of the Product ordered, the desired shipment date for the order and any special shipping instructions. Otsuka shall submit each purchase order to ARIAD in advance of the desired delivery date specified in such
purchase order, within the number of days (lead time) set forth in the Supply Agreement. No purchase order shall be binding upon ARIAD if such purchase order is (a) inconsistent with the approved binding portion of the Forecast, and
(b) rejected in writing by ARIAD within [***] ([***]) [***] of receipt of the purchase order. In the event that a purchase order is rejected, ARIAD shall provide the reasons for rejection in writing to Otsuka and ARIAD and Otsuka shall
cooperate in good faith to resolve any supply issues raised by such order. For clarity, ARIAD shall have no right to reject any purchase order that is consistent with the approved binding portion of the Forecast. Any purchase orders for the Product
submitted by Otsuka to ARIAD shall reference this Agreement and shall be 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 38 

	 	
governed exclusively by the terms of the Supply Agreement and the terms contained herein (to the extent not in conflict with the Supply Agreement). The Parties hereby agree that the terms and
conditions of the Supply Agreement and this Agreement (to the extent not in conflict with the Supply Agreement) shall supersede any term or condition in any order, confirmation or other document furnished by Otsuka or ARIAD that is in any way
inconsistent with, or supplementary to, the terms and conditions of the Supply Agreement and this Agreement (to the extent not in conflict with the Supply Agreement), unless expressly accepted in writing by the other Party. 

 

	10.6	Otsuka shall carry a reasonable quantity of inventory of the Product sufficient to avoid Product shortages in the Territory in the event of an interruption to the supply chain, including a safety stock of Product (in
bulk or final packaging) in quantities sufficient to meet demand as set forth in the Supply Agreement. 

 ARTICLE 11 –
SHIPMENT AND DELIVERY 
  

	11.1	Delivery Terms. ARIAD shall use commercially reasonable efforts to deliver each lot of the Product in the quantity and by the delivery date specified for it on Otsuka’s purchase order. At the time of
Delivery, the Product in the Tablet Formulation shall have no less than [***] ([***]) [***] of remaining shelf life assuming approved Product shelf life of [***] ([***]) [***] for all strengths. If the approved Product shelf life is greater than
[***] ([***]) [***] for any strength, the Product in the Tablet Formulation shall have no [***] than [***] ([***]%) of the approved Product shelf life remaining at the time of Delivery. If the approved Product shelf life is less than [***] ([***])
[***] for any strength, the [***] of remaining shelf life at the time of Delivery shall be as set forth in the applicable Supply Agreement(s). The Launch Quantities shall be shipped to Otsuka sufficiently in advance of the anticipated First
Commercial Sale in the Territory, in order to allow Otsuka sufficient time to complete Final Manufacturing in advance of the anticipated First Commercial Sale in the Territory, provided that Otsuka submits a binding purchase order for the Launch
Quantities before the anticipated First Commercial Sale in accordance with the lead time requirements set forth in the Supply Agreement. 

  

	11.2	Deliveries shall be made [***] (Incoterms 2010) at the [***], the address of which shall be notified by Otsuka to ARIAD in writing in advance of the first shipment, or such other location as the Parties may agree in
writing (such [***] or other agreed location, the “Destination Terminal”). Delivery shall take place when the Product shipment reaches the Destination Terminal (“Delivery”); however, title to, and risk in, the
Product shall pass to Otsuka when Product is loaded at [***]. 

  

	11.3	 Otsuka shall be the importer of record for all Product supplied under this Agreement and the Supply Agreement. Otsuka shall be responsible for
clearing the Product through customs in the Territory [***]. For clarity, as the importer of record for the Product, Otsuka shall be responsible for [***]. At all times, Otsuka shall maintain, [***], a valid import license for the Products, and
shall be responsible, [***], for all 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 39 

	 	
required documentation and communications with the applicable customs office in connection therewith. ARIAD shall provide assistance with such documentation and communications upon Otsuka’s
reasonable request (e.g., by providing export documents or assisting with documentation as the exporter of the Product.) 

  

	11.4	ARIAD shall provide its standard international shipping and handling specifications to Otsuka upon request. 

  

	11.5	Acceptance and Rejection. The Parties agree to the following provisions, which shall be incorporated in substantially the same form into the Supply Agreement. 

 

	 	11.5.1	Product Testing. At the point of Delivery in accordance with Section 11.2, Otsuka shall visually inspect all shipments of the Product to identify any damage to the external packaging. Otsuka may reject any
shipment (or portion thereof) of the Product that is damaged or is otherwise Non-Conforming by returning a representative sample of the damaged or Non-Conforming Product or other reasonable evidence of damage, and providing to ARIAD written notice
of such rejection and the reasons therefor within [***] ([***]) [***] Delivery of such Product. If Otsuka does not so reject any shipment (or portion thereof) of the Product within [***] ([***]) [***] of Delivery of such Product, Otsuka shall be
deemed to have accepted such shipment of the Product; provided, however, that in the case of the Product having any Latent Defect, Otsuka shall notify ARIAD promptly once it becomes aware that a Product contains a Latent Defect and subsequently may
reject such Product by giving written notice to ARIAD of Otsuka’s rejection of such Product and shipping a representative sample of such Product to ARIAD within [***] ([***]) [***] becoming aware of such Latent Defect, which notice shall
include a description of the Latent Defect. 

  

	 	11.5.2	 Replacement of Product and Dispute Procedure. If Otsuka rejects, in accordance with Section 11.5.1 any shipment (or portion thereof) of
the Product as Non-Conforming and ARIAD disagrees that the alleged Non-Conformance exists, ARIAD shall so notify Otsuka in writing (an “Objection Notice”) within [***] ([***]) [***] of receipt of Otsuka’s notice of rejection
and the following procedures shall apply: ARIAD shall inspect the returned representative sample of Product and its Reference Sample and attempt to reach agreement with Otsuka as to whether or not the Product is Non-Conforming. If Otsuka and ARIAD
fail within [***] ([***]) [***] after delivery of the Objection Notice to agree as to whether the Product is Non-Conforming, representative samples of the batch of the Product in question and their Reference Samples shall be submitted to a
mutually-acceptable, independent, qualified Third Party laboratory or consultant for analysis or review. The results of such evaluation shall be binding upon the Parties. The Parties initially shall share equally the cost of such evaluation, except
that the Party that is determined to have been incorrect in its determination of whether the Product was or was not Non-Conforming shall 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 40 

	 	
assume the responsibility for, and pay, the costs of any such evaluation and reimburse the other Party for any amounts previously paid to the independent laboratory or consultant in connection
with that determination. 

  

	 	11.5.3	Cost of Replacement of Rejected Product. If any shipment of the Product is rejected by Otsuka due to an alleged Non-Conformance, Otsuka’s duty to pay all amounts payable to ARIAD in respect of the rejected
Product shall be suspended unless and until there is a determination by the independent laboratory or consultant in support of ARIAD’s Objection Notice, or the Parties otherwise reach agreement that the Product was not Non-Conforming. If only a
portion of a shipment is rejected, Otsuka’s duty to pay the amount allocable to the Non-Conforming portion only shall be suspended. 

  

	 	11.5.4	Return of Rejected Product. If a shipment or partial shipment is rejected by Otsuka pursuant to the provisions of Section 11.5.1 and (i) ARIAD does not provide an Objection Notice within the [***]
([***]) [***] period set forth in Section 11.5.3, (ii) the Parties agree that the Product is Non-Conforming within the [***] ([***]) [***] period set forth in Section 11.5.3, or (iii) there is not a determination by the
independent laboratory or consultant in support of ARIAD’s Objection Notice, Otsuka shall return to ARIAD at ARIAD’s request and expense (or, at the election of ARIAD, destroy at ARIAD’s cost and provide evidence of such destruction
to ARIAD) any such rejected Product (provided that if the Product has been packaged by or on behalf of Otsuka at the time of rejection, Otsuka shall not be obliged to remove any packaging prior to its return). ARIAD shall (i) credit the
original invoice in respect of the rejected Product and reimburse Otsuka for any duties, freight, insurance, handling or other charges incurred by Otsuka in respect of such rejected Product, and (ii) adjust the invoice to Otsuka for the Product
that was not rejected, payment of which is due in accordance with the terms of the original invoice. Except as set forth in Article 14 and Section 22.2, such credit or adjustment shall be ARIAD’s sole liability, and Otsuka’s sole
remedy, with respect to any rejected Product. 

  

	 	11.5.5	Supply of Replacement Product. During the pendency of any rejection discussions, upon Otsuka’s request, ARIAD shall use commercially reasonable efforts to supply Otsuka with additional Product which Otsuka
shall purchase on the same terms as the Product that is the subject of the rejection discussions. For clarity, the lead time for any such orders shall be no less than the lead time set forth in the applicable Supply Agreement. 

 

	 	11.5.6	Detection of Latent Defect by ARIAD. If ARIAD detects a Latent Defect in any Product supplied to Otsuka, ARIAD shall notify Otsuka in writing, specifying the affected lots, and credit Otsuka for the
Non-Conforming Product as provided in Section 11.5.4. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 41 

	 	11.5.7	No Product Returns Policy. Except as expressly provided elsewhere in this Section 11.5 or in Article 14, no Products supplied by or on behalf of ARIAD to Otsuka may be returned by Otsuka to ARIAD after they
have been Delivered to Otsuka at the location designated under Section 11.2. 

 ARTICLE 12 – MANUFACTURE AND FINAL
MANUFACTURING OF THE PRODUCT 
  

	12.1	Manufacture of the Product. ARIAD shall use commercially reasonable efforts to Manufacture or have Manufactured the Product in accordance with the Specifications, cGMP and Applicable Laws in the country of
Manufacture and, to the extent applicable, in the Territory. 

  

	12.2	Packaging. ARIAD shall package the Product in bulk packaging in accordance with the standard operating procedures to be used by ARIAD in Manufacturing the Product under this Agreement in accordance with the
Specifications and requirements notified to it with sufficient advance notice by Otsuka to comply with Applicable Laws. 

  

	12.3	 Changes to the Specifications or to the Manufacturing Process. If ARIAD proposes (a) a change to the Specifications or the Raw Materials,
equipment (other than changes for maintenance, repair, and like-for-like replacement) or process used to Manufacture the Product, or (b) a change to the procedures or facilities used to Manufacture the Product (collectively, the
“Manufacturing Process”) that, in the case of (a) or (b) would require approval of the applicable Regulatory Authority in the Territory or would require an amendment of any Marketing Authorization application or
Registration, ARIAD shall provide written notice to Otsuka. If a change to the Specifications, Raw Materials, equipment or Manufacturing Process is required by one or more Regulatory Authorities or regulatory authorities outside the Territory or
shall be applied globally, including for the manufacture of Products inside and outside the Territory, and if such change would require approval of any Regulatory Authority in the Territory or an amendment of any Marketing Authorization application
or Registration, ARIAD shall provide Otsuka with all information needed to amend the Marketing Authorization application or Registration and/or obtain the approval of the Regulatory Authority, as applicable, and the Parties shall cooperate with each
other in obtaining any necessary modifications to any Registrations in the Territory to allow such change to be implemented. If the proposed change is required by a Regulatory Authority, then such notice shall include disclosure of the Regulatory
Authority request and relevant correspondence. If any change to the Specifications, Raw Materials, equipment or Manufacturing Process is not required by any Regulatory Authority (or any regulatory authorities outside the Territory) and shall not be
applied globally and would require approval of any Regulatory Authority in the Territory or an amendment of any Marketing Authorization application or Registration, ARIAD shall not implement such change without the prior written approval of Otsuka.
If the change is required by a Regulatory Authority inside the Territory but not in any other part of the world, then Otsuka shall bear any expenses of implementing such change. If the change proposed

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 42 

	 	
by ARIAD is required only by one or more regulatory authorities outside the Territory, or is not required by any Regulatory Authority, then ARIAD shall bear any expenses of implementing such
change. If the change is required by one or more Regulatory Authorities inside the Territory and by one or more regulatory authorities outside the Territory, the Parties shall share the expenses of implementing such change in proportion to the last
calendar year’s Net Sales in the Territory as a percentage of the global net sales of the Product (calculated in the same manner as Net Sales) during the same time period, as may be reasonably estimated by ARIAD to the extent that complete
global sales figures are not available. For the avoidance of doubt, Otsuka shall only be required to bear expenses of implementing a change to the Specifications, Raw Materials, equipment or Manufacturing Process if such change is mandated by a
Regulatory Authority inside the Territory, and ARIAD shall solely bear the expenses of implementing such a change that is not mandated by any Regulatory Authority, including any such non-mandated change that Otsuka approves and that requires an
amendment of a Marketing Authorization application or Registration or approval of a Regulatory Authority in the Territory. The Parties agree that the notification and approval procedures with respect to changes to the Specifications and the
Manufacturing Process set forth in this Section 12.3 shall take effect commencing on filing of an application for Marketing Authorization of the applicable Product. For clarity, ARIAD shall have the right, at its sole cost, to change equipment
for maintenance, repair, and like-for-like replacement, and to make other changes that ARIAD reasonably determines shall not require approval of any Regulatory Authority or affect the Marketing Authorization application(s) or Registration(s) in the
Territory, without notice to or consent of Otsuka. Further for clarity, the Quality Agreements shall contain change control procedures, and any changes made to the Specifications, Raw Materials, equipment or Manufacturing Process shall be made in
accordance with the Quality Agreements and in compliance with cGMP and Applicable Laws. 

  

	12.4	Final Manufacturing. Except as set forth in Section 10.2, Otsuka shall be responsible for the Final Manufacturing of all Product, including performing primary and secondary packaging, labeling and providing
product inserts in accordance with the Registrations, final release and stability testing in accordance with the Regulatory Authorization in the country in the Territory that is the intended market for such lot of Product, and in accordance with all
Applicable Laws. ARIAD shall support Otsuka’s stability testing of Finally Manufactured Product by conducting a stability testing program for the Product in Otsuka’s packaging and providing reports and updates to Otsuka at regular
pre-defined time points. ARIAD shall bear the costs of such stability testing program for [***] ([***]) [***] per strength per packaging size of Finally Manufactured Product per [***]. If Otsuka requests that the stability testing program include
additional batches of per strength per packaging size of Finally Manufactured Product per [***], Otsuka shall bear any additional costs relating thereto. 

  

	12.5	 Quality. Each Party agrees to give the other Party full, accurate and prompt information in writing with regard to quality defects and quality
complaints associated with the use of the Product within the Territory in strict accordance with the terms and 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 43 

	 	
conditions of the quality technical agreements described below. The details of quality obligations and responsibilities of the Parties, including responsibility for submissions of reports to
Regulatory Authorities, shall be set forth in one or more separate quality technical agreements (each, a “Quality Agreement”) that shall be agreed to by the Parties (and their respective Affiliate(s), as appropriate) within [***]
([***]) days after the Effective Date (or such longer period as agreed by the Parties but in any event at least [***] ([***]) [***] prior to the first shipment of Product to Otsuka). In any event, no commercial launch or sale of the Product shall
take place in the Territory until the Parties have entered into a Quality Agreement for the relevant Product and country. Prior to executing the Quality Agreements, the Parties agree to work together in good faith to coordinate regarding quality
matters with respect to the Product in the Field, including by exchanging standard operating procedures and other relevant information. In the event of a conflict between the terms of the Quality Agreements and the terms of this Agreement, the
provisions of this Agreement shall govern; provided, however, that the Quality Agreements shall govern in respect of quality matters. 

  

	12.6	Japanese Pharmaceutical Affairs Law, Regulatory Authority Inspection. ARIAD shall, as a foreign manufacturer and supplier of the Product, comply with the Japanese Pharmaceutical Affairs Law, including with
respect to the content and filing of the Quality Agreement for Japan and accreditation as a manufacturer at the time of filing the JNDA for Product. ARIAD shall advise Otsuka as soon as reasonably practicable after it becomes aware of any
inspection, or request for any inspection, by any governmental authority, including the FDA or any Regulatory Authority or any environmental regulatory authority, of a facility (whether owned by ARIAD or an Affiliate or a Third Party contract
manufacturer) where such inspection concerns the manufacture, handling, storage or supply of Product supplied or to be supplied to Otsuka (a “Product-Related Inspection”). ARIAD shall, to the extent it is permitted to do so, provide
a summary report of the results of a Product-Related Inspection to Otsuka as soon as reasonably practicable after such Inspection. Nothing contained within this Section 12.5 shall restrict the right of either Party to make a timely report to
any Regulatory Authority or take other action that it is required to take by Applicable Laws. 

 ARTICLE 13 –
QUALITY ASSURANCE 
  

	13.1	Specifications; Testing for Manufacture of Product. 

  

	 	13.1.1	Batch Testing. ARIAD shall have standard analytical testing performed on each batch of the Product to be shipped to Otsuka to verify that it meets the Specifications, according to the procedure described in the
corresponding documentation, and ARIAD shall provide the results of such analytical testing to Otsuka. 

  

	 	13.1.2	 Certificate of Analysis. If required under Applicable Laws in the relevant country of the Territory, in connection with shipment of any batch
of the 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 44 

	 	
Product, ARIAD shall provide Otsuka with a certificate of analysis for the Product in finished product, bulk-packaged form (the “Certificate of Analysis”). Such Certificate of
Analysis shall certify with respect to each shipment (i) the batch number of the Product delivery; and (ii) that the Product Delivered conforms to the Specifications, as well as any further information required by the relevant Regulatory
Authorities in the Territory. Otsuka shall be under no obligation to accept any shipment of the Product without an accompanying Certificate of Analysis. 

  

	 	13.1.3	Certificate of Conformance. If required under Applicable Laws in the relevant country of the Territory, in connection with shipment of any batch of the Product, ARIAD shall provide Otsuka with a document
certifying with respect to a particular batch (identified by batch number) that such batch was Manufactured in accordance with applicable cGMP in the country of Manufacture, all other Applicable Laws, and the Specifications (the “Certificate
of Conformance”). 

  

	13.2	cGMP Compliance and QA Audits for Manufacture of Product. ARIAD shall be responsible for performing cGMP compliance and quality assurance reviews and inspections of its Third Party manufacturers in accordance
with ARIAD’s standard procedures regarding the same. 

  

	13.3	Quality Control Problems. In addition, in the event Otsuka or ARIAD identifies a quality problem after Delivery to Otsuka from ARIAD or its representative with respect to any batch of the Product, then, if
requested by Otsuka in writing, ARIAD shall authorize Otsuka to review at ARIAD’s facilities the full batch records corresponding to the applicable batch. 

  

	13.4	Reference Samples. ARIAD shall retain sufficient samples from each batch of Product (each, a “Reference Sample”) to allow retesting to be performed. In no event shall the amount retained from
each batch be less than the amount needed to perform [***] ([***]) complete sets of necessary tests excluding bioburden. ARIAD shall retain each Reference Samples from the date of production until the date that is [***] ([***]) [***] following the
expiry date for the relevant batch (or, if longer, the minimum period required by Applicable Laws). 

  

	13.5	Certificate of Analysis for Final Release. Otsuka shall issue a Certificate of Analysis compliant with the Product Registration for purposes of final release of the Product for sale in the Territory. Otsuka shall
provide ARIAD with copies of such Certificates of Analysis upon request. 

  

	13.6	cGMP Compliance and QA Audits for Final Manufacturing. Otsuka shall be responsible for performing cGMP compliance and quality assurance reviews and inspections of the sites used for Final Manufacturing in
accordance with Otsuka’s standard procedures regarding the same. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 45 

	13.7	Inspection and Compliance Audits. 

  

	 	13.7.1	Each Party (the “Inspected Party”) shall permit the other Party (the “Inspecting Party”), or the Inspecting Party’s authorized representative, to enter the Inspected Party’s
premises, as well as the premises of the Inspected Party’s Affiliates, Sublicensees or Third Party contractors (to the extent the Inspected Party has the right to allow the Inspecting Party to audit or inspect such Third Parties) where the
Product undergoes Manufacture or Final Manufacturing or is stored, during normal business hours and upon reasonable advance notice, to audit and verify compliance by the Inspected Party, its Affiliates and Third Party contractors with Applicable
Laws, this Agreement and the Quality Agreements and to confirm the correction of any deficiencies previously identified, in each case to ensure safe Manufacture and Final Manufacturing of the Product, or in connection with any recall contemplated by
Section 14.1 of this Agreement. Each Party shall use commercially reasonable efforts to obtain the rights for the other Party to audit and inspect its Third Party contractors that Manufacture, store or conduct Final Manufacturing. No such
inspection by an Inspecting Party shall relieve the Inspected Party of any obligation under this Agreement, the Pharmacovigilance Agreement or the Quality Agreements. 

 

	 	13.7.2	Such audit rights shall include the right to examine any internal procedures or records of the Inspected Party, its Affiliates or Third Party contractors relating to the Manufacture or Final Manufacturing of Product.
The Inspected Party shall give and shall cause its Affiliates and Third Party contractors to give all necessary assistance for completion of the audit by the Inspecting Party. All information obtained by Inspecting Party or its authorized
representative in any such inspection or audit, including without limitation the findings and results related thereto, shall be the confidential information of the Inspected Party. 

 

	 	13.7.3	In the event that any Regulatory Authority or any other competent governmental authority in the country of Manufacture or Final Manufacturing carries out or gives notice of its intention to carry out any inspection or
audit of a Party, or its Affiliates or Third Party contractors in relation to the Manufacture or Final Manufacturing of Product, such Party shall notify the other Party in reasonable detail as soon as possible and shall use commercially reasonable
efforts to ensure that the other Party shall have the right to be present at any such inspection or audit to the extent specifically related to the Manufacture or Final Manufacturing of Product. 

 

	 	13.7.4	 The Inspected Party shall take, or cause its Affiliates or Third Party contractors to take, as soon as practicable, all actions necessary to correct
any deficiency or non-compliance with this Agreement, the Pharmacovigilance Agreement or the Quality Agreements that is identified 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 46 

	 	
in the course of any audit by the Inspecting Party or any Regulatory Authority. The Inspected Party shall provide the other Party with written documentation concerning the steps taken and any
further testing or internal or external auditing to confirm that the deficiency or non-compliance has been corrected. 

ARTICLE 14 – RECALLS AND PRODUCT WITHDRAWAL 
  

	14.1	Notice. Each Party shall make every reasonable effort to notify the other Party promptly following the first Party’s determination that any event, incident, or circumstance has occurred that may result in
the need for a Product Withdrawal anywhere in the world (including in the Territory) or a Recall in the Territory. Such Party shall include in such notice the reasoning behind such determination, and any supporting facts. 

 

	14.2	Product Withdrawal. With respect to a Product Withdrawal within the Territory, immediately after receipt of such notification, the JDCC (or its co-chairpersons) shall discuss and, unless the Product Withdrawal is
mandated by a Regulatory Authority, shall attempt to agree on whether to voluntarily implement the Product Withdrawal within the Territory. If a Regulatory Authority mandates that the Product Withdrawal within the Territory be implemented then
Otsuka, in consultation and coordination with ARIAD, shall initiate the Product Withdrawal within the Territory as and to the extent mandated by the Regulatory Authority and in compliance with Applicable Laws. In the case of a Product Withdrawal
that is not mandated by Regulatory Authority, if the JDCC (or its co-chairpersons) fail(s) to agree within a reasonably appropriate time period (depending upon the circumstances) whether to voluntarily implement or undertake a Product Withdrawal
within the Territory, then ARIAD shall have the right to make the determination whether or not to voluntarily implement such Product Withdrawal within the Territory; provided that, to the extent practicable prior to deciding to initiate a Product
Withdrawal within the Territory, ARIAD shall consult with Otsuka’s JDCC co-chairperson or Senior Officer, and shall consider Otsuka’s reasonable comments in good faith. Notwithstanding that ARIAD shall have the right to decide whether or
not to initiate a voluntary Product Withdrawal, if Otsuka, as the distributor of Product in the Territory, is responsible for carrying out and physically recovering the withdrawn Product in the Territory, Otsuka shall carry out such Product
Withdrawal activities in coordination and consultation with ARIAD, in a manner which enables ARIAD to meet its regulatory requirements as expeditiously as possible, and in compliance with all Applicable Laws. If ARIAD does not choose to undertake a
voluntary Product Withdrawal in the Territory, despite Otsuka’s written notice to ARIAD that such Product Withdrawal should be undertaken, then, notwithstanding anything to the contrary herein, ARIAD shall indemnify and hold harmless Otsuka
from and against any Losses that may arise or result thereafter from ARIAD’s failure to undertake such Product Withdrawal following such written notice from Otsuka. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 47 

	14.3	Recall. If a Regulatory Authority mandates that a Recall be implemented or undertaken by Otsuka in the Territory, Otsuka, in consultation and coordination with ARIAD, shall initiate the Recall as and to the
extent mandated by the Regulatory Authority and in compliance with Applicable Laws. With respect to a Recall in the Territory that is not mandated by a Regulatory Authority, (i) the Parties’ JDCC co-chairs shall discuss and attempt to
agree on whether to voluntarily implement the Recall and (ii) if the Parties’ JDCC co-chairs fail to agree within a reasonably appropriate time period (depending upon the circumstances), then Otsuka shall have the right to make the
determination whether or not to voluntarily implement a Recall in the Territory. If Otsuka does not choose to undertake a voluntary Recall in the Territory, despite ARIAD’s written notice to Otsuka’s JDCC co-chair that such Recall should
be undertaken, then, notwithstanding anything to the contrary herein, Otsuka shall indemnify and hold harmless ARIAD from and against any Losses that may arise or result thereafter from Otsuka’s failure to undertake such Recall following such
written notice from ARIAD. 

  

	14.4	Expenses. All costs and expenses of any Recall or Product Withdrawal in the Territory (including Otsuka’s previously-incurred costs of Final Manufacturing and the Transfer Price previously paid by Otsuka for
the destroyed, retrieved, withdrawn or recalled Product) shall be borne by ARIAD, unless and to the extent the Recall or Product Withdrawal is based on the fault of Otsuka or its Sublicensees, Affiliates, or Subcontractors in which case such costs
and expenses shall be borne by Otsuka. 

 ARTICLE 15 – MARKETING AND DISTRIBUTION OF THE PRODUCT 

 

	15.1	Otsuka shall store and Commercialize the Product at its cost and in accordance with applicable cGMP and any other Applicable Laws and Industry Guidelines in each country of the Territory. 

 

	15.2	Otsuka shall use commercially reasonable efforts to launch the Product no later than [***] ([***]) [***] after the receipt of Pricing and Reimbursement Approval on a country-by-country basis, provided that ARIAD has
timely complied with its obligations to supply Product to Otsuka as expressly set forth in this Agreement and the Supply Agreement. At least [***] ([***]) [***] prior to the expected date of the receipt of the first Pricing and Reimbursement
Approval, Otsuka shall prepare and submit to the JDCC a sales and marketing plan for the Product in [***], [***] and [***] (the “Commercialization Plan”) for the JDCC’s review and discussion. The Commercialization Plan shall be
updated and shared with ARIAD via the JDCC at least annually and shall be expanded to cover additional countries in the Territory, as applicable. Disputes over the content of the Commercialization Plan shall be resolved in accordance with
Section 4.6, and shall not be subject to arbitration or any other form of external dispute resolution. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 48 

	15.3	Promotion. 

  

	 	15.3.1	Otsuka shall use all commercially reasonable efforts, at its cost, to promote diligently the sale of, and stimulate interest in, and use of, the Product in accordance with the Marketing Authorization to Healthcare
Professionals in all countries within the Territory where Marketing Authorization has been received, in accordance with the terms of this Agreement. 

  

	 	15.3.2	Promptly after the filing of the first JNDA in Japan, ARIAD shall provide Otsuka with copies, in English, of ARIAD’s marketing, advertising and promotional materials, used for the Product in the USA and the United
Kingdom. ARIAD shall keep Otsuka reasonably informed regarding any updates to such marketing, advertising and promotional materials, in English. 

  

	 	15.3.3	Otsuka’s promotion of the Product in the Territory shall be consistent with the global Product profile and positioning provided to it in writing by ARIAD (the “Global Product Profile”). The JDCC
shall appoint a project team with representatives of each Party to discuss and generate a Territory specific Product profile and positioning plan for the promotion and marketing of the Product in the Territory that is consistent with the Global
Product Profile (the “Territory Product Profile”). The project team representatives shall gather and consider input from each Party with respect to the Territory Product Profile. On or before [***] ([***]) [***] prior to the
anticipated launch of the Product in a country in the Territory and thereafter in such country not later than [***] of [***] throughout the Term, Otsuka shall supply to ARIAD, via the JDCC, the marketing and promotion plans (including the planned
number of primary and total detail numbers to target Healthcare Professionals, consistent with Section 15.5.2) that Otsuka intends to implement with respect to the marketing and promotion of the Product in [***], [***] and [***] during the next
calendar year. Such marketing and promotion plans shall be consistent with the Global Product Profile and the Territory Product Profile. Otsuka shall keep ARIAD informed of its promotional and marketing activities of the Product in the Territory
through the JDCC or project team meetings. 

  

	 	15.3.4	 All initial print marketing, advertising and promotional materials to be used upon the launch of the Product in any country in the Territory, and all
training manuals for Otsuka’s medical science liaisons and sales representatives shall be developed and prepared by Otsuka in accordance with ARIAD’s trademark and global branding guidelines provided to Otsuka in writing in advance by
ARIAD (“Trademark Guidelines”), the Global Product Profile and the Territory Product Profile, and provided to ARIAD for review in advance of the launch of the Product in such country (with English translation). ARIAD shall provide
any comments or request changes to such materials within [***] ([***]) [***] of receipt of such materials, and Otsuka shall make all changes requested by ARIAD to the extent necessary to comply with the Trademark Guidelines, the Global

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 49 

	 	
Product Profile, or the Territory Product Profile, provided that such changes are consistent with Applicable Law and Industry Guidelines, and Otsuka shall provide the finalized copies of such
print materials (with English translation) to ARIAD free of charge. For clarity, ARIAD shall not be obliged to review the materials for compliance with local laws and regulations, which shall be Otsuka’s sole responsibility. 

 

	 	15.3.5	Unless requested by ARIAD, after the launch of the Product in a particular country in the Territory, Otsuka shall not be obligated to submit any additional marketing, advertising, promotional or training materials
concerning such Product in such country provided that such materials are consistent with the Trademark Guidelines, the Global Product Profile and the Territory Product Profile. Upon ARIAD’s reasonable request, Otsuka shall provide ARIAD with
untranslated copies of all current print marketing, advertising and promotional materials for the Product in the Territory for ARIAD’s review to ensure such materials are consistent with the Trademark Guidelines, the Global Product Profile and
the Territory Product Profile. 

  

	 	15.3.6	Otsuka shall not promote or advertise the Product for any indication or patient segment that is not included in the Marketing Authorization of the Product. 

 

	15.4	Training.  

  

	 	15.4.1	Promptly after the Effective Date, ARIAD shall provide Otsuka with copies of ARIAD’s training manuals for its sales representatives for the Product outside the Territory. ARIAD shall keep Otsuka reasonably informed
regarding any updates to such training manuals. 

  

	 	15.4.2	Otsuka’s training manuals for its sales representatives shall be consistent with the training manuals provided by ARIAD pursuant to Section 15.4.1. 

 

	 	15.4.3	ARIAD shall provide Otsuka’s trainers remote access via ARIAD’s global training portal (known as [***]) to ARIAD’s internal training programs for ARIAD’s sales representatives (and trainers) who
market and promote the Product outside the Territory. Such training shall be in English and provided without charge to Otsuka, provided that Otsuka shall bear the out-of-pocket travel and other expenses associated with its trainers attending any
in-person training sessions that may be held by ARIAD. 

  

	15.5	Market Development and Staffing. 

  

	 	15.5.1	Otsuka undertakes to Commercialize the Product in the Field throughout the Territory in accordance with the Commercialization Plan. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 50 

	 	15.5.2	Without limiting the generality of the obligations set forth in Section 15.5.1, Otsuka shall allocate to the Otsuka Iclusig Staff a sufficient number of appropriately qualified personnel, including contracted Third
Party medical representatives (provided that the percentage of such contracted Third Party medical representatives used by Otsuka in Japan to Commercialize the Product shall be [***]), to successfully Commercialize the Product in the Field in the
Territory and Otsuka shall allocate to the Otsuka Iclusig Staff a sufficient number of appropriately qualified personnel, including Subcontractors, to perform Final Manufacturing in the Field in the Territory. The Otsuka Iclusig Staff that
Commercializes the Product, including contracted Third Party medical representatives, shall be experienced in the promotion of hematological oncology products (and for clarity, [***] shall be considered a hematological oncology product for purposes
of this Agreement). Otsuka shall use commercially reasonable efforts to provide details in the primary and second position that are appropriate in light of [***], and also taking into account the approved indications in the Territory. Otsuka shall
promote the Product in the primary position in all details (on a country-by-country basis) at least until the earlier of (A) the [***] ([***]) anniversary of the First Commercial Sale of the Product in such country, and (B) the date on
which [***]. Notwithstanding the foregoing, however, Otsuka shall promote the Product in the primary position in all details in each country in the Territory for at least ([***]) [***] after the First Commercial Sale of the Product (on a
country-by-country basis). 

  

	 	15.5.3	Otsuka represents and certifies that all Otsuka Iclusig Staff and Subcontractors have never been and are not currently debarred pursuant to the US Generic Drug Enforcement Act of 1992, 21 U.S.C. §335(a), as
amended, or any similar law or regulation (collectively “Debarred”), excluded by the US Office of Inspector General pursuant to 42 U.S.C. § 1320a-7, et seq. or any agency from participation in any health care program
(collectively “Excluded”) or otherwise disqualified or restricted by the US FDA pursuant to 21 C.F.R. 312.70, or Regulatory Authority in the Territory (collectively “Disqualified”). Otsuka shall not employ any
Debarred, Excluded or Disqualified Otsuka Iclusig Staff or allow any Debarred, Excluded or Disqualified Subcontractor to be involved in any clinical trial relating to this Agreement. Otsuka shall notify ARIAD promptly if any Otsuka Iclusig Staff or
Subcontractors are threatened to become Debarred, Excluded or Disqualified. 

  

	15.6	Independent Contractor. Otsuka shall make clear in all dealings with its actual and prospective Customers that it is selling the Product in its own name and for its own account as an independent contractor and
not as agent of ARIAD. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 51 

	15.7	Use of Internet.  

  

	 	15.7.1	With the exception of the purpose of communicating selling prices and sales terms and conditions and safety related information, Otsuka shall comply with this Section 15.7 with respect to all internet related
advertising, marketing and promoting in any way connected with the Compound, the Product, the Trademarks and/or ARIAD. All of Otsuka’s internet marketing, advertising and promotional materials concerning the Compound, the Product, the
Trademarks and/or ARIAD shall be developed and prepared by Otsuka in accordance with the Trademark Guidelines, the Global Product Profile and the Territory Product Profile. Upon ARIAD’s reasonable request, Otsuka shall provide ARIAD with links
to all current internet marketing, advertising and promotional materials for the Product in the Territory for ARIAD’s review to ensure such materials are consistent with the Trademark Guidelines, the Global Product Profile and the Territory
Product Profile. Otsuka shall promptly remove or cause to be removed from any website under the control of Otsuka or its Affiliates any information connected with the Compound, the Product, the Trademarks and/or ARIAD upon ARIAD’s reasonable
request if such information is not consistent with the Trademark Guidelines, the Global Product Profile or the Territory Product Profile, and/or upon expiration or termination of this Agreement for compliance or quality reasons. Any websites shall
not contain links to ARIAD websites without ARIAD’s prior approval. 

  

	 	15.7.2	ARIAD may grant to Otsuka the right to operate a website under a domain name registered in the name of ARIAD and relevant to or which contains information about ARIAD, the Compound, the Product, and the Trademarks,
subject to terms and conditions to be defined by separate domain name license agreement. 

  

	 	15.7.3	 In the event that any Applicable Law or regulation in the Territory requires the domain name of any website relevant to the Compound, the Product, the
Trademarks and/or ARIAD to be registered in the name of Otsuka or an Affiliate, then any such domain name shall be registered in the name of Otsuka or Affiliate as legally required. All such content shall be or shall become the exclusive property of
ARIAD upon expiration or termination of the Agreement. Otsuka and its Affiliates agree to execute any and all further documentation required to ensure that all such content and all copyright in such content is owned by ARIAD. Otsuka hereby grants to
ARIAD a semi-exclusive, irrevocable, perpetual, fully paid up, license to each such domain name during the Term. To the extent permitted by Applicable Law, Otsuka shall be required to assign to ARIAD or its designee all domain name registrations
containing the name of the Compound, the Product, the Trademarks or the name ARIAD, or variants thereof, upon the expiration or termination of this Agreement. To the extent that any of the foregoing may not be assigned, or be required to be
assigned, to ARIAD or its designee as a matter of law, the license grant in 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 52 

	 	
this Section 15.7.3 shall survive expiration or termination of this Agreement for any reason. Neither Otsuka nor its Affiliate may assign or license any such domain name to any other Third
Party. 

  

	15.8	Target Net Sales. At least [***] ([***]) [***] before the [***] of the [***] after the [***] of the First Commercial Sale in the Territory, the Parties (through the JDCC) shall mutually agree upon a [***]
forecast of target annual Net Sales in [***], [***] and [***] for each of the [***] ([***]) [***] following such [***] of the First Commercial Sale, taking into account the Net Sales in [***] to date, the [***] of Net Sales, [***] during such [***]
([***]) [***] and all other relevant factors (the “[***] Forecast”). The [***] Forecast shall be updated and agreed upon by the Parties (through the JDCC) every [***] thereafter at least [***] ([***]) [***] prior to the relevant
next [***] ([***]) [***] period. In the event the [***] Forecast cannot be agreed upon by the JDCC at least [***] ([***]) days before the [***] of the [***] after the [***] of the First Commercial Sale in the Territory or at least [***] ([***])
[***] prior to the relevant [***] ([***]) [***] period, and if the matter is not resolved by [***], then the matter shall be resolved by [***]. In the event the actual Net Sales in [***], [***] and [***]in any calendar year, beginning [***] after
the [***] of the First Commercial Sale in the Territory, are in the aggregate less than [***] percent ([***]%) of the target annual Net Sales set forth in the [***] Forecast for such year, the Parties (through the JDCC) shall mutually agree upon a
plan to increase the resources (e.g., advertising and promotion expenditures and/or number of details) to be applied by Otsuka to the Commercialization of the Product in [***], [***] and [***] in the [***] by [***] percent ([***]%), and Otsuka
shall, or shall cause its Sublicensees, to carry out such plan. In the event such plan cannot be agreed upon by the JDCC before the [***] of the [***], and the matter is not resolved by [***], then the matter shall be resolved by [***].

 ARTICLE 16 – CO-PROMOTION 
  

	16.1	 Co-Promotion Option. ARIAD shall have an option (the “Co-Promotion Option”) to co-promote Product in the Field in [***] and
[***] in accordance with the remainder of this Article 16. The Co-Promotion Option shall be exercisable at any time between the [***] of the First Commercial Sale in [***] or [***] (as applicable) and the expiration of the Full Royalty Term in such
country (the “Option Exercise Period”); provided, however, that the Co-Promotion Option shall only be exercisable in [***] if co-promotion of pharmaceutical products is permitted pursuant to Applicable Laws in [***] and is
authorized under Otsuka’s (or its relevant Sublicensee’s) and ARIAD’s (or its Affiliate’s) operating licenses and permits in [***]. Upon Otsuka’s receipt of written notice from ARIAD that ARIAD in good faith intends to
exercise its Co-Promotion Option, Otsuka shall use commercially reasonable efforts, and shall cause its relevant Sublicensee, if any, to use commercially reasonable efforts, to obtain authorization to co-promote pharmaceutical products under its
operating licenses and permits in [***]. ARIAD may exercise the Co-Promotion Option (with respect to [***], if permitted and authorized) by giving Otsuka at least [***] ([***]) [***] prior written notice (each, a

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 53 

	 	
“Co-Promotion Notice”), with such Co-Promotion Notice to take effect no earlier than the first day of the Option Exercise Period for the relevant country. In the event ARIAD
exercises the Co-Promotion Option in [***] (if permitted and authorized), Otsuka shall invoice ARIAD for [***] percent ([***]%) of all out-of-pocket costs incurred by Otsuka and/or its Sublicensees in connection with development and Registration of
Product in [***], and ARIAD shall pay the invoiced amount to Otsuka within [***] ([***]) days of receipt of such invoice. 

  

	16.2	Coordination. The JDCC shall oversee all promotional activities relating to the Parties’ co-promotion of Products in [***] and/or [***] (as applicable) 

 

	16.3	Co-Promotion Agreement. As soon as practicable after ARIAD gives a Co-Promotion Notice for [***] and/or [***] (as applicable), the Parties shall negotiate in good faith and enter into an agreement that governs
the co-promotion, medical affairs activities and other Commercialization activities to be conducted by the Parties in the relevant country (each, a “Co-Promotion Agreement”). Each Co-Promotion Agreement shall be consistent with this
Agreement and shall include other, mutually agreed, customary and commercially reasonable terms, including provisions relating to training, field assignments, qualifications for sales representatives and medical science liaisons, the minimum number
of sales representatives and/or medical science liaisons to be provided by ARIAD in the applicable country, advertising, marketing plans, ethics and compliance, recordkeeping, reporting and auditing, and performance metrics. In the event of any
inconsistency between the terms of this Agreement and a specific term of a Co-Promotion Agreement, the terms of this Agreement shall prevail. 

  

	16.4	Performance. If ARIAD exercises the Co-Promotion Option in [***] and/or [***], the Commercialization license under Section 2.1.1 shall be co-exclusive in such country, ARIAD shall perform all co-promotion,
medical affairs and other Commercialization activities in the relevant country in accordance with the applicable Co-Promotion Agreement and all Applicable Laws and Industry Guidelines, and the terms of Article 21 shall apply mutatis mutandis
to ARIAD. 

  

	16.5	Co-Promotion Fees. As soon as practicable following ARIAD’s provision of a Co-Promotion Notice, the Parties shall confer and negotiate a baseline Net Sales forecast that would be achieved in the relevant
country without ARIAD’s co-promotion (the “Baseline”). For all actual Net Sales above the Baseline (the “Incremental Sales”), Otsuka shall pay ARIAD, on a [***] basis at the same time Otsuka pays royalties
pursuant to Section 19.3.4, a co-promotion fee of [***] percent ([***]%) of the Incremental Sales during the Full Royalty Term and the Reduced Royalty Term (the “Co-Promotion Fee”), in addition to the Transfer Price. Such
Co-Promotion Fees shall be in lieu of the royalties that would otherwise be due on such Incremental Sales, but royalties pursuant to Section 19.3 shall remain due on the portion of Net Sales below the Baseline, regardless of the selling party.
For clarity, if no Incremental Sales are achieved, then only the applicable Transfer Price (on all Net Sales) and royalty under Section 19.3 (on the Net Sales of the Product below the Baseline) shall be payable by Otsuka with respect to such
period. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 54 

	16.6	Co-Promotion Costs. ARIAD shall be solely responsible for the costs that ARIAD or its Affiliates incur to co-promote the Product in the Territory, including any such costs for medical science liaisons, detailing,
and advertising and promoting the Product. 

  

	16.7	Promotional Materials. Otsuka shall supply, and ARIAD shall purchase from Otsuka, promotional and training materials for use by ARIAD in its co-promotion of Product in [***] and/or [***] (as applicable), at [***]
to Otsuka’s [***] for producing such materials. In addition, ARIAD shall reimburse Otsuka all out-of-pocket costs incurred by Otsuka or its Sublicensees in connection with making any modifications to promotional materials to reflect
ARIAD’s co-promotion of the Product. Such materials shall be supplied in languages appropriate for ARIAD’s co-promotion of Product in [***] and/or [***] (as applicable), and shall comply in all respects with Applicable Laws and Industry
Guidelines in such countries in the Territory. 

 ARTICLE 17 – MEDICAL AFFAIRS ACTIVITIES 

 

	17.1	Otsuka shall be responsible, at its cost, for medical affairs activities in the Territory, including providing medical science liaisons (or the local equivalent), medical information and medical education programs and
medical publications in the Territory, and attending relevant medical or scientific meetings and congresses, and shall allocate sufficient, appropriately qualified personnel and resources to conduct such activities, as further set forth herein.

  

	17.2	Otsuka shall appropriately disseminate medical information relating to the Compound and the Product in accordance with Applicable Laws and in a manner consistent with any medical affairs materials provided by ARIAD to
Otsuka in writing, if any (provided such materials provided by ARIAD are compliant with Applicable Laws and Industry Guidelines). Through discussion by the JDCC or an appropriate project team, Otsuka shall discuss and align with ARIAD regarding
Otsuka’s medical affairs activities relating to Product in the Territory. Through the JDCC, Otsuka shall keep ARIAD informed on its medical affairs activities relating to the Compound or Product in the Territory and the Parties shall discuss
aspects relevant to the scientific communications and activities pertaining to the Compound or the Product in the Territory. 

  

	17.3	Otsuka shall ensure that requests for information by Healthcare Professionals are answered in an appropriate, accurate and lawful manner by appropriately qualified personnel. Requests for information that are
inconsistent with the Marketing Authorization for the relevant country shall be handled by the medical affairs personnel only. 

ARTICLE 18 – PRODUCT TRADEMARKS 
  

	18.1	 Subject to approval by the relevant Regulatory Authorities in the Territory, the Product shall be Commercialized under the Trademarks within the Field
in the Territory 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 55 

	 	
throughout the Term. Otsuka shall not use, or permit the use of, any other trademark (other than the Trademarks and Otsuka’s and its Sublicensees’ names and logos) for the
Commercialization of the Product in the Territory. 

  

	18.2	ARIAD shall determine whether to display its or its Affiliate’s name and logo on Product labels, inserts and packaging and/or on Product promotional materials used in a country in the Territory. If ARIAD elects to
display its or its Affiliate’s name and logo on such Product labels, inserts and packaging and/or promotional materials in any country in the Territory then, subject to, and to the extent permitted by, Applicable Laws, such Product labels,
inserts and packaging and/or promotional materials shall display the names and logos of Otsuka and ARIAD, in each case with such prominence and in such format or presentation as is approved by the JDCC; provided that, unless otherwise agreed by the
JDCC (with neither Party having the final decision-making authority, including through the Escalation Notice process) or unless otherwise required by Applicable Laws, Otsuka’s or its Sublicensee’s, as applicable, name and logo shall in all
events be listed first on such Product labels, inserts and packaging and/or promotional materials. 

  

	18.3	Otsuka shall use the Trademarks only and exclusively in connection with and for the purpose of the Commercialization of the Product in the Field in the Territory. Otsuka acknowledges that it shall not be entitled to any
rights whatsoever in the Trademarks or ARIAD’s corporate name or logo except as is specifically granted pursuant to this Agreement. 

  

	18.4	The Trademarks shall appear on all Product packaging, labels and inserts and other materials which Otsuka uses for the Commercialization of the Product, in such form, location and manner as shall be approved by the
JDCC. All uses by Otsuka of the Trademarks shall be consistent with the Trademark Guidelines submitted to Otsuka in writing. The Trademarks shall always be used together with the sign “R” or the sign “TM” or such other customary
symbol or legend that correctly identifies the status of the Trademark (i.e., registered or unregistered) in the Territory. 

  

	18.5	Except as otherwise set forth in this Agreement (including in Section 15.9) or as otherwise agreed by the JDCC (with neither Party having final decision-making authority, including through the Escalation Notice
process), Otsuka shall not use nor apply for registration anywhere in the world of any trademarks, trade-names, domain names, logos or designs in connection with the Product, nor shall it use or apply for registration of any trademarks, trade-names,
domain names, logos or designs which include any of the Trademarks, the word “ARIAD” or “ICLUSIG” or any variation of either (including translations or transliterations thereof) or any word, term, name, domain name, logo or
design confusingly similar to any of the Trademarks (or translations or transliterations thereof), alone or in combination, without the prior written authorization of ARIAD, which authorization ARIAD may withhold in its sole and absolute discretion.

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 56 

	18.6	Nothing contained in this Agreement shall be construed as giving Otsuka the right to use any of the Trademarks or the name or logo of ARIAD outside the Territory or for any other product than the Product. Otsuka
recognizes the exclusive ownership rights of ARIAD in and to the Trademarks and the name and logo of ARIAD and acknowledges that it shall not acquire any ownership or other rights in respect of the Trademarks or the name or logo of ARIAD and/or of
the goodwill associated therewith and that all such rights and goodwill are, and shall at all times remain, vested in ARIAD. Otsuka acknowledges and agrees that all use of the Trademarks and the name and logo of ARIAD inures to and is for the
benefit of ARIAD. Otsuka shall, if requested by ARIAD, execute an assignment to ARIAD of any and all rights that Otsuka may acquire in respect of any of the Trademarks or the name or logo of ARIAD and/or of the goodwill associated therewith.

  

	18.7	ARIAD shall use commercially reasonable efforts to maintain the validity of the Trademarks in the Territory throughout the Term, at its sole cost and expense. Otsuka agrees to provide any reasonable assistance in this
effort at its own internal cost, provided, however, that ARIAD shall bear Otsuka’s reasonable out-of-pocket expenses incurred in connection with such assistance. 

 

	18.8	Otsuka shall promptly notify ARIAD with respect to any threatened, potential or presumed counterfeits, copies, imitations, simulations of, or infringements upon, the Trademarks or the name “ARIAD” which comes
to its attention. ARIAD shall decide on the steps to be taken after having discussed such threatened, potential or presumed counterfeits, copies, imitations, simulation and/or infringements with Otsuka. Otsuka shall provide all reasonable assistance
(with Otsuka bearing its own internal costs and ARIAD bearing the reasonable out-of-pocket expenses incurred by Otsuka solely for the purpose of engaging any Third Party to assist in the performance of any action contemplated by this
Section 18.8) to ARIAD in taking legal action, if deemed necessary by ARIAD, in its sole and absolute discretion, with respect to such matters. 

  

	18.9	Otsuka acknowledges that ARIAD would have no adequate remedy under this Agreement or at law in the event that Otsuka were to use the Trademarks in a manner not authorized by this Agreement and that ARIAD would, in such
circumstances, be entitled to specific performance, injunctive or other equitable relief. 

 ARTICLE 19 – CONSIDERATION
AND PAYMENTS 
  

	19.1	 Initial Fee. Otsuka shall pay ARIAD a one-time, non-refundable, non-creditable payment of seventy-seven million five hundred thousand US
Dollars ($77,500,000) in consideration for the rights and licenses granted hereunder (the “Initial Fee”). The Initial Fee shall be paid by wire transfer to an account designated in writing by ARIAD within [***] ([***]) [***] after
the Effective Date, provided that Otsuka has received from ARIAD, on or before the Effective Date, wire transfer instructions and all of the following currently effective (un-expired) completed and signed documents: one (1) copy of the United
States Internal Revenue Service Form 6166 (United States 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 57 

	 	
Residency Certification); two (2) copies of Form 3 (Application Form for Income Tax Convention); and one (1) copy of Form 17 (Attachment Form for Limitation on Benefits Article). In the
event ARIAD does not deliver all of the foregoing completed and signed documents to Otsuka on or before the Effective Date, Otsuka shall pay ARIAD the Initial Fee less the amount required to be withheld for Japanese income tax, and Otsuka shall
remit such withheld amount to the appropriate Japanese governmental authority. ARIAD shall deliver to Otsuka all of the foregoing completed and signed documents and two (2) copies of completed and signed Form 11 (Application Form for Refund of
Overpaid Withholding Tax). Otsuka shall use commercially reasonable efforts to assist ARIAD in its application for the refund of this withholding tax, including by certifying certain items on Form 11 (Refund of Overpaid Withholding Tax). As soon as
practicable, Otsuka shall transmit the completed documents to the appropriate Japanese governmental authority in order for ARIAD to receive a refund of the withheld amount from such Japanese governmental authority. 

 

	19.2	Milestone Payments. Otsuka shall pay ARIAD the following non-refundable, non-creditable milestone payments within [***] ([***]) [***] after the first achievement or occurrence of the following: 

 

	 	(a)	[***] US dollars ($[***]) upon the first approval of a JNDA in which the product indications, including precautions for indications, in the approved package insert (tenpu-bunsho) include the use of the Product as
a second line (i.e., second tyrosine kinase inhibitor) treatment of patients with CML or Ph+ALL that is resistant or intolerant to any one tyrosine kinase inhibitor, [***]. For the avoidance of doubt, no milestone payment shall be made in the event
of an approval of a JNDA in which the product indications, including precautions for indications, in the approved package insert [***]. 

  

	 	(b)	[***] US dollars ($[***]) upon the first approval of a JNDA in which the product indications, including precautions for indications, in the approved package insert (tenpu-bunsho) include the use of the Product as
a [***] 

  

	 	(c)	[***] US dollars ($[***]) upon each approval of a JNDA in which the product indications, including precautions for indications, in the approved package insert (tenpu-bunsho) include the use of the Product for an
indication [***]. 

 For clarity, such milestone payments are intended to be cumulative. Milestone payments shall be paid on or
prior to the due date by wire transfer to an account designated in writing by ARIAD. 
  

	19.3	Royalties.  

  

	 	19.3.1	Full Royalty Term. Otsuka shall pay to ARIAD a royalty of [***] percent ([***]%) of Net Sales in each country as to which the Full Royalty Term is in effect. For clarity, if ARIAD exercises the Co-Promotion
Option in [***] and/or [***], the royalty payable under this Section 19.3.1 shall apply only to the Net Sales in the relevant country that are equal to or below the Baseline. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 58 

	 	19.3.2	Reduced Royalty Term. Otsuka shall pay to ARIAD a royalty of [***] percent ([***]%) of Net Sales in each country in the Territory as to which the Full Royalty Term has expired. Such royalty obligation shall begin
in each country in the Territory on the day after the Full Royalty Term has expired and continue until the [***] ([***]) [***] of such expiration (the “Reduced Royalty Term”). For clarity, if ARIAD exercises the Co-Promotion Option
in [***] and/or [***], the royalty payable under this Section 19.3.2 shall apply only to the Net Sales in the relevant country that are equal to or below the Baseline. Further for clarity, after the expiration of the Reduced Royalty Term in
each country in the Territory, no further royalties shall be due with respect to Net Sales in such country and the licenses granted to Otsuka hereunder shall become fully paid-up and royalty-free with respect to such country for the remainder of the
Term. 

  

	 	19.3.3	Net Sales Reports and Royalty Payments. Within [***] ([***]) days of [***] of [***], Otsuka shall deliver to ARIAD a report setting out the details necessary to calculate the royalty payments under
Section 19.3 and the Transfer Price due ARIAD under Section 19.4 with respect to Net Sales made in the [***], including: 

  

	 	(a)	[***]; 

  

	 	(b)	[***]; 

  

	 	(c)	[***]; 

  

	 	(d)	all relevant deductions from invoiced amounts made in the calculation of Net Sales in accordance with the definition of Net Sales; and 

 

	 	(e)	all exchange rate conversions in accordance with Section 19.6. 

  

	 	19.3.4	Royalties shall be paid on or before the submission of the Royalty Report, but no later than [***] ([***]) days following [***]. 

  

	19.4	 Transfer Price. Otsuka shall pay ARIAD a transfer price (the “Transfer Price”) for the supply of (i) Bulk Product for use
in the Final Manufacturing of Product and (ii) Secondary Packaged Product, in each case for commercial sale in the Territory, equal to [***] percent ([***]%) of the weighted average Net Sales in the Territory, calculated as set forth in
Section 19.5. The Parties acknowledge and agree that the Transfer Price is expressed exclusive of any consumption tax, goods and services tax, value-added tax or any other form of sales tax, and if such taxes are required to be charged on any
sale of the Product to Otsuka, the provisions set forth in Section 19.8 shall apply. For each unit (tablet) of Bulk Product supplied by ARIAD to Otsuka for use in the Final 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 59 

	 	
Manufacturing of Product for promotional sampling (in quantities agreed upon by the JDCC) and clinical trials, Otsuka shall pay ARIAD the Bulk Tablet Cost. In addition, for each unit (tablet) of
Bulk Product supplied to Otsuka for non-commercial, non-clinical investigational use, including for process validation and performance qualification testing, Otsuka shall pay ARIAD the Bulk Tablet Cost. For clarity, the Transfer Price shall only be
payable for Bulk Product to be used for Final Manufacturing for commercial requirements for the Territory, and shall not be payable for Bulk Product supplied by ARIAD for Final Manufacturing for use in clinical studies or promotional samples of
Product or for investigational use, such as for process validation and performance qualification testing. Further for clarity, Otsuka shall use promotional samples of Product for the purpose of confirming the appearance of Product, and shall not
sell or otherwise provide promotional samples of Product for use in the treatment of patients. ARIAD shall not be obligated to supply Secondary Packaged Product to Otsuka for clinical trials and promotional sampling. 

 

	19.5	[***] Price; Invoices; Reconciliation; and Inventory Risk. 

  

	 	19.5.1	At a reasonable time prior to Otsuka’s initial purchase of Bulk Product for use in Final Manufacturing for commercial requirements for the Territory, and thereafter prior to [***] during the Term (or [***] in the
event of a Price Cut as provided in Section 19.5.3), the Parties shall [***] (the “[***] Price”) at which ARIAD shall invoice Otsuka [***] of Product (both Bulk Product and Secondary Packaged Product) for such commercial
requirements for the Territory. The Parties shall attempt in good faith to establish the [***] Price as close to the anticipated Transfer Price as the Parties can reasonably estimate for [***] (or [***] following a Price Cut), based on [***]. For
each shipment of Bulk Product and Secondary Packaged Product purchased by Otsuka for commercial requirements, [***], ARIAD shall invoice Otsuka an amount equal to [***]. Otsuka shall pay ARIAD such invoiced amount in US dollars not later than [***]
([***]) days following [***] of the applicable invoice [***]. 

  

	 	19.5.2	 On a [***], the Parties shall reconcile in writing the Transfer Price due ARIAD in respect of Product in the Tablet Formulation purchased by Otsuka
from ARIAD for commercial purposes during [***] against the [***] Price paid by Otsuka for such Product in the Tablet Formulation. Within [***] ([***]) [***] after the end of [***] after the First Commercial Sale of the first Product in the
Territory, Otsuka shall submit to ARIAD a written top-line report of Net Sales (i.e., a report of Net Sales without a detailed breakdown of deductions from the invoiced prices taken to reach Net Sales) of Product in the Tablet Formulation in local
currency for each country in the Territory (i.e., aggregate Net Sales and number of units (tablets) of Product in Tablet Formulation) and a calculation of the Reconciliation Payment (defined below) owed for such calendar quarter based on the
weighted average of such top-line Net Sales. If applicable, such written report shall also include the amount (if any) to be included in 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 60 

	 	
the Reconciliation Payment in accordance with Section 19.5.3 and/or Section 19.5.4. With respect to any calendar quarter, the “Reconciliation Payment” shall be an
amount payable by Otsuka to ARIAD or due from ARIAD to Otsuka (as the case may be) to account for (i) the difference between the amounts invoiced by ARIAD at the [***] Price for the quantities of Product in Tablet Formulation sold to Otsuka
(supplied as Bulk Product or Secondary Packaged Product) for commercial purposes during such calendar quarter and the Transfer Price of such quantities of Product sold to Otsuka, and (ii) [***] percent ([***]%) wastage (Product scrap) that
occur from losses in the Final Manufacturing of Product (including in connection with quality control analysis) during such calendar quarter, calculated at [***]. 

 

	 	(a)	The Reconciliation Payment with respect to clause (i) of Section 19.5.2 shall be calculated as follows: 

R = [***], where 
 [***] 

[***] 
 [***] 

[***] 
  

	 	(b)	The Reconciliation Payment with respect to clause (ii) shall be calculated as follows: 

[***] If the wastage arises in the ordinary course of the Final Manufacturing process (including quality control analysis), the Reconciliation
Payment shall include a credit for the amount calculated by [***] the quantity of the wastage ([***], [***]%) by the [***] between the [***]. 

For example, [***] 
  

	 	19.5.3	 In the event there is a [***] percent ([***]%) or greater reduction in the approved reimbursement price of Product in [***],[***]or [***] (including
the NHI List Price in Japan) (“Price Cut”) in any [***] during the Term, the Reconciliation Payment for such [***] (or for the immediately preceding [***] if the Price Cut goes into effect on the first day of a [***]) shall include
a reconciliation for Product inventory purchased by Otsuka during such [***] (or during the immediately preceding [***] if the Price Cut goes into effect on the first day of a [***]) and held by Otsuka at the time of such Price Cut, based on [***]
paid by Otsuka for such Product inventory 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 61 

	 	
held by Otsuka, [***]. As soon as reasonably possible after Otsuka obtains knowledge that there is likely to be a Price Cut, Otsuka will inform ARIAD of the same. 

 

	 	19.5.4	To the extent applicable, the Reconciliation Payment for each of the [***] ([***]) [***] following the First Commercial Sale of Product in the Territory shall include a reconciliation to account for any Bulk Product,
from a [***] of [***] ([***]) batches supplied to Otsuka, that cannot be sold by Otsuka as finished Product due to Customer (including wholesalers) shelf-life requirements, by [***]. Notwithstanding the foregoing, if the remaining shelf life of the
Bulk Product at the time of delivery to Otsuka is less than [***] ([***]) months, the foregoing shall not apply and provisions relating to unsold Products shall be addressed in the Supply Agreement. 

 

	 	19.5.5	The applicable Party shall pay to the other Party the Reconciliation Payment within [***] ([***]) days after ARIAD’s receipt of each such [***] statement from Otsuka. 

 

	19.6	Payment Currency and Exchange Rate. All amounts due under this Agreement shall be paid in US dollars. The amount of Net Sales under Sections 19.3 and 19.4 shall be determined in Local Currency. The Net Sales
amount shall be converted from Local Currency into US dollars using the interbank exchange rate for conversion of one unit of Local Currency to one US dollar as of the last day of the quarter prior to the payment due date. For purposes of the 19.5.2
Reconciliation Payment, the Net Sales in local currency shall be converted at the average exchange rate for the period beginning with the first day of the quarter and ending with the last day of the quarter. Exchange rates shall be as published by
OANDA.com “The Currency Site” under the heading “FxHistory: historical currency exchange rates” at www.OANDA.com/convert/fxhistory. All payments under this Agreement shall be made by bank wire transfer in immediately available
funds to a bank account designated in writing by the payee Party or by other means as directed by the payee Party in writing. 

  

	19.7	Interest. Payments made under this Agreement shall be considered to be made as of the day on which they are received by the payee Party’s designated bank. In the event that any payment due under this
Agreement is not made when due, the payment shall accrue simple interest from the date due at a rate per annum equal to [***] percent ([***]%) above the US prime rate published in the Wall Street Journal, (or, if the Wall Street Journal, ceases to
publish such rates, such other reputable financial news source as ARIAD may select) in effect on the date of the scheduled date of payment; provided that, in no event shall such rate exceed the applicable maximum legal annual interest rate then in
effect. The payment of such interest shall not limit the payee Party from exercising any other rights it may have as a consequence of the lateness of any payment. Such interest shall accrue on a daily basis from the due date until the date of actual
payment of the overdue amount. The payer Party shall pay the interest together with the overdue amount. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 62 

	19.8	Tax Matters. Unless otherwise agreed in writing by the Parties or required by Applicable Laws, the consideration payable in connection with this Agreement excludes all withholding, sales, use, consumption,
value-added, customs, excise and other taxes, duties or governmental assessments (collectively, “Taxes”). The Parties shall use commercially reasonable efforts to structure all amounts payable by one Party to the other Party
pursuant to this Agreement (each a “Payment”) to minimize the applicability of withholding taxes to the maximum extent consistent with Applicable Laws. If any Payment is subject to a deduction or withholding of Tax pursuant to
Applicable Laws, the Parties shall use commercially reasonable efforts to perform all acts (including by executing all appropriate documents) so as to enable the payee Party to take advantage of any applicable double taxation agreement or treaty or
to otherwise secure any applicable exemption from or reduction in withholding Taxes. In the event there is no applicable double taxation (or other exemption) agreement or treaty, or if an applicable double taxation (or other) agreement or treaty
reduces but does not eliminate such withholding Tax, the payer Party shall pay the applicable Tax to the appropriate governmental authority, shall provide to the payee Party evidence of such payment, and shall deduct the amount paid from the Payment
due the payee Party. Any withholding tax imposed on a payment from an Otsuka Affiliate, Sublicensee or distributor in the Territory to Otsuka is the responsibility of Otsuka. 

 

	19.9	No Set-Off. Otsuka shall in no case be entitled to set off or otherwise withhold or adjust any payment due to ARIAD under this Agreement in view of claims, whether justified or unjustified, that Otsuka may have
against ARIAD for any reason. 

  

	19.10	Books, records and accounts. Throughout the Term and for a period of at least [***] ([***]) months thereafter, Otsuka shall keep complete and accurate books, records and accounts in accordance with all Regulatory
Laws and Regulatory Requirements and sound accounting practice covering all its operations hereunder. ARIAD shall have the right, throughout the Term and for a period of [***] months thereafter, at reasonable times during business hours and upon
reasonable notice to Otsuka, to have such books, records and accounts inspected and audited by ARIAD’s or its Affiliates’ duly authorized representatives or by an independent auditor to be nominated by ARIAD and reasonably acceptable to
Otsuka, to ensure the accuracy of all reports and payments made hereunder. Such audit shall be covered by confidentiality obligations of the auditor. Such inspection and audit may not be (i) conducted for any calendar year more than [***]
([***]) [***] after the end of such year, (ii) conducted more than [***] in any [***] ([***]) [***] period, or (iii) [***]. Otsuka shall cooperate with ARIAD and its Affiliates and their respective authorized representatives or independent
auditor and make available all work papers and other information related to this Agreement reasonably requested in connection herewith (subject to written obligations of confidentiality to Otsuka). 

 

	19.11	Currency embargoes. If at any time currency embargoes or similar legal restrictions in any country in the Territory prevent the prompt remittance of any payments hereunder, Otsuka shall make such payments by
depositing the amount thereof in local currency to the account of ARIAD in a bank or depository in such country designated by ARIAD. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 63 

 ARTICLE 20 – REPRESENTATIONS AND WARRANTIES 

 

	20.1	ARIAD hereby represents and warrants to Otsuka as of the Effective Date, and with respect to Sections 20.1.6 and 20.1.7 only, throughout the Term, as follows: 

 

	 	20.1.1	Organization. ARIAD has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Delaware, USA. ARIAD has the corporate power and authority to enter into this
Agreement and to consummate the transactions contemplated by this Agreement. 

  

	 	20.1.2	Authorization. The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated by this Agreement, by ARIAD have been duly and validly authorized by all requisite
corporate actions. This Agreement constitutes a legal, valid and binding agreement of ARIAD, enforceable against ARIAD in accordance with its terms. 

  

	 	20.1.3	Execution. The persons executing this Agreement on behalf of ARIAD are duly authorized to do so and by so doing have bound ARIAD to the terms and conditions of this Agreement. 

 

	 	20.1.4	No Inconsistent Obligations. The execution, delivery and performance by ARIAD of this Agreement, and the consummation of the transactions contemplated by this Agreement, do not and shall not (i) contravene
or conflict with the charter or bylaws of ARIAD or its Affiliates, as applicable, or (ii) conflict with, constitute a default in any material respect under or give rise to any right of termination or cancellation of, any agreement or instrument
to which ARIAD or its Affiliates is a party that would have a material adverse effect on the ability of ARIAD or its Affiliates to perform its obligations hereunder. As of the Effective Date, there is no action, suit, investigation or proceeding
pending against, or to the Knowledge of ARIAD, threatened against or affecting, ARIAD or its Affiliates before any court, arbitrator or any governmental authority, including Regulatory Authorities, which, if decided against ARIAD or its Affiliates,
would have a material adverse effect on the ability of ARIAD or its Affiliates to perform their obligations hereunder. 

  

	 	20.1.5	Registrations. ARIAD understands and acknowledges that, as of the Effective Date, there is no assurance that Registrations can be obtained for the Product in each or all of the countries of the Territory.

  

	 	20.1.6	Product in the Tablet Formulation. Product in the Tablet Formulation Delivered hereunder shall: 

  

	 	(a)	be Manufactured in all material respects in accordance with the Marketing Authorization, the applicable Quality Agreements, and cGMPs; 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 64 

	 	(b)	conform to the Specifications at the time of Delivery until the expiry date set forth on the label for the given lot of the Product in the Tablet Formulation; 

 

	 	(c)	not be adulterated or misbranded under Applicable Laws; and 

  

	 	(d)	at the time of Delivery, be free and clear of any lien or encumbrance. 

  

	 	20.1.7	Secondary Packaged Product. Secondary Packaged Product Delivered hereunder shall: 

  

	 	(a)	be Manufactured in all material respects in accordance with the Marketing Authorization for the US or EU, as applicable, the applicable Quality Agreements, and applicable cGMPs; 

 

	 	(b)	conform to ARIAD’s US or EU specifications (as applicable) at the time of Delivery until the expiry date set forth on the US or EU label (as applicable) for the given unit of Secondary Packaged Product;

  

	 	(c)	not be adulterated or misbranded under Applicable Laws; and 

  

	 	(d)	at the time of Delivery, be free and clear of any lien or encumbrance. 

  

	 	20.1.8	Right to Grant License. ARIAD and its Affiliates are the sole and exclusive owners of the Patents listed in Appendix 1, and ARIAD is entitled to grant the licenses to Otsuka specified in Article 2.

  

	 	20.1.9	Patent Validity and No Patent Challenge. To the Knowledge of ARIAD, the claims of the issued patents included in the Patents listed in Appendix 1 are not invalid and the issued patents included in the Patents
listed in Appendix 1 are not unenforceable in the Territory. No Third Party has challenged in writing, or, to the Knowledge of ARIAD, has threatened to challenge, the enforceability or validity of any issued patents included in the Patents listed in
Appendix 1 or any claims therein, respectively in the Territory through the institution of legal proceedings in a court or through interference, reexamination, nullity or similar invalidity proceedings before the U.S. Patent and Trademark Office or
any analogous foreign entity in the Territory. 

  

	 	20.1.10	No Know-How or Trademark Challenge. No Third Party has challenged in writing, or, to the Knowledge of ARIAD, has threatened to challenge, ARIAD’s right to use and license the Know-How and/or the Trademarks
in the Territory. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 65 

	 	20.1.11	No Infringement by Third Parties. To the Knowledge of ARIAD, no Third Party is infringing or threatening to infringe the Patents, or misappropriating or threatening to misappropriate the Know-How existing as of
the Effective Date. 

  

	 	20.1.12	No Claim that Development or Commercialization Infringes Third Party IP. There are no claims asserted in writing, judgments, or settlements in effect against, or amounts with respect thereto owed by, ARIAD or any
of its Affiliates relating to the Patents or the Know-How in the Territory existing as of the Effective Date. No claim or litigation is pending or, to the Knowledge of ARIAD, threatened alleging that the disclosing, copying, making, or licensing of
the Patents or the Know-How existing as of the Effective Date, or the development or Commercialization of the Products in the Tablet Formulation in the manner reasonably contemplated herein as of the Effective Date, infringes or would infringe any
issued patent in the Territory existing as of the Effective Date of any Third Party. 

  

	 	20.1.13	No Claim that Manufacturing Infringes Third Party IP. There are no claims asserted in writing, judgments, or settlements in effect against, or amounts with respect thereto owed by, ARIAD or any of its Affiliates
relating to the Manufacturing of Compound or Products in the Tablet Formulation. No claim asserted in writing or litigation is pending or, to the Knowledge of ARIAD, threatened alleging that the Manufacturing of Compound or Products in the Tablet
Formulation infringes or would infringe any issued patent in the Territory existing as of the Effective Date of any Third Party. 

  

	 	20.1.14	Right to Conduct Ongoing Study. ARIAD has the right to use all Patents and Know-How existing as of the Effective Date that are necessary to conduct the Ongoing Study. To the Knowledge of ARIAD the conduct of the
Ongoing Study does not infringe any issued patent in the Territory existing as of the Effective Date of any Third Party. 

  

	 	20.1.15	Regulatory Documentation. ARIAD has provided or made available to Otsuka accurate and complete copies of all material Regulatory Documentation in the Territory in ARIAD’s Control existing prior to the
Effective Date, including all final Product-related clinical trial reports. In addition, and without limiting the foregoing, ARIAD has provided the following documents, which ARIAD represents contain a full disclosure of material adverse information
with respect to the safety and efficacy of the Compound Known to ARIAD as of the Effective Date: Integrated Safety Summary, Investigator’s Brochure, final Product-related clinical trial reports, PACE and Phase I updates presented at ASH 2014.

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 66 

	 	20.1.16	Patent Prosecution. The Patents listed in Appendix 1 have been filed and maintained, and are being diligently prosecuted, in the respective patent offices where filed in the Territory in accordance with
Applicable Laws. All applicable and material fees due prior to the Effective Date in connection with the prosecution and maintenance of the Patents listed in Appendix 1 in the Territory have been paid. 

 

	 	20.1.17	Compliance with Law. ARIAD and its Affiliates and, to the Knowledge of ARIAD, their respective contractors and consultants, have complied in all material respects with Applicable Laws, including Good Clinical
Practices, Good Laboratory Practices and cGMP (to the extent applicable), in the development, manufacture and Commercialization of the Compound and Product in the Tablet Formulation in the Territory prior to the Effective Date. 

 

	 	20.1.18	Accurate Information. The information, documentation, and other materials furnished or made available by ARIAD in connection with Otsuka’s diligence related to the transactions contemplated hereby prior to
the Effective Date are true, complete, and correct copies of what they purport to be in all material respects. 

  

	20.2	Otsuka hereby represents and warrants to ARIAD as of the Effective Date as follows: 

  

	 	20.2.1	Organization. Otsuka has been duly organized and is validly existing as a corporation in good standing under the laws of Japan. Otsuka has the corporate power and authority to enter into this Agreement and to
consummate the transactions contemplated by this Agreement. Otsuka’s Affiliates have been duly organized and are validly existing as corporations in good standing under the laws of the respective countries of their organization.

  

	 	20.2.2	Authorization. The execution, delivery and performance by Otsuka of this Agreement and the consummation of the transactions contemplated by this Agreement by Otsuka have been duly and validly authorized by all
requisite corporate actions. This Agreement constitutes a legal, valid and binding agreement of Otsuka, enforceable against Otsuka in accordance with its terms. 

  

	 	20.2.3	Execution. The persons executing this Agreement on behalf of Otsuka are duly authorized to do so and by so doing have bound Otsuka to the terms and conditions of this Agreement. 

 

	 	20.2.4	 No Inconsistent Obligations. The execution, delivery and performance by Otsuka of this Agreement, and the consummation of the transactions
contemplated by this Agreement, do not and shall not (i) contravene or conflict with the charter or bylaws of Otsuka or its Affiliates, as applicable, 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 67 

	 	
(ii) conflict with, constitute a default in any material respect under or give rise to any right of termination or cancellation of, any agreement or instrument to which Otsuka or its Affiliates
is a party that would have a material adverse effect on the ability of Otsuka or its Affiliates to perform their obligations hereunder, or (iii) or conflict with, constitute a default in any material respect under any contractual restriction or
obligation, including non-competition obligations, that survives the expiration or termination of any agreement or instrument to which Otsuka or its Affiliates was a party at any time. As of the Effective Date, there is no action, suit,
investigation or proceeding pending against, or to the Knowledge of Otsuka, threatened against or affecting, Otsuka or its Affiliates before any court, arbitrator or any governmental authority, including Regulatory Authorities, which, if decided
against Otsuka or its Affiliates, would have a material adverse effect on the ability of Otsuka or its Affiliates to perform their obligations hereunder. 

  

	 	20.2.5	Promotion. Otsuka is not promoting or otherwise commercializing [***] in any country in the Territory other than Japan. 

  

	 	20.2.6	Registrations. Otsuka understands and acknowledges that, as of the Effective Date, there is no assurance that Registrations can be obtained for the Product in each or all of the countries of the Territory. Otsuka
shall not be entitled to a return or a refund of any payments made hereunder if, for any reason, one or more Registrations are not obtained or a commercial market does not develop for the Product. 

 

	 	20.2.7	Qualified. Otsuka is a pharmaceutical company having the size and a position on the market adequate to Commercialize the Product and it and its Affiliates have the necessary qualified and experienced Personnel to
adequately Commercialize the Product in the Field in the Territory. 

  

	 	20.2.8	Accurate Information. The information, documentation, and other materials furnished or made available by Otsuka in response to ARIAD’s requests for information pertaining to Otsuka’s business as part of
ARIAD’s due diligence process prior to the Effective Date are true, complete, and correct copies of what they purport to be in all material respects. 

ARTICLE 21 – COMPLIANCE WITH LAW; DATA PRIVACY; ANTI-BRIBERY AND ANTI-CORRUPTION 

 

	21.1	Otsuka shall obtain and keep current all licenses, certificates, approvals and permits of whatever nature required under the Regulatory Laws and the Regulatory Requirements for the fulfilment of Otsuka’s
obligations under this Agreement. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 68 

	21.2	In the performance of its obligations hereunder, Otsuka shall comply and shall cause its employees and Affiliates involved in the performance of this Agreement and its Sublicensees and Subcontractors to comply with all
Applicable Laws and Industry Guidelines and Otsuka’s Global Anti-Corruption Policy; and without limiting the foregoing, in connection with any Named Patient Program, Otsuka shall comply and shall cause its Sublicensees, employees and
Subcontractors involved in any Named Patient Program to comply with all Industry Guidelines, Regulatory Laws, Regulatory Requirements and all other Applicable Laws with respect to Named Patient Programs. 

 

	21.3	As of the Effective Date, Otsuka represents that, to Otsuka’s Knowledge no (i) owners (ii) directors, or (iii) executive management members of Otsuka or of any of its Affiliates listed in Appendix 2
is a Government Official. Otsuka agrees to make prompt written disclosure to ARIAD of any changes to this information during the Term. 

  

	21.4	Otsuka shall certify to ARIAD on an annual basis the following: 

  

	 	(a)	training and training materials on Otsuka’s Global Anti-Corruption Policy (including Anti-Corruption Laws), as well as applicable rules on interactions with Healthcare Professionals and payors, including under any
Industry Guidelines, have been provided to all persons employed by Otsuka who perform work under this Agreement and interact with Government Officials or Healthcare Professionals in the normal course of their responsibilities; 

 

	 	(b)	to Otsuka’s Knowledge, except as may disclosed by Otsuka to ARIAD, there have been no violations of any Industry Guidelines or Anti-Corruption Laws by Persons employed by or Subcontractors used by Otsuka in the
performance of this Agreement; and 

  

	 	(c)	Otsuka has maintained true and accurate records necessary to demonstrate compliance with the requirements of this Section 21.4. 

 

	21.5	In the performance of its obligations hereunder, ARIAD shall comply and shall cause its Affiliates, employees and contractors involved in the performance of this Agreement to comply with all Applicable Laws, including
Anti-Corruption Laws, and Industry Guidelines; and without limiting the foregoing, in connection with any Named Patient Program, including the Named Patient Program involving Preexisting Named Patients, ARIAD shall comply and shall cause its
Affiliates, employees and contractors involved in such Named Patient Program(s) to comply with all Industry Guidelines, Regulatory Laws, Regulatory Requirements and all other Applicable Laws with respect to Named Patient Programs. 

 

	21.6	 At times, either Party may provide the other Party with personal information that falls under the protection of certain data security and privacy laws
(“Protected Personal Information”). Without limiting the generality of Section 21.1, each Party agrees to 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 69 

	 	
comply with all Applicable Laws relating to the use, storage, collection or other processing of such Protected Personal Information (“Data Protection Laws”). The Parties agree to
use good-faith efforts to agree upon and implement any security protocols and information handling guidelines that their respective legal advisors recommend in connection with the Parties’ compliance with such data security and privacy laws.

  

	21.7	Notice of Compliance Events. Each Party agrees that if it learns of any violation of Data Protection Laws, Regulatory Laws, Export Control Laws, or Anti-Corruption Laws by an employee or Subcontractor (in the
case of Otsuka) or contractor (in the case of ARIAD) that performs work under this Agreement (a “Compliance Event”), such Party (the “Notifying Party”) shall promptly notify the other Party (the “Notified
Party”) in writing of such Compliance Event and the measures Notifying Party has taken and intends to take to remedy such Compliance Event and to prevent its recurrence. The Notified Party reserves the right to require the Notifying Party
to prohibit the employee, Subcontractor or contractor (as the case may be) from performing any work related to this Agreement after due consultation with Notifying Party. 

ARTICLE 22 – INDEMNIFICATION, LIMITATIONS OF LIABILITY AND INSURANCE 

 

	22.1	 Upon the terms and conditions of this Article 22, Otsuka shall defend, indemnify and hold ARIAD and its Affiliates, and their respective officers,
directors and employees and agents, wholly free and harmless from and against any and all liabilities, damages, losses, costs, taxes, expenses (including reasonable attorneys’ fees and other expenses of litigation and arbitration), claims,
demands, suits, penalties, judgments or administrative and judicial orders (collectively, “Losses”) relating to any Proceeding or Proceeding threatened in writing to the extent arising out of or resulting from (a) the use of
the Know-how and the Trademarks by Otsuka, its Affiliates, Sublicensees, or Subcontractors, or any of their respective officers, directors, employees or agents other than in accordance with the terms and conditions of this Agreement; (b) any
failure by Otsuka, its Affiliates, Sublicensees, Subcontractors, or its service providers, or any of their respective officers, directors, employees or agents to comply with any Industry Guidelines or any Applicable Laws; (c) the performance
(or failure to perform) by Otsuka, its Affiliates, or Sublicensees, Subcontractors, or its service providers, or any of their respective officers, directors, employees, or agents of any Commercialization activities relating to the Product, the
exercise of any right or performance of any obligation of Otsuka under this Agreement, the Pharmacovigilance Agreement and/or the Quality Agreements; (d) the storage, sampling, record-keeping or transfer of the Product by Otsuka, its
Affiliates, Sublicensees, Subcontractors, or its service providers, or any of their respective officers, directors, employees or agents; (e) the Final Manufacturing of the Product by Otsuka, its Affiliates, Sublicensees, or Subcontractors, or
any of their respective officers, directors, employees or agents, including any failure of the Product to comply with the applicable specifications to the extent resulting from 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 70 

	 	
such Final Manufacturing of the Product; (f) any expired Product distributed by Otsuka, its Affiliates, Sublicensees, Subcontractors, or service providers, or any of their respective
officers, directors, employees and agents; (g) any negligent act or omission or willful misconduct of Otsuka, its Affiliates, Sublicensees, Subcontractors, or its service providers, or any of their respective officers, directors, employees or
agents; (h) any breach by Otsuka, its Affiliates, Sublicensees, Subcontractors, or service providers, or any of their respective officers, directors, employees or agents, of any of Otsuka’s representations, warranties, covenants or
material obligations contained in this Agreement or (i) the [***], the termination or breach of the [***], or the cessation of co-promotion of [***] in Japan by Otsuka. 

 

	22.2	Upon the terms and conditions of this Article 22, ARIAD shall defend, indemnify and hold Otsuka and its Affiliates, and their respective officers, directors and employees and agents, wholly free and harmless from and
against any and all Losses relating to any Proceeding or Proceeding threatened in writing to the extent arising out or resulting from (a) any failure by ARIAD, its Affiliates, subcontractors or its service providers or any of their respective
officers, directors, employees or agents to comply with any Industry Guidelines or any Applicable Laws, or any regulations and/or administrative decision regarding the Registration and/or the Product; (b) the performance (or failure to perform)
by ARIAD, its Affiliates, subcontractors or its service providers, or any of their respective officers, directors, employees or agents of any of ARIAD’s obligations under this Agreement (including the Manufacture of Product by ARIAD, its
Affiliates or its or their Third Party contract manufacturers), the Pharmacovigilance Agreement and/or Quality Agreements; (c) any negligent act or omission or willful misconduct of ARIAD, its Affiliates, subcontractors or its service
providers, or any of their respective officers, directors, employees or agents; (d) the use of the Know-How or the Trademark as expressly permitted under the terms of this Agreement; (e) any breach by ARIAD, its Affiliates, subcontractors
or its service providers, or any of their respective officers, directors, employees or agents of any of ARIAD’s representations, warranties, covenants or obligations contained in this Agreement, or (f) the storage, sampling, record-keeping
or transfer of the Product by ARIAD, its Affiliates, subcontractors, or its service providers, or any of their respective officers, directors, employees or agents. 

 

	22.3	The Parties acknowledge and agree that neither Party shall have an obligation to defend, indemnify or hold harmless the other Party or its Affiliates, or their respective officers, directors, employees or agents from
any Losses relating to any Proceeding or Proceeding threatened in writing to the extent arising out of or resulting from the infringement of Third Party patent rights in the Territory due to (i) the Final Manufacturing and/or Commercialization
of the Product by Otsuka in accordance with the terms of this Agreement or (ii) the Manufacture and/or supply of the Product by ARIAD to Otsuka in accordance with the terms of this Agreement or the Supply Agreements, and that the procedures for
addressing any such infringement of Third Party patent rights is set forth in Section 23.5. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 71 

	22.4	Procedure. The following shall apply to all Proceedings subject to the obligations set forth in Sections 22.1 and 22.2 above: 

 

	 	22.4.1	A Party or its indemnified entity seeking indemnification pursuant to Section 22.1 or Section 22.2 (an “Indemnified Party”) shall give to the Party from whom such indemnification is sought
(the “Indemnifying Party”) prompt written notice (a “Claim Notice”) of the assertion of any claim, or the commencement of any Proceeding for which the Indemnified Party believes the Indemnifying Party may be liable
under Section 22.1 or Section 22.2 of this Agreement, as the case may be. The failure by any Indemnified Party so to notify the Indemnifying Party shall not relieve the Indemnifying Party from liability under Section 22.1 or
Section 22.2 of this Agreement, as the case may be, except to the extent that the Indemnifying Party shall have been prejudiced in any material respect as a result of such failure. A Claim Notice shall describe the nature of the claim or
Proceeding and shall indicate the amount of Losses (estimated to the extent that the Losses in respect of any claim or Proceeding are reasonably capable of being estimated); provided, however, that the failure to estimate Losses (or the inaccuracy
thereof) shall not affect the validity of a Claim Notice or the amount of Losses to which the Indemnified Party may be entitled. 

  

	 	22.4.2	The Indemnifying Party shall have the right at its discretion to control the defense of any claim or Proceeding and the right to settle or compromise any such claim or Proceeding; provided that the prior written
consent of the Indemnified Party shall be required in connection with any settlement or compromise unless such settlement, compromise, discharge or consent to judgment (i) includes the delivery of a written release from all liability in respect
of such claim or Proceeding, (ii) does not contain any admission or statement suggesting any wrongdoing or liability on behalf of the Indemnified Party, and (iii) does not contain any equitable order, judgment or term which in any manner
affects, restrains or interferes with the business of the Indemnified Party or any of its Affiliates. The Indemnifying Party shall exercise such right by delivering written notice of its intent to undertake the defense of such claim or Proceeding to
the Indemnified Party within [***] ([***]) days after the receipt of a Claim Notice. If the Indemnifying Party elects to control the defense of the claim or Proceeding, then all expenses and legal fees of such defense shall be borne by the
Indemnifying Party. If the Indemnifying Party elects to control the defense of the claim or Proceeding, then the Indemnified Party may participate therein through counsel of its choice, but the cost of such counsel shall be borne solely by the
Indemnified Party. Only in the event that the Indemnifying Party does not assume such defense within [***] ([***]) days after its receipt of a Claim Notice or the Indemnifying Party notifies the Indemnified Party that it will not assume such
defense, the Indemnified Party may control the defense of such claim or Proceeding at the Indemnifying Party’s cost and the Indemnified Party may settle the claim or Proceeding on behalf of and for the account and risk of the Indemnifying
Party, who shall be bound by the result. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 72 

	 	22.4.3	The Indemnifying Party or the Indemnified Party, as the case may be, shall at all times use commercially reasonable efforts to keep the Indemnifying Party or the Indemnified Party, as the case may be, reasonably
appraised of the status of the defense of any matter the defense of which it is maintaining and to cooperate in good faith with the Indemnifying Party or the Indemnified Party, as the case may be, with respect to the defense of any such matter.

  

	22.5	EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY
SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, NON-INFRINGEMENT, COMMERCIAL POTENTIAL, CAPACITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE
KNOW-HOW, THE PATENTS AND/OR THE PRODUCT. NEITHER PARTY NOR ANY OF ITS RESPECTIVE EMPLOYEES OR REPRESENTATIVES IS AUTHORIZED TO GIVE ANY WARRANTIES OR MAKE ANY REPRESENTATION ON BEHALF OF THE OTHER PARTY. 

 

	22.6	Subject to Section 22.7, to the maximum extent permitted by Applicable Law, neither of the Parties shall be liable to the other Party for indirect, special, punitive, exemplary, incidental or consequential damages
or losses arising out of this Agreement, including loss of profits or revenues, regardless of whether such damages were foreseeable or not and regardless of any notice of such damages or losses. 

 

	22.7	The limitations and exclusions of liability set forth in Sections 22.6 shall not limit or restrict: (a) the indemnification rights or obligations of either Party with respect to Losses awarded to Third Party
claimants in Third Party Proceedings that are subject to the obligations in Section 22.1 or Section 22.2; (b) Otsuka’s liability with respect to breach by Otsuka of the limitations of grant or rights set forth in Article 2;
(c) either Party’s liability with respect to breach by a Party of its respective non-competition obligations set forth in Article 3; (d) damages or losses resulting from a breach by either Party of the confidentiality and non-use
obligations set forth in this Agreement; or (e) any liability that cannot be limited or excluded under Applicable Law. 

  

	22.8	 Each Party agrees to procure and maintain in full force and effect during the Term valid and collectible insurance policies in connection with its
activities as contemplated herein in amounts that are normal and customary in the pharmaceutical industry generally for prudent companies similarly situated. In particular, Otsuka’s coverage shall have limits of liability which are commercially
reasonable in the Territory but shall be not less than [***] US dollars ($[***]) per loss occurrence. Otsuka shall use commercially reasonable efforts to include a waiver of subrogation against ARIAD and a clause making ARIAD an additional insured
under such insurance policy. Each Party shall provide to the other Party upon such other Party’s request a certificate evidencing 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 73 

	 	
the coverage required hereby and the amount thereof. Each Party’s coverage shall be with a reputable insurance company and shall have to be maintained for not less than [***] ([***]) [***]
following expiration or termination of this Agreement for any reason. 

 ARTICLE 23 – THE PATENTS 

 

	23.1	Patent Marking. Otsuka acknowledges and agrees that any of the Product Commercialized by it shall be marked with a notice of patent rights as necessary or desirable under Applicable Law to enable the Patents to
be enforced to the maximum extent permissible under Applicable Laws. 

  

	23.2	Claims Relating to Patent Validity. Otsuka shall reasonably cooperate with ARIAD in connection with any claim, action, lawsuit, hearing, patent office review or other Proceeding relating to the validity of the
Patents in the Territory, including by being joined as a necessary party to any such Proceeding at ARIAD’s expense. For clarity, any Proceeding attacking the validity of a Patent in connection with an action under Section 23.4 (for
example, an alleged infringer’s attack on the validity of a Patent as a defense to an allegation of infringement of such Patent) shall be dealt with pursuant to Section 23.4. 

 

	23.3	Patent Prosecution and Maintenance.  

  

	 	23.3.1	ARIAD shall have the first right to prepare, file, prosecute (including any reissues, re-examinations, post-grant proceedings, requests for patent term extensions, supplementary protection certificates, interferences,
and defense of invalidation or opposition proceedings or of other challenges to validity or enforceability) and maintain the Patents in the Territory, and shall keep Otsuka reasonably informed regarding any such matters. Otsuka shall provide
reasonable assistance in connection with any such prosecution and maintenance, including reasonably cooperating with ARIAD, as may be reasonably requested by ARIAD from time to time for the purpose of filing for and obtaining patent extensions and
supplementary or complementary protection certificates, if available, of the Patents under the relevant Applicable Laws of the Territory. 

  

	 	23.3.2	In the event that ARIAD intends to cease to prosecute, or maintain a Patent in a country in the Territory, ARIAD shall provide reasonable prior written notice to Otsuka of such intention (which notice shall, in any
event, be given no later than [***] ([***]) days prior to the next deadline for any action that may be taken with respect to prosecution or maintenance of such ARIAD Patent in such country), and Otsuka shall thereupon have the option, in its sole
discretion, to assume the control and direction of the, prosecution and maintenance of such Patent in such country. Upon Otsuka’s written exercise of such option, Otsuka shall assume responsibility and full control for the prosecution and
maintenance of such patent in such country at its own expense. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 74 

	23.4	Patent Enforcement.  

  

	 	23.4.1	Each Party shall promptly inform the other Party in writing upon its becoming aware of any potential infringement or misappropriation of any of the Patents. Otsuka shall provide reasonable assistance in connection with
any Proceedings to stop such infringement and/or recover damages for such infringement (including joining any action if necessary), as may be reasonably requested by ARIAD. ARIAD shall have the first right to control any such Proceedings and shall
pay any and all costs related to the Proceedings, including but not limited to attorneys fees, expert fees, and court costs. 

  

	 	23.4.2	If ARIAD does not institute an action or proceeding or take other action to prevent or terminate such possible infringement in the Territory within [***] ([***]) days following receipt of notice of such possible
infringement, and if ARIAD does not provide Otsuka with commercially reasonable reason(s) why such action has not been taken within such [***] ([***])-day period, then, Otsuka shall have the right at its sole discretion to institute an action or
proceeding or take other appropriate action that it believes is reasonably required to prevent or terminate such possible infringement in the Territory, including possible infringement of the Composition Patent in the Territory if (and only if) such
possible infringement involves the development or commercialization of a product that contains the Compound, with the reasonable assistance and cooperation of ARIAD. In the event that Otsuka institutes an action or proceeding or takes other
appropriate action that it believes is reasonably required to prevent or terminate such possible infringement in the Territory, Otsuka reserves that right to have sole control over such proceedings, but shall not have the right to enter into
settlement agreements with any Third Party without ARIAD’s prior written consent. For clarity, the foregoing right of Otsuka to institute an action or proceeding or take other appropriate action that it believes is reasonably required to
prevent or terminate such possible infringement in the Territory shall only apply with respect to the Composition Patent if such possible infringement involves the development or commercialization of a product that contains the Compound.

  

	 	23.4.3	Any recoveries from such Proceedings or amounts received by ARIAD or Otsuka from the settlement of the same shall be allocated as follows: First, each Party shall be reimbursed for its direct, out-of-pocket expenses for
conducting, or cooperating with, such Proceeding, and second, the balance shall be split equally between the Parties, provided that any recovery or settlement amount that includes countries outside of the Territory shall be apportioned between the
Territory and countries outside the Territory by ARIAD, acting reasonably and in good faith, prior to such allocation between the Parties. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 75 

	23.5	Infringement Claims by Third Parties.  

  

	 	23.5.1	Each Party shall promptly notify the other Party in writing of any allegation by a Third Party in the Territory that any Product development, Commercialization (including import or export) or manufacturing activities
conducted by the Parties pursuant to this Agreement infringe or misappropriate or may infringe or misappropriate the Intellectual Property Rights in the Territory of such Third Party (a “Third Party Infringement Claim”). The Parties
shall discuss which Party shall defend the Third Party Infringement Claim, and absent mutual agreement otherwise, each Party shall have the right to control the defense of any such Third Party Infringement Claim brought against it, by counsel of its
own choice. If a Third Party Infringement Claim is brought against one Party (the “Defending Party”) but not the other Party, the non-Defending Party shall have the right, at its own expense, to be represented in such Third Party
Infringement Claim by counsel of its own choice. 

  

	 	23.5.2	Each Defending Party shall keep the other Party reasonably informed of all material developments in connection with any Third Party Infringement Claim. Each Defending Party agrees to provide the other Party with copies
of all pleadings filed in any suit or proceeding relating to such Third Party Infringement Claim. The Defending Party may enter into a settlement or compromise of any Third Party Infringement Claim, provided that, if such settlement or compromise
would admit liability on the part of the non-Defending Party or any of its Affiliates or would otherwise have a material adverse effect on the rights or interests of the non-Defending Party or its Affiliates, the Defending Party shall not enter into
such settlement or compromise without the prior written consent of the non-Defending Party. 

  

	 	23.5.3	If a Third Party Infringement Claim is brought against both Parties, all out-of-pocket expenses incurred by each Defending Party in defending such Third Party Infringement Claim in the Territory (including outside
counsel fees), and all amounts payable by either Defending Party as a judgment based on such Third Party Infringement Claim or in settlement of such Third Party Infringement Claim (excluding payments pursuant to any Third Party License, which is
governed by Section 23.6), shall be paid for by the Parties as follows: [***]% by Otsuka and [***]% by ARIAD. 

  

	 	23.5.4	 If a Third Party Infringement Claim is brought against only one Defending Party, all out-of-pocket expenses incurred by such Defending Party in
defending such Third Party Infringement Claim in the Territory (including outside counsel fees), and all amounts payable by such Defending Party as a judgment based on such Third Party Infringement Claim or in settlement

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 76 

	 	
of such Third Party Infringement Claim (excluding payments pursuant to any Third Party License, which is governed by Section 23.6), shall be paid for by such Defending Party.

  

	 	23.5.5	Any recovery by a Party of any sanctions or other amounts awarded to such Party against a Third Party asserting a Third Party Infringement Claim shall be applied in the same manner as recoveries in an action as set
forth in Section 23.4.3 

  

	 	23.5.6	If a Defending Party elects to enter into an agreement with a Third Party to obtain a license under such Third Party’s Intellectual Property Rights (“Third Party License”) in settlement of a Third
Party Infringement Claim asserted by such Third Party, the provisions of Section 23.6 shall apply. 

  

	23.6	Third Party Licenses.  

  

	 	23.6.1	Final Manufacturing. With respect to any Third Party License that is necessary or useful for Otsuka to perform Final Manufacturing of Product in the Territory and is not necessary for such Final
Manufacturing to conform to any specifications provided by ARIAD under this Agreement, [***] shall have the final decision-making authority and responsibility for negotiating such Third Party License and for making any payments due thereunder, at
its sole cost and expense. 

  

	 	23.6.2	Territory-Only Third Party License.  

  

	 	(a)	With respect to any Third Party License that is necessary or useful for Otsuka to develop Product, or Commercialize, or perform Final Manufacturing of Product (to the extent necessary to conform to any specifications
provided by ARIAD under this Agreement) in the Territory and that is not necessary or useful for the development, commercialization or manufacture of Product outside the Territory (“Territory-Only Third Party License”), the Parties
(through the JDCC) shall discuss whether such license is so necessary or useful and whether to obtain such Territory-Only Third Party License. 

  

	 	(b)	If a Territory-Only Third Party License is necessary for Otsuka to develop Product, or Commercialize, or perform Final Manufacturing of Product (to the extent necessary to conform to any specifications provided by ARIAD
under this Agreement) in the Territory, [***] shall have the responsibility for negotiating such license and shall have the final decision-making authority regarding the terms of such license, subject to Section 23.6.4. 

 

	 	(c)	 If a Territory-Only Third Party License is useful (but not necessary) for Otsuka to develop Product, or Commercialize, or perform Final

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 77 

	 	
Manufacturing of Product (to the extent necessary to conform to any specifications provided by ARIAD under this Agreement) in the Territory, the JDCC shall determine (with neither Party having
final decision-making authority) whether to obtain such Territory-Only Third Party License and, if such a determination is made to obtain such license, [***] shall have responsibility for negotiating such license in accordance with terms agreed upon
by the Parties. If the Parties are unable to agree upon terms for a useful Territory-Only Third Party License that the JDCC has determined to obtain, [***] shall have the final decision-making authority regarding the terms of such license, subject
to Section 23.6.4. For clarity, if Otsuka determines to obtain a useful Territory-Only Third Party License despite the absence of a determination by the JDCC to obtain such license, the terms of this Section 23.6 shall not apply and [***]
shall have the sole responsibility and authority for negotiating such Territory-Only Third Party License and for making any payments due thereunder, at its sole cost and expense. 

 

	 	(d)	In the event Otsuka enters into a Territory-Only Third Party License (i) in accordance with Section 23.6.2(b) or (ii) in accordance with Section 23.6.2(c) in the event of a determination by the JDCC
to obtain such license, Otsuka shall have the right to deduct [***] percent ([***]%) of all royalties paid pursuant to such Territory-Only Third Party License from the royalties payable to ARIAD pursuant to Section 19.3; provided, that in no
event shall the royalty rate otherwise payable to ARIAD pursuant to Section 19.3.1 and Section 19.3.2 be reduced by more than [***] percent ([***]%) in the aggregate (i.e. the royalty rate during the Full Royalty Term never below [***]%
and the royalty rate during the Reduced Royalty Term never below [***]%); and provided further that, if, but for the preceding proviso, the deduction under this Section 23.6.2(b) would have reduced a royalty payment made by Otsuka to ARIAD by
more than [***] percent ([***]%), then the amount of such deduction that exceeds [***] percent ([***]%) will be carried over to subsequent royalty payments until the full amount that Otsuka would have been entitled to deduct (absent the preceding
proviso) is deducted. 

  

	 	23.6.3	Global Third Party License. 

  

	 	(a)	With respect to any Third Party License that is necessary or useful for Otsuka to develop Product, or Commercialize, or perform Final Manufacturing of Product (to the extent necessary to conform to any specifications
provided by ARIAD under this Agreement) in the Territory and is also necessary or useful for the development, commercialization or manufacture of Product outside the Territory (“Global Third Party License”), the Parties (through the
JDCC) shall discuss whether to obtain such Global Third Party License. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 78 

	 	(b)	If a Global Third Party License is necessary for Otsuka to develop Product, or Commercialize, or perform Final Manufacturing of Product (to the extent necessary to conform to any specifications provided by ARIAD under
this Agreement) in the Territory, [***] shall have the responsibility for negotiating such license and shall have the final decision-making authority regarding the terms of such license, subject to Section 23.6.4. 

 

	 	(c)	If a Global Third Party License is useful (but not necessary) for Otsuka to develop Product, or Commercialize, or perform Final Manufacturing of Product (to the extent necessary to conform to any specifications provided
by ARIAD under this Agreement) in the Territory, the JDCC shall determine (with neither Party having final decision-making authority) whether to obtain such Global Third Party License and, if such a determination is made to obtain such license,
[***] shall have responsibility for negotiating such license in accordance with terms agreed upon by the Parties. If the Parties are unable to agree upon terms for a useful Global Third Party License that the JDCC has determined to obtain, [***]
shall have the final decision-making authority regarding the terms of such license, subject to Section 23.6.4. For clarity, if ARIAD determines to obtain a useful Global Third Party License despite the absence of a determination by the JDCC to
obtain such license, the terms of this Section 23.6 shall not apply and [***] shall have the sole responsibility and authority for negotiating such Global Third Party License and for making any payments due thereunder, at its sole cost and
expense. 

  

	 	(d)	In the event ARIAD enters into a Global Third Party License (i) in accordance with Section 23.6.3(b) or (ii) in accordance with Section 23.6.3(c) in the event of a determination by the JDCC to obtain
such license, the royalties owed by ARIAD under such Global Third Party License that are attributable to Net Sales of Product in the Territory shall be paid for by the Parties as follows: [***]% by Otsuka and [***]% by ARIAD. For clarity, ARIAD
shall be responsible for payment of any other amounts under a Global Third Party License that the JDCC has determined to obtain, and Otsuka shall not bear any costs related to such Global Third Party License other than its [***]% share of royalties
attributable to Net Sales of the Product in the Territory. 

  

	 	23.6.4	 In the case of Section 23.6.2 and 23.6.3 the negotiating Party shall keep the other Party reasonably informed with respect to the negotiations
and deal terms relating to such license (including scope of the license and financial terms) and the negotiating Party shall consider in good faith any comments, 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 79 

	 	
recommendations or analysis provided by the other Party. With respect to any Global Third Party License, ARIAD shall ensure that such license includes the right for ARIAD to sublicense such
licensed Intellectual Property Rights to Otsuka pursuant to this Agreement. 

 ARTICLE 24 – CONFIDENTIALITY 

 

	24.1	Each Party shall treat as strictly confidential any information and/or document received from the other Party or its Affiliates hereunder, and not generally known to the trade (all hereinafter referred to as the
“Confidential Information and non-public information relating to the business of the disclosing Party or its Affiliates (which shall be deemed to be the Confidential Information of the disclosing Party), and Otsuka shall treat as
strictly confidential non-public information relating to the Patents, the Know-How and the Improvements (which shall be deemed to be the Confidential Information of ARIAD) and each receiving Party shall use the Confidential Information of the
disclosing Party solely for the purpose of and in accordance with this Agreement. Each Party may disclose Confidential Information of the other Party to its employees and agents and to the employees and agents of its Affiliates, Sublicensees (in the
case of Otsuka), Subcontractors (in the case of Otsuka) and other Third Party contractors solely for purposes, and only to the extent reasonably required, to facilitate the performance of such Party’s rights or obligations under this Agreement,
provided that each such employee and agent and such Sublicensee, Subcontractor or other Third Party contractor, as applicable, has executed a written confidentiality agreement with such receiving Party containing provisions that protect the
Confidential Information of the disclosing Party that are materially equivalent to, or more protective than, the provisions of this Article 24. In addition, ARIAD and Otsuka each agrees that the other Party may disclose its Confidential Information
(a) to such other Party’s legal and financial advisors, (b) as reasonably necessary in connection with an actual or potential (i) debt or equity financing of such other Party, (ii) merger, acquisition, consolidation, share
exchange or other similar transaction involving such Party and any Third Party, or (iii) prosecution, defense or enforcement of any patent pursuant to Article 24 and (c) for any other purpose with the other Party’s consent, not to be
unreasonably withheld, conditioned or delayed. Except as set forth in the two preceding sentences, neither Party shall make Confidential Information of the other Party available to any Third Party, or any of its Affiliates, except in accordance with
Section 24.2 or to applicable government agencies as required by Applicable Laws, and in this case (a) solely to the extent required by such Applicable Laws (based on advice of legal counsel) and (b) only upon exercise of its
reasonable efforts to cause said agencies to maintain confidentiality thereof. Notwithstanding the foregoing, [***], except to the extent required for Otsuka to perform its obligations under this Agreement or to comply with Applicable Laws, Otsuka
shall not disclose the Confidential Information of ARIAD or Confidential Information of Otsuka relating to the Compound, the Product, this Agreement, or any other agreement executed pursuant to this Agreement (other than the Pharmacovigilance
Agreement) to any employee or agent of Otsuka or its Affiliates who is involved in Otsuka’s activities related to [***] under the [***]. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 80 

	24.2	Subject to any different arrangements agreed in writing by the Parties pursuant to Section 5.9, prior to the publication or presentation of any information or data arising from any Third Party Research Project,
development work performed by Otsuka or its Affiliates pursuant to Section 5.2, or other research or development activities performed hereunder, Otsuka shall submit to ARIAD a summary of the proposed publication or presentation at least [***]
([***]) days prior to the submission thereof for publication or presentation. The purposes for such prior submission are: (i) to provide ARIAD with the opportunity to review and comment on the contents of the proposed publication or
presentation; and (ii) to identify any Confidential Information to be deleted from the proposed publication or presentation. Any said publication or presentation may however be made only upon the prior written consent of ARIAD, which consent
may be withheld by ARIAD in its sole and absolute discretion. 

  

	24.3	Notwithstanding expiration or termination of this Agreement for any reason, the foregoing confidentiality and non-use obligations shall continue for a period of [***] ([***]) [***] after expiration or termination of
this Agreement, provided that the foregoing confidentiality and non-use obligations relating to Confidential Information relating to the Patents, the Know-How and the Improvements shall continue until such Confidential Information falls within one
of the provisions below in this Section 24.3. Notwithstanding the foregoing, nothing contained in this Article 24 shall in any way restrict or impair the right of either Party to use, disclose or otherwise deal with Confidential Information of
the disclosing Party, which the receiving Party can demonstrate by competent written evidence: 

  

	 	24.3.1	is or hereafter becomes part of the public domain through no act or omission of the receiving Party, its employees, Affiliates, sublicensees and/or subcontractors; or 

 

	 	24.3.2	was in the lawful possession of the receiving Party prior to receipt of the Confidential Information from the disclosing Party; or 

  

	 	24.3.3	previously was, or at any time hereafter is, provided to the receiving Party by a Third Party having the right to do so and which did not originate directly or indirectly from the disclosing Party; or 

 

	 	24.3.4	at the time of disclosure, was known by the receiving Party or an Affiliate, sublicensee or subcontractor other than as a result of disclosure to such party by the disclosing Party, or after disclosure was independently
developed by the receiving Party, an Affiliate, sublicensee or subcontractor without use of the Confidential Information of the disclosing party. 

  

	24.4	The content of this Agreement shall constitute Confidential Information of each Party and shall be treated by both Parties in accordance with the provisions of this Article 24 and Section 31.9 (Public Statements).

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 81 

 ARTICLE 25 – TERM 

 

	25.1	This Agreement comes into force at the Effective Date hereof and shall remain in effect for the Term. 

  

	25.2	ARIAD shall have the option, at its sole discretion, to take over Commercialization of the Product in the Territory or to appoint another distributor at the expiration of the Term (including on a country-by-country
basis in the event of a partial termination of this Agreement by ARIAD pursuant to Section 26.4; provided that, in the event of termination of this Agreement pursuant to Section 26.4.1, ARIAD shall only have such option if Otsuka does not
elect to revive this Agreement within the [***] ([***]) [***] period provided under Section 26.4.1). 

 ARTICLE 26
– TERMINATION 
  

	26.1	Uncured Material Breach. If either Party (the “Non-Breaching Party”) believes that the other Party (the “Breaching Party”) is in material breach of any of its obligations under
this Agreement or under the Pharmacovigilance Agreement or the Quality Agreements, then the Non-Breaching Party may deliver written notice of such material breach to the Breaching Party specifying the nature of the breach (a “Default
Notice”). The Breaching Party shall have [***] ([***]) [***] (or [***] ([***]) days in the event of a payment breach) from the receipt of the Default Notice to cure such breach or to dispute the allegation of breach. If the Breaching Party
fails to cure, and fails to dispute, such breach within such [***]-day period (or [***] ([***]) day period in the event of a payment breach by Otsuka), then the Non-Breaching Party may terminate this Agreement by giving the Breaching Party written
notice of termination, which termination shall be effective immediately upon the Breaching Party’s receipt of such notice of termination. If the Breaching Party disputes in good faith the existence or materiality of a breach specified in a
Default Notice or disputes any allegation that the Breaching Party failed to cure or remedy such breach, and the Breaching Party provides written notice of such dispute to the Non-Breaching Party within the above [***] period (or [***] ([***]) [***]
with respect to payment obligations), the matter shall be addressed under the dispute resolution procedures in Article 30 (and during the pendency of such dispute resolution, the Non-Breaching Party may not terminate this Agreement). If, as a result
of the application of such dispute resolution procedures, the Breaching Party is determined to be in material breach of any provision of this Agreement (an “Adverse Ruling”), and if the Breaching Party fails to complete the actions
specified by the Adverse Ruling to cure such material breach within [***] ([***]) [***] after its receipt of such Adverse Ruling (or within [***] ([***]) [***] in the case of an Adverse Ruling resulting from a payment breach), then the Non-Breaching
Party may terminate this Agreement by giving the Breaching Party written notice of termination, which termination shall be effective immediately upon the Breaching Party’s receipt of such notice of termination. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 82 

	26.2	Bankruptcy or Insolvency.  

  

	 	26.2.1	Either Party shall have the right to terminate this Agreement immediately upon written notice to the other Party, if such other Party (i) files a petition under any bankruptcy act or has any such petition filed
against it that is not discharged within [***] ([***]) [***] of the filing thereof, (ii) makes an assignment for the benefit of creditors, or (iii) appoints or suffers appointment of a receiver or trustee over substantially all of its
property that is not discharged within [***] ([***]) [***] after such filing. 

  

	 	26.2.2	All licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or
jurisdiction, licenses of rights to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that Otsuka, as licensee of such rights under this Agreement, shall retain and may fully exercise
all of its rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against ARIAD under
the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction which proceeding is not terminated or withdrawn within [***] ([***]) [***] after such commencement, Otsuka shall be entitled (unless ARIAD elects to continue
to perform all of its obligations under this Agreement) to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property necessary to exercise its license rights
granted hereunder, which, if not already in the Otsuka’s possession, shall be promptly delivered to it (i) after [***] ([***]) [***] following any such commencement of a bankruptcy proceeding, upon Otsuka’s written request therefor
(unless ARIAD elects to continue to perform all of its obligations under this Agreement), or (ii) if not delivered under clause (i) above, following the rejection of this Agreement by or on behalf of ARIAD, upon written request therefor by
Otsuka. 

  

	26.3	Otsuka’s Right to Terminate. Without limiting Otsuka’s rights set forth elsewhere in this Agreement, at any time, Otsuka may terminate this Agreement on a country-by-country basis or for the entire
Territory, at its sole discretion for any reason or no reason, by providing written notice of termination to ARIAD, which termination shall be effective one hundred eighty (180) days after the date of such notice (or such longer time period as
may be specified in such notice), provided, that if Otsuka elects to terminate this Agreement with respect to Japan pursuant to this Section 26.3, Otsuka must simultaneously terminate this Agreement with respect to the entire Territory.

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 83 

	26.4	ARIAD’s Rights to Terminate. Without limiting ARIAD’s rights set forth elsewhere in this Agreement, ARIAD shall have the right to terminate this Agreement with respect to all Products (except as set
forth in Section 26.4.1) within a country in the Territory or the Territory as a whole, as applicable, by written notice to Otsuka as follows: 

  

	 	26.4.1	ARIAD shall have the right to terminate this Agreement for the entire Territory, on a Product-by-Product basis, [***] ([***]) [***] after a Product Withdrawal from the entire Territory (unless, prior to the expiration
of such [***] ([***])-[***] period, such Product is authorized pursuant to Applicable Laws to be re-launched and Commercialized in the Territory) if such Product Withdrawal results from a significant safety risk inherent in such Product and not due
to tampering, a remediable Manufacturing problem or other Non-Conformance that can be cured with respect to such Product Manufactured after such risk has been discovered; provided, that if ARIAD terminates this Agreement pursuant to this
Section 26.4.1 and such Product is subsequently able to be Commercialized in the Territory in accordance with Applicable Law, then ARIAD shall promptly provide Otsuka with written notice thereof and for a period of [***] ([***]) [***] from
Otsuka’s receipt of such notice, Otsuka shall have an exclusive right of first refusal to elect to revive this Agreement under the same terms and conditions in effect as of the date of termination, with such revival being effective as of the
date of any such election by Otsuka. 

  

	 	26.4.2	ARIAD shall have the right to terminate this Agreement on a country-by-country basis in the Territory if (a) ARIAD has timely complied with its obligations to supply Product to Otsuka as expressly set forth in this
Agreement and the Supply Agreement, (b) Otsuka has failed to launch the Product within [***] ([***]) [***] of receipt of Pricing and Reimbursement Approval in such country, and (c) Otsuka has not provided written notice to ARIAD of a good
faith commercially reasonable excuse or reason for not launching the Product in such country by such date, provided, that if ARIAD disputes in good faith whether such excuse or reason provided by Otsuka is commercially reasonable, then the
dispute shall be resolved pursuant to Article 30 and if, as a result of the application of such dispute resolution procedures, such excuse or reason is determined to not be commercially reasonable, then ARIAD may terminate this Agreement by written
notice to Otsuka, and provided further, that any termination pursuant to this Section 26.4.2 with respect to Japan shall give ARIAD the right to simultaneously terminate this Agreement with respect to the entire Territory.

  

	 	26.4.3	ARIAD shall have the right to terminate this Agreement on a country-by-country basis in the Territory if (a) ARIAD has delivered all required data and other information to Otsuka on a timely basis, and
(b) Otsuka or its Sublicensee has failed to file (x) an application for Marketing Authorization in such country (if such country does not require additional clinical trials) within [***] ([***]) months of the Effective Date, or (y) an
investigational new drug application for conducting clinical trials of the Product in such country (if such country requires such additional clinical trials to support an application for Marketing Authorization) within [***] ([***]) [***] of the

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 84 

	 	
Effective Date; provided, that any termination pursuant to this Section 26.4.3 with respect to Japan shall give ARIAD the right to simultaneously terminate this Agreement with respect
to the entire Territory. For clarity, if the initial JNDA filing in Japan is delayed beyond [***] ([***]) [***] of the Effective Date due to causes beyond Otsuka’s control (such as ARIAD’s delay in preparing the initial JNDA or PMDA
actions, requests or requirements), ARIAD shall not have the right to terminate this Agreement pursuant to this Section 26.4.3. 

  

	 	26.4.4	ARIAD shall have the right to terminate this Agreement on a country-by-country basis in the Territory or with respect to the entire Territory, in ARIAD’s discretion, if Otsuka breaches its obligations set forth in
Section 3.2. 

  

	26.5	Regulatory Non-compliance. Additionally, ARIAD shall have the right to terminate this Agreement in its entirety upon written notice to Otsuka if Otsuka’s development or Commercialization of the Product is in
violation of Applicable Laws, as evidenced by an order, directive or other official action of a Regulatory Authority, court or other competent authority (provided, that any action of a Regulatory Authority, court or other competent authority against
an employee or individual that is not against the company of Otsuka as a whole shall be excluded from the foregoing) and Otsuka has not cured such failure within [***] ([***]) [***] after notice from ARIAD (provided that there shall be no
opportunity for cure the [***] that ARIAD provides notice of termination under this Section 26.5). Any such termination shall become effective at the end of such [***] ([***]) [***] period unless Otsuka has cured any such failure prior to the
end of such period (or, if applicable, immediately upon notice the third time that ARIAD provides notice of termination under this Section 26.5). 

  

	26.6	Termination for Force Majeure. For the avoidance of doubt, this Agreement also may be terminated as set forth in Article 28 (Force Majeure). 

 

	26.7	Effects of Termination and Expiration. 

  

	 	26.7.1	Termination or expiration of this Agreement for any reason shall not extinguish any existing claims either of the Parties may have for indemnification pursuant to the terms and conditions of this Agreement, and shall
not preclude either of the Parties from pursuing any claim for indemnification such Party otherwise may have pursuant to the terms and conditions of this Agreement to the extent that the circumstances giving rise to such claim arose prior to, on or
after the date of termination or expiration of this Agreement. Furthermore, the termination or expiration this Agreement shall have no effect on a Party’s obligation to make any payment accruing prior to the date of termination or expiration.

  

	 	26.7.2	 In the event of termination or expiration of this Agreement for any reason the payments already made by Otsuka as of the effective date of termination

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 85 

	 	
shall be retained by ARIAD, provided, that the foregoing shall not limit any rights or remedies Otsuka may have at law or equity under this Agreement, including any remedies for a material
breach of this Agreement. 

  

	 	26.7.3	Subject to any arrangements agreed upon in writing between the Parties to facilitate Otsuka’s sell-off right pursuant to Section 26.7.5 in the event that ARIAD does not exercise its right to purchase
Otsuka’s remaining stocks of Product, upon expiration or termination of this Agreement for any reason, all rights granted hereunder to Otsuka shall be terminated with respect to the terminated Product(s) (each, a “Terminated
Product”) and the terminated country(ies) within the Territory (each, a “Terminated Country”), such rights to the Terminated Products in the Terminated Countries shall revert to ARIAD, and, to the extent required or
permitted by Applicable Laws, all information, copyrights, permits, licenses, contracts, documentation, drug approvals, Pricing and Reimbursement Approvals, Marketing Authorizations, customer lists and other information and materials specifically
and directly related to the Terminated Products in the Terminated Countries shall be transferred to ARIAD. Solely with respect to such Terminated Products in such Terminated Countries, Otsuka shall: 

 

	 	(a)	(i) promptly cease any use and/or exploitation of the Marketing Authorization and Registrations with respect to the Terminated Products in the Terminated Countries and (ii) promptly and unconditionally assign all
and every lawfully assignable official title, or certificate or equivalent document concerning the Marketing Authorization or Registrations with respect to the Terminated Products in the Terminated Countries to ARIAD or to ARIAD’s nominee;

  

	 	(b)	promptly cease any use of the Trademarks and Patents with respect to the Terminated Products in the Terminated Countries and not hold itself out as a distributor of the Terminated Products in the Terminated Countries;

  

	 	(c)	promptly terminate using (i) the Know-how with respect to the Terminated Products in the Terminated Countries, (ii) the Improvements with respect to the Terminated Products in the Terminated Countries,
including the results of its development work on the Terminated Products, (iii) any and all Confidential Information of ARIAD relating solely to the Terminated Products in the Terminated Countries, (iv) any and all correspondence and
exchanges with any Regulatory Authority with respect to the Terminated Products in the Terminated Countries, and (v) pharmacovigilance and/or regulatory files and documentation relating to the Terminated Products in the Terminated Countries,
and return or deliver all such materials to ARIAD without retaining copies, notes, summaries or translations thereof (except as expressly required by law or to monitor Otsuka’s compliance with the terms of this Agreement); 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 86 

	 	(d)	promptly cease Commercializing the Terminated Products in the Terminated Countries; 

  

	 	(e)	assign to ARIAD all right, title and interest, including all Intellectual Property Rights in and to the Terminated Products marketing, sales and medical affairs materials. Otsuka shall execute any documents and take all
actions reasonably required by ARIAD to perfect the foregoing assignment; 

  

	 	(f)	promptly comply with all other post-expiration and/or post-termination obligations provided in this Agreement; and 

  

	 	(g)	cooperate with all reasonable requests of ARIAD relating to the transition of activities relating to Product to ARIAD or its designee. 

 

	 	26.7.4	Otsuka shall not destroy any documentation pertaining to the Product or Compound without the prior written consent of ARIAD. 

  

	 	26.7.5	Upon the expiration or termination of this Agreement, ARIAD shall have the right but not the obligation to purchase all or a part of Otsuka’s remaining stocks of the Product at the prices paid by Otsuka to ARIAD
for such stocks. In case ARIAD elects not to purchase such remaining stocks, if permitted by applicable Regulatory Authorities, Otsuka shall have the right to sell such stock for an additional [***] ([***]) [***] following termination, or any such
other period of time agreed upon by the Parties (the “Sell-Off Period”). In such event, to the extent that the consent or approval of any Regulatory Authority is required for Otsuka’s lawful sell-off of its remaining stocks
during the Sell-Off Period, the Parties shall use good-faith efforts to obtain such consent or approval. If, during the Sell-Off Period, ARIAD is the MAH for the Product in any country in the Territory, the Parties shall use good-faith efforts to
negotiate a distribution agreement if necessary to allow Otsuka to exercise its sell-off right during the Sell-Off Period in the country in question. The Sell-Off Period shall not be deemed to extend the Term, but all provisions of this Agreement
applicable to the lawful Commercialization of Product in the Territory, and the Quality Agreements and the Pharmacovigilance Agreement, shall continue to apply with respect to Otsuka’s Commercialization of Product during the Sell-Off Period.

  

	 	26.7.6	 Upon expiration or termination of this Agreement, however arising, neither Party shall be entitled to any compensation or fee as a result of such
termination. Following such expiration or termination, ARIAD shall have no obligations to compensate Otsuka for helping to build or maintain the 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 87 

	 	
market for Products or for its expectations that it shall continue to enjoy the benefits of its position in accordance with this Agreement. In no case shall any provision of Applicable Laws
entitle Otsuka to notice of termination in excess of that to which it is entitled in accordance with the explicit provisions of this Agreement or to compensation in lieu of such notice. Otsuka shall have no right to any compensation or damages for
loss of goodwill in the event of any expiration or termination of this Agreement. The Parties agree that the Transfer Price and other financial terms set forth in this Agreement were determined on the basis of their mutual understanding that Otsuka
is not a commercial agent as that term is defined in Applicable Laws and that law does not apply to their relationship.

ARTICLE 27 – STANDSTILL 
  

	27.1	Standstill Obligation. 

  

	 	27.1.1	Except as permitted by [***], during the Term, without the prior written consent of the Board of Directors [***] or encourage others to) directly or indirectly in any manner: [***] or agree to acquire, directly or
indirectly, alone or in concert with others, [***] or in any way participate in, directly or indirectly, alone or in concert with others, any [***] or in any way participate in a “group” [***] directly or indirectly, alone or in concert
with others [***], other than in the ordinary course of business; [***] with others to do any of the actions [***] otherwise act in concert with others, [***], or (vii) take any action to control or influence the [***] or [***] of [***].

  

	 	27.1.2	The provisions of Section 27.1.1 [***] announces publicly that it is seeking [***], [***] or one or more of its subsidiaries to a third party [***] immediately prior to [***]. For clarity, the foregoing provisions
shall prohibit [***] unless one of the exceptions in the preceding sentence [***]. For avoidance of doubt, nothing in the Agreement shall prevent [***]. Notwithstanding the above, [***] shall not be deemed a breach of this provision.

 ARTICLE 28 – FORCE MAJEURE 
  

	28.1	 If the performance of this Agreement is prevented or restricted by government action, war, fire, explosion, flood, strike, lockout, embargo,
epidemics, pandemics, quarantines, acts of terrorism, lockouts or other labor disturbances, act of God, failures of common carriers, or any other similar cause beyond the control of the defaulting Party, or supply failures due to the foregoing or
similar causes beyond the control of the defaulting Party’s suppliers or contractors, the Party so affected shall be released for the duration of the force majeure, or such other period agreed between the Parties as being

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 88 

	 	
reasonable in all circumstances, from its contractual obligations directly affected by the force majeure, provided that the Party concerned shall: 

 

	 	(a)	give prompt notice in writing to the other Party of the cause of force majeure; 

  

	 	(b)	use commercially reasonable efforts to avoid or remove such cause of non-performance; and 

  

	 	(c)	continue the full performance of this Agreement as soon as such cause is removed. 

  

	28.2	The Parties shall take all reasonable steps to minimize the effects of force majeure on the performance of this Agreement and shall, if necessary, agree upon appropriate measures to be taken. Should the force majeure
continue for more than [***] ([***]) [***], then the Party not affected by such force majeure shall have the right to terminate this Agreement immediately upon written notice to the affected Party. 

 

	28.3	Notwithstanding anything contained in this Article 28, obligations to pay money are never excused by force majeure. 

ARTICLE 29 – LAW TO GOVERN AND JURISDICTION 
  

	29.1	This Agreement shall be governed by and construed in accordance with the law of the Commonwealth of Massachusetts, United States of America, excluding any conflicts or choice of law rule or principle that might
otherwise make this Agreement subject to the substantive law of another jurisdiction. The federal courts of the United States of America located in Boston shall have exclusive jurisdiction with regard to any (i) a dispute, controversy or claim
that concerns (A) the validity, enforceability or infringement of a patent, trademark or copyright or (B) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory, and (ii) any dispute between the
Parties as to whether Article 30 requires a particular matter to be subject to arbitration. Either Party may seek injunctive relief from any court of competent jurisdiction with respect to any claim for specific performance or injunctive or other
equitable relief as a remedy for a breach or threatened breach of Article 24. Either Party may seek the enforcement of any award of damages, including arbitral awards, in any court of competent jurisdiction.  

ARTICLE 30 – DISPUTE RESOLUTION 
  

	30.1	Generally. The Parties recognize that disputes as to matters arising under or relating to this Agreement or either Party’s rights and/or obligations hereunder may arise from time to time. It is the objective
of the Parties to establish procedures to facilitate the resolution of such disputes in an expedient manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in
this Article 30 to resolve any such dispute if and when it arises. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 89 

	30.2	Escalation to Senior Officers. If an unresolved dispute as to matters arising under or relating to this Agreement or either Party’s rights and/or obligations hereunder arises (other than any dispute at the
JDCC which is subject to the dispute resolution procedures set forth in Section 4.6, or any other matter that is expressly subject to either Party’s final decision-making authority or final approval as set forth elsewhere herein), either
Party may refer such dispute to the Senior Officers or their respective designees, who shall meet in person or by telephone within [***] ([***]) [***] after such referral to attempt in good faith to resolve such dispute. If such matter cannot be
resolved by discussion of such officers within such [***] ([***]) [***] period (as may be extended by mutual written agreement), such dispute shall be resolved in accordance with Section 30.3. The Parties acknowledge that these discussions
between the Parties to resolve disputes are settlement discussions under applicable rules of evidence and without prejudice to either Party’s legal position. 

 

	30.3	Binding Arbitration. 

  

	 	30.3.1	If the Parties do not resolve a dispute as provided in Section 30.2, and a Party wishes to pursue the matter, each such dispute that is neither an Excluded Claim nor subject to resolution in accordance with
Section 30.4 shall be resolved by binding arbitration administered by the International Centre for Dispute Resolution (“ICDR”) in accordance with its International Arbitration Rules as then in effect, and judgment on the
arbitration award may be entered in any court having jurisdiction thereof. The decision rendered in any such arbitration shall be final and not appealable. If either Party intends to commence binding arbitration of such dispute, such Party shall
provide written notice to the other Party informing the other Party of such intention and the issues to be resolved. Within [***] ([***]) [***] after the receipt of such notice, the other Party may by written notice to the Party initiating binding
arbitration, add additional issues to be resolved. 

  

	 	30.3.2	The arbitration shall be conducted by a panel of three (3) persons, none of whom shall be a current or former employee or director, or a then-current stockholder, of either Party or their respective Affiliates.
Within [***] ([***]) [***] after receipt of the original notice of binding arbitration, each Party shall select one (1) person to act as arbitrator and the two (2) Party-selected arbitrators shall select a third arbitrator within [***]
([***]) [***] of their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by the ICDR. The place of arbitration shall be New York, New York, and all
proceedings and communications shall be in English. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 90 

	 	30.3.3	It is the intention of the Parties that discovery, although permitted as described herein, shall be limited except in exceptional circumstances. The arbitrators shall permit such limited discovery necessary for an
understanding of any legitimate issue raised in the arbitration, including the production of documents. No later than [***] ([***]) [***] after selection of the third arbitrator, the Parties and their representatives shall hold a preliminary meeting
with the arbitrators, to mutually agree upon and thereafter follow procedures seeking to assure that the arbitration shall be concluded within [***] ([***]) [***] from such meeting. Failing any such mutual agreement, the arbitrators shall design and
the Parties shall follow procedures to such effect. 

  

	 	30.3.4	Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this
Agreement, seek from any court having jurisdiction any preliminary injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award. The arbitrators shall have no authority to award punitive or
any other non-compensatory damages. The arbitrators shall have the power to order that all or part of the legal or other costs incurred by a Party in connection with the arbitration be paid by the other Party. Each Party shall bear an equal share of
the arbitrators’ and any administrative fees of arbitration. 

  

	 	30.3.5	Except to the extent necessary to confirm or enforce an award or as may be required by Applicable Law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the
prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable Massachusetts
statute of limitations. 

  

	 	30.3.6	 The term “Excluded Claim” means (i) a dispute, controversy or claim that concerns (A) the validity, enforceability or
infringement of a patent, trademark or copyright or (B) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory; (ii) a claim for specific performance or injunctive or other equitable relief as a remedy for
a breach or threatened breach of Article 24; (iii) any dispute concerning a matter that is subject to either Party’s final decision-making authority or final approval, as expressly set forth in this Agreement; or (iv) any dispute
concerning a matter that is subject to the mutual agreement of the Parties, including through the JDCC, as expressly set forth in this Agreement. As set forth in Section 30.3.1, Excluded Claims shall not be subject to arbitration. Furthermore,
the Parties irrevocably agree that they shall not institute any action in a court of law or equity with respect to any dispute to the extent such dispute falls within the scope of subsections (iii) or (iv) of the

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 91 

	 	
definition of “Excluded Claim,” it being the intent of the parties that disputes within the scope of subsection (iii) be resolved by the Party that has express authority under this
Agreement to make such decision or give final approval, and that disputes within the scope of subsections (iv) be resolved by mutual agreement of the Parties. 

 

	30.4	Expedited Arbitration. Any disagreement of the JDCC regarding (i) [***], (ii) the [***], (iii) the [***], or (iv) [***] shall be finally decided by expedited arbitration in accordance with
this Section 30.4. Following the end of the [***] ([***]) [***] (or longer if extended by the Senior Officers) period referenced in Section 4.6.1(c), either Party may request expedited arbitration of such issue by written notice to the
other Party. The place of such expedited arbitration shall be New York, New York, and all proceedings and communications shall be in English. Promptly following receipt of any such notice requesting expedited arbitration, the Parties shall meet and
discuss in good faith and agree on a single expert to resolve the matter, which expert shall have expertise with respect to the disputed matter. If the Parties cannot agree on such expert within [***] ([***]) [***] of a Party’s receipt of
notice requesting expedited arbitration, then such expert, who must have expertise with respect to the disputed matter, shall be appointed by appointed by the ICDR. Within [***] ([***]) [***] after an expert is selected (or appointed, as the case
may be), the Parties shall each submit to the expert, and to one another, a written statement of their respective positions on the issue to be resolved and their specific proposed resolution of the issue. The Parties shall also provide the expert a
copy of this Agreement, as may be amended at such time. Each Party shall have [***] ([***]) [***] from receipt of the other Party’s submission to provide to the expert a written response thereto. Neither Party may have any communication (either
written or oral) with the expert other than for the sole purpose of engaging the expert at the outset or as expressly permitted in this Section 30.4; provided that, the expert shall have the right to meet with the Parties, either alone or
together, as necessary in the expert’s opinion to make a determination. Within [***] ([***]) [***] after the expert’s selection or appointment, the expert must, to resolve the dispute or disagreement at issue, select one of the two
proposed resolutions provided by the Parties – without any modification by the expert – that he or she believes, taken as a whole, is the most fair and reasonable to the Parties in light of the totality of the circumstances, consistent
with the intention underlying, and the agreed principles set forth in, this Agreement. The decision of the expert, which shall be in writing and delivered to both Parties, shall be final, binding, and unappealable. For the avoidance of doubt, the
expert must select, as the only method to resolve the matter at issue, one Party’s proposed resolution, and may not combine elements of both Parties’ proposals or devise any alternative or compromise resolution, award any other relief, or
take any other action. 

  

	30.5	 Entire Agreement. Each schedule, exhibit or appendix hereto is integral to this Agreement and is hereby incorporated herein. This Agreement
supersedes all prior agreements and understandings, including the CDA, whether oral or written, made by either Party or between the Parties and constitutes the entire Agreement of the Parties

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 92 

	 	
with regard to the subject matter hereof. It shall not be considered extended, cancelled or amended in any respect unless done so in writing and signed on behalf of the Parties hereto.
Information disclosed by either Party or its Affiliates under the CDA shall be governed by the CDA until the Effective Date of this Agreement, and shall be deemed to be Confidential Information of the applicable Party disclosed hereunder and subject
to the confidentiality provisions of this Agreement from and including the Effective Date for the duration set forth herein. If there is any conflict between any provision of the main body of this Agreement and any provision set forth in a schedule,
exhibit or appendix hereto (each of which is hereby incorporated herein), the provision set forth in the main body of this Agreement shall govern. 

  

	30.6	Severability. The Parties hereby expressly state that neither Party intends to violate any rule, law or regulation. If any provision of this Agreement is in violation of any rule, law or regulation it shall be
invalid and unenforceable, without affecting the validity or enforceability of other provisions of this Agreement. The Parties agree to renegotiate such provision in good faith and, to the extent possible, to replace it with valid and enforceable
provisions in such a way as to reflect as nearly as possible the intent and purpose of the original provision. 

  

	30.7	Independent contractor status. The status of ARIAD and Otsuka under the business arrangement established by this Agreement is that of independent contractors. Otsuka shall acquire Product from ARIAD or
ARIAD’s nominee and Commercialize them to its Customers in its own name, at its own risk and for its own account. Except as explicitly permitted in writing by ARIAD or its Affiliate, Otsuka has no authority whatsoever to act as an agent or
representative of ARIAD except as expressly set forth in this Agreement, nor any authority or power to contract in the name of or create any liability against or otherwise bind ARIAD or its Affiliate in any way for any purpose, nor shall ARIAD or
its Affiliate have such authority or power to so bind Otsuka. 

  

	30.8	Notices. Other than routine communications made through the JDCC, its subcommittees or project teams, or the Alliance Managers within the remit of such committees or persons, as contemplated elsewhere herein, all
reports, notices, approvals and communications required or permitted to be made pursuant to this Agreement by one Party to the other shall be validly given or made for all purposes, in the absence of acknowledgement of receipt, on the date of
mailing if mailed by registered airmail or by international courier to the addressee Party at the following addresses, respectively: 

Notices to ARIAD: 
 ARIAD
Pharmaceuticals, Inc. 
 26 Landsdowne Street 

Cambridge, Massachusetts 02139-4234 

USA 
 Attention: General Counsel

 Tel: +1 (617) 621-2200 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 93 

 With copies (which shall be required but shall not itself constitute notice) to: 

ARIAD Pharmaceuticals, Inc. 
 26
Landsdowne Street 
 Cambridge, Massachusetts 02139-4234 

USA 
 Attention: Harvey J.
Berger, M.D. 
 Chairman and Chief Executive Officer 

Tel: +1 (617) 621-2200 

and 
 Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C. 
 One Financial Center 

Boston, Massachusetts 02111 

USA 
 Attention: Jeffrey M.
Wiesen, Esq. 
 Tel: +1 (617) 542-6000 

Notices to Otsuka: 
 Otsuka
Pharmaceutical Co., Ltd. 
 Shinagawa Grand Central Tower 

2-16-4 Konan, Minato-ku 
 Tokyo,
108-8242 Japan 
 Attn: Director, Pharmaceutical Division 

Tel: [***] 
 with a copy,
including by email to the Email addresses set forth below, (which shall be required but shall not itself constitute notice) to: 
 Otsuka
Pharmaceutical Co., Ltd. 
 1-7-1 Doshomachi, Chuo-Ku, 

Osaka, 541-0045, Japan 
 Attn:
Director, Licensing Department 
 Email: [***] 

Tel: [***] 
 Otsuka
Pharmaceutical Co., Ltd. 
 Shinagawa Grand Central Tower 

2-16-4 Konan, Minato-ku 
 Tokyo,
108-8242 Japan 
 Attn: Director, Legal Affairs Department 

Email: [***] 
 Tel: [***] 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 94 

	30.9	Binding Effect. This Agreement shall inure to the benefit of, and be binding upon, the respective successors of the Parties. For the avoidance of doubt, the continued existence of this Agreement shall not be
affected in case of change of control of either Party whether by merger with or acquisition by a Third Party. 

  

	30.10	Waiver. The delay or failure of a Party to insist upon strict performance of any of the terms and conditions of this Agreement by the other Party shall not constitute a waiver of any of the provisions hereof and
no waiver by a Party of any of said terms and conditions shall be deemed to have been made unless expressed in writing and signed by such waiving Party. 

  

	30.11	Interpretation. 

  

	 	30.11.1	The language of this Agreement is English. No translation into any other language shall be taken into account in the interpretation of the Agreement itself. 

 

	 	30.11.2	The headings in this Agreement are inserted for convenience only and shall not affect its construction. 

  

	 	30.11.3	Where appropriate, the terms defined in this Agreement and denoting a singular number only shall include the plural and vice versa. Unless otherwise stated, references to days means calendar days, references to quarters
means calendar quarters beginning on the first of January, April, July and October and references to years means calendar years beginning on January 1. 

  

	 	30.11.4	The word “including” and similar words and phrases mean including without limitation, whether or not expressly stated. The words “herein,” “hereof” and “hereunder” and other words
of similar import refer to this Agreement as a whole and not to any particular Articles or other subdivision. References to the singular include the plural. References to one gender include all genders. 

 

	 	30.11.5	References to any law, regulation, statute or statutory provision includes a reference to the law, regulation, statute or statutory provision as from time to time amended, extended or re-enacted. 

 

	30.12	Assignment. 

  

	 	30.12.1	 This Agreement and the rights conferred upon Otsuka under this Agreement cannot be transferred or assigned by Otsuka without the prior, written
authorization of ARIAD, which authorization shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, Otsuka may make such transfer or assignment without ARIAD’s consent to its

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 95 

	 	
Affiliates or to a successor of all or substantially all of Otsuka’s business to which this Agreement relates, whether in a merger, sale of stock, sale of assets or any other transaction,
provided that Otsuka gives ARIAD written notice of the transfer or assignment. With respect to an assignment to an Affiliate, Otsuka shall remain responsible for the performance by such Affiliate of all of Otsuka’s rights and obligations
hereunder. 

  

	 	30.12.2	ARIAD shall have the right to assign or transfer, in whole or in part, this Agreement to its Affiliates or any Third Parties by giving written notice to Otsuka. 

 

	 	30.12.3	This Agreement shall be binding upon and inure to the benefit of the Parties’ respective successors and permitted assigns. 

  

	30.13	Public Statements. 

  

	 	30.13.1	Subject to Section 31.9.2, Otsuka shall not make any public announcement concerning this Agreement or the subject matter hereof without the prior written consent of ARIAD. Upon the execution of this Agreement by
both Parties, the Parties shall issue a joint press release substantially in the form set forth in Appendix 4. Once initial consent to a particular disclosure or public announcement has been given and the disclosure or statement has been made
concerning particular subject matter, Otsuka may make any further public statement concerning such subject matter so long as any such public statement is not inconsistent with the prior public disclosures or public statements approved by ARIAD
pursuant to this Section 31.9.1 and does not reveal non-public information about ARIAD or the Product. 

  

	 	30.13.2	In the event that a Party is, based on the advice of the disclosing Party’s counsel, required by Applicable Laws or the rules of a stock exchange on which its securities are listed (or to which an application for
listing has been submitted) to make a public disclosure regarding this Agreement or its subject matter (including the terms of this Agreement), such Party shall submit the proposed disclosure (or proposed redacted copy of the Agreement, as
applicable) in writing to the other Party as far in advance as reasonably practicable (and in no event less than [***] ([***])[***] prior to the anticipated date of disclosure) so as to provide a reasonable opportunity for the other Party to comment
thereon. Neither Party shall be obligated to obtain approval from the other Party with respect to any filings made with the applicable securities exchange commission. Neither Party shall be required to seek the permission of the other Party to
repeat any information regarding the terms of this Agreement or any amendment thereto that has already been publicly disclosed by such Party, or by the other Party, in accordance with the terms of this Agreement, provided such information remains
accurate as of such time and provided the frequency and form of such disclosure are reasonable. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 96 

	 	30.13.3	Except as expressly permitted in this Agreement or as required by Applicable Law (or the regulations of applicable stock exchanges), neither Party may use the other Party’s trademarks, service marks or trade names,
or otherwise refer to or identify that other Party in marketing or promotional materials, press releases, statements to news media or other public announcements, without the other Party’s prior written consent, which that other Party may grant
or withhold in its sole discretion. 

  

	30.14	Expenses. Unless specifically and expressly provided for to the contrary in this Agreement, a Party who has an obligation or right to take an action under this Agreement shall be solely responsible for any and
all expenses associated with such action. 

  

	30.15	Survival. The following Articles and Sections shall survive expiration or termination of this Agreement for any reason: 1 (to the extent necessary to give force to, or otherwise understand, surviving provisions),
3.2.2, 3.2.3, 3.3, 5.7, 11.5.4, 11.5.6, 11.5.7, 13.4, 14.2 and 14.3 (with respect to indemnification, indefinitely, and with respect to the remainder of Sections 14.2 and 14.3, until the expiration date of the last full or partial lot of Product
purchased by Otsuka hereunder), 14.4, 15.7.3, 19.6 through 19.11 (inclusive), 21.7 (with respect to any Compliance Event that occurred during the Term and is discovered thereafter), 22, 24, 25.2, 26.4.1, 26.7, 29, 30, 31.1 through 31.4 (inclusive),
31.6, 31.7, 31.9, and 31.11 through 31.14 (inclusive). 

  

	30.16	Third Parties Beneficiaries. The Parties intend that any Affiliate of ARIAD that may subsequently become an MAH in the Territory shall have the benefit of this Agreement. Except for any such Affiliate of ARIAD,
or otherwise expressly provided in this Agreement, the provisions of this Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights in any other persons.

  

	30.17	Waiver of Contra Proferendum Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Agreement.
Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

  

	30.18	Remedies to be cumulative. Each Party’s remedies under this Agreement and under the law are intended to be cumulative, and not mutually exclusive. 

[Remainder of page intentionally blank; signature page follows] 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 97 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed in duplicate by their duly
authorized officers. 
  

									
	For and on behalf of				For and on behalf of
			
	ARIAD Pharmaceuticals, Inc.				Otsuka Pharmaceutical Co., Ltd
			
	/s/ Harvey J. Berger				/s/ Taro Iwamoto
					
	Name:		Harvey J. Berger, M.D.				Name:		Taro Iwamoto, Ph.D.
					
	Title:		Chairman and Chief Executive Officer				Title:		President and Representative Director
				
							Otsuka Pharmaceutical Co., Ltd
				
							/s/ Tetsuya Tachikawa
					
							Name:		Tetsuya Tachikawa, Ph.D.
					
							Title:		 Senior Operating Officer and Director
 of
Licensing Department

 Signature Page to Collaboration Agreement 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

 APPENDIX 1 

PATENTS 
 1. Patents and Pending
National Patent Applications 
  

									
	 Country
	  	 Patent App. No.
	  	 Patent Pub. No.
	  	 Patent No.
	  	 Status

	 [***]

[***]

	 China
	  	[***]	  	[***]	  	[***]	  	[***]
	 China
	  	[***]	  	[***]	  		  	[***]
	 Japan
	  	[***]	  	[***]	  	[***]	  	[***]
	 Japan
	  	[***]	  	[***]	  		  	[***]
	 Korea
	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]

[***]

	 China
	  	[***]	  	[***]	  		  	[***]
	 Indonesia
	  	[***]	  		  		  	[***]
	 Japan
	  	[***]	  	[***]	  		  	[***]
	 Korea
	  	[***]	  	[***]	  		  	[***]
	 Malaysia
	  	[***]	  		  		  	[***]
	 Philippines
	  	[***]	  		  		  	[***]
	 Singapore
	  	[***]	  		  		  	[***]
	 Thailand
	  	[***]	  		  		  	[***]
	 Vietnam
	  	[***]	  	[***]	  		  	[***]

 2. National Patents in the Territory based on the following
published 
 International Patent Applications 
  

									
	 PCT Publication Number
	  	 	  	 Filed

	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 Appendix 1 

 APPENDIX 2 

PRE-APPROVED SUBLICENSEES 
 1. List of
Affiliates of Otsuka* 
  

					
	 Country
	  	 Company name
	  	 Shareholders

	 Indonesia
	  	[***]	  	[***]
	  	  	[***]
	  	  	[***]
	 China
	  	[***]	  	[***]
	  	[***]	  	[***]
	  	  	[***]
	 Philippines
	  	[***]	  	[***]
	 South Korea
	  	[***]	  	[***]
	  	  	[***]
	  	  	[***]
	  	[***]	  	[***]
	 Taiwan
	  	[***]	  	[***]
	  	  	[***]
	 Thailand
	  	[***]	  	[***]
	  	  	[***]
	  	  	[***]
	 Vietnam
	  	[***]	  	[***]
	  	  	[***]
	  	  	[***]

  

	*	[***] 

 2. List of Third Party Contractors 

 

					
	 Country
	  	 Third Party Contractor
	  	 Role

	 Malaysia
	  	[***]	  	[***]
	 Singapore
	  	[***]	  	[***]
	 Philippines
	  	[***]	  	[***]
	 Vietnam
	  	[***]	  	[***]
	 Hong Kong
	  	[***]	  	[***]

  

	1)	[***] 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 Appendix 2 

 APPENDIX 3 

TRADEMARKS 
  

															
	 Mark
	  	 Country
	  	 Serial No.
	  	 Filing Date
	  	 Status
	  	 Reg’n No.
	  	 Reg’n

Date
	  	 Class

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	1	Registered 

	2	Pending 

	3	

  
 

 
  

	*	[***] 

	**	[***] 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 Appendix 3 

 APPENDIX 4 

PRESS RELEASE 
  

 
 News Release 

ARIAD AND OTSUKA ANNOUNCE CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR
ICLUSIG® TO TREAT LEUKEMIAS IN JAPAN AND NINE OTHER ASIAN COUNTRIES 
  

	•	 	ARIAD to receive upfront payment of USD 77.5 million and subsequent milestone-based payments 

  

	•	 	Otsuka to obtain rights in ten Asian countries to Iclusig, a newest-generation treatment for patients with refractory chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia 

Cambridge, MA and Tokyo, Japan December 23, 2014 – ARIAD Pharmaceuticals, Inc. (ARIAD; NASDAQ: ARIA) and Otsuka Pharmaceutical Co., Ltd.
(Otsuka) today announced that they have entered into an agreement for Otsuka to commercialize ARIAD’s Iclusig® (ponatinib) in Japan and nine other Asian countries and to fund future
clinical trials in those countries. ARIAD will lead the completion of the Japanese New Drug Application (NDA) for Iclusig, and Otsuka will file the NDA on behalf of both companies for regulatory approval in resistant and intolerant chronic myeloid
leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) in 2015. Iclusig is an approved BCR-ABL inhibitor in the United States and Europe. 

The agreement provides for Otsuka to receive exclusive rights to market Iclusig in Japan and nine other Asian countries (the “Territory”) in return
for an upfront payment of $77.5 million to ARIAD, a milestone payment upon regulatory approval in Japan for patients with resistant and intolerant Philadelphia-positive leukemias, and additional milestone payments for approval in other indications.

 Following approvals in the Territory, Otsuka will conduct sales activities and record sales. ARIAD will also receive a substantial share of net product
sales. 
 ARIAD will continue to fund until the completion its ongoing pivotal trial of Iclusig that will form the basis of the filing for regulatory
approval in Japan, while Otsuka will fund additional agreed-upon clinical studies in the Territory. For ARIAD-sponsored global studies that include sites in Japan, Otsuka has the option to contribute to the funding and gain access to the data for
use in the Territory. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 Appendix 4 

 “This agreement meets one of our key strategic objectives – establishing a strong partnership with an
experienced and committed Japanese pharmaceutical company to commercialize and co-develop Iclusig in Japan and Asia,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “Otsuka is building a leading hematology and
oncology business in Japan and Asia and is an outstanding partner to successfully commercializing Iclusig in these markets.” 
 “Over the past
several years, we have worked with the leading hematology experts in Japan and have run the Phase 1/2 clinical trial that will form the basis for our marketing authorization application,” he added. “Together with Otsuka, we will be able to
make this cancer medicine available to refractory Philadelphia-positive leukemia patients in need of new treatment options.” 
 Otsuka Pharmaceutical
President and Representative Director Taro Iwamoto noted, “The future arrival of ARIAD’s ponatanib in Japan and elsewhere in Asia will be an important evolution for patients with CML and Philadelphia-positive ALL with BCR-ABL gene
expression, said to be particularly difficult to treat. Treatments have been inadequate for patients with these life-threatening conditions and we aim to contribute to improve the treatment available to them. ARIAD’s high-level drug discovery
technology powered its discovery of ponatanib and Otsuka aims to maintain this momentum by making it part of our expanded portfolio in blood cancers from pre-treatment conditioning to treatments.” 

A joint development and commercialization committee will oversee clinical development and commercialization of Iclusig in the Territory, including approval of
any development or commercialization plans. Otsuka will have exclusive commercial rights to Iclusig and will promote it as its sole tyrosine kinase inhibitor in the Territory. In addition to Japan, the other Asian countries that are included in this
agreement are China, South Korea, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam. 
 About Iclusig® (ponatinib) tablets 
 Iclusig is a kinase inhibitor discovered by ARIAD. The primary
target for Iclusig is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Iclusig was designed using ARIAD’s computational and
structure-based drug-design platform specifically to inhibit the activity of BCR-ABL. Iclusig targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has
been associated with resistance to other approved TKIs. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 Appendix 4 

 Important U.S. Safety Information for Iclusig®
(ponatinib) 
 WARNING: VASCULAR OCCLUSION, HEART FAILURE, and HEPATOTOXICITY 

See full U.S. prescribing information for complete boxed warning 
  

	•	 	Vascular Occlusion: Arterial and venous thrombosis and occlusions have occurred in at least 27% of Iclusig-treated patients, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of
the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients less than 50 years old, experienced these events. Monitor for evidence of
thromboembolism and vascular occlusion. Interrupt or stop Iclusig immediately for vascular occlusion. A benefit risk consideration should guide a decision to restart Iclusig therapy. 

 

	•	 	Heart Failure, including fatalities, occurred in 8% of Iclusig-treated patients. Monitor cardiac function. Interrupt or stop Iclusig for new or worsening heart failure. 

 

	•	 	Hepatotoxicity, liver failure and death have occurred in Iclusig-treated patients. Monitor hepatic function. Interrupt Iclusig if hepatotoxicity is suspected. 

Please see the full U.S. Prescribing Information for Iclusig, including the Boxed Warning, for additional important safety information. 

About ARIAD 
 ARIAD Pharmaceuticals, Inc., headquartered
in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various
forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional
information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm). 
 About Otsuka Pharmaceutical Co., Ltd. 

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health
worldwide.’ Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 Appendix 4 

 In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research
programs in several under-addressed diseases including several cancer categories and tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a “big venture” company at
heart, applying a youthful spirit of creativity in everything it does. 
 Otsuka Pharmaceutical Co., Ltd., which employs approximately 28,700 people
worldwide, is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group that is headquartered in Tokyo, Japan. The Otsuka Group has business operations in 27 countries and regions around the world, with
consolidated sales of approximately USD 14.1 billion for fiscal year 2013 (4/1/2013-3/31/2014.) Otsuka Pharmaceutical welcomes you to visit its global website at https://www.otsuka.co.jp/en. 

ARIAD Forward-Looking Statements 
 This press release
contains “forward-looking statements” which are based on management’s good-faith expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to
differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to the Company’s ability to manufacture and supply Iclusig to Otsuka; the ability of Otsuka to perform the
contracted services, such as obtaining marketing authorizations, other regulatory approvals, and pricing and reimbursement approvals for Iclusig in the countries covered by the collaboration agreement (“Territory”); Otsuka’s ability
to distribute, promote, market and sell Iclusig in the Territory; Otsuka’s ability to fund the clinical development of Iclusig in the Territory; the timing and scope of the marketing authorizations obtained in the Territory, as well as the
level of pricing obtained in Territory; third-party reimbursement; and the timing and success of sales of Iclusig in the Territory. These factors, risks and uncertainties also include, but are not limited to the costs associated with ARIAD’s
development and manufacturing, commercial and other activities; the adequacy of capital resources and the availability of additional funding; and other factors detailed in the Company’s public filings with the U.S. Securities and Exchange
Commission. The information contained in this press release is believed to be current as of the date of original issue. After the date of this document, the Company does not intend to update any of the forward-looking statements to conform to actual
results or to changes in the Company’s expectations, except as required by law. 
  

			
	 For Investors
	  	 For Media

	 Kendra Adams
	  	Liza Heapes

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 Appendix 4 

					
	 Contacts at

        ARIAD
		 Kendra.adams@ariad.com
 (617)
503-7028
		 Liza.heapes@ariad.com
 (617)
621-2315

			
	 Contacts at

        Otsuka
		 Yoko Ishii
 Ishiiyo@Otsuka.jp

+81 3 6361 7411
		 Jeffrey Gilbert

Gilbert.jeffrey@Otsuka.jp
 +81 3 6361 7379, +81 80 8728
6039

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 Appendix 4EX-10.9.1

 Exhibit 10.9.1 

AMENDED AND RESTATED LICENSE AGREEMENT 

This Amended and Restated License Agreement (this “Agreement”) is made effective as of March 7, 2011 (the
“Effective Date”) by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 26 Landsdowne Street, Cambridge, MA 02139 (“ARIAD”), and Bellicum Pharmaceuticals, Inc., a
Delaware corporation with a place of business at 6400 Fannin St., Suite 2300, Houston, TX 77030 (“Bellicum”). ARIAD and Bellicum are each hereafter referred to individually as a “Party” and together as the
“Parties”. 
 WHEREAS, ARIAD is the owner of or otherwise controls certain proprietary Licensed Patent Rights
and Licensed Technology (each as defined below); and  
 WHEREAS, Bellicum owns or otherwise controls the Bellicum Patent
Rights and Bellicum Technology (as defined below); and  
 WHEREAS, the Parties and ARIAD Gene Therapeutics, Inc.
(“AGTI”) previously entered into that certain License Agreement, dated July 25, 2006 (the “2006 Agreement”), under which ARIAD and Bellicum each granted certain licenses to the other, subject to the terms and
conditions of the 2006 Agreement; and  
 WHEREAS, AGTI has merged into ARIAD; and  

WHEREAS, ARIAD has certain rights pursuant to its [***] with [***], including a non-exclusive license to certain intellectual property
and a separate right to enter negotiations to obtain an exclusive license to intellectual property, both cases involving [***]; and  

WHEREAS, Bellicum desires that ARIAD waive the right to pursue an exclusive license to intellectual property relating to [***] so that
Bellicum may obtain a license to that intellectual property from [***]; and 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

 WHEREAS, Bellicum desires to convert its non-exclusive license to Licensed Patent Rights
and Licensed Technology under the 2006 Agreement to an exclusive license to develop and commercialize Licensed Products (as defined below) and to expand the Primary Indications to which such exclusive license will apply; and  

WHEREAS, the Parties now desire to amend and restate the 2006 Agreement in its entirety as of the Effective Date as set forth in this
Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable
consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows: 
  

	 	1.	DEFINITIONS 

 Whenever used in the Agreement with an initial capital letter, the terms
defined in this Article 1 shall have the meanings specified. 
 1.1 “Additional Indication” shall mean each specific
cancer indication (other than [***]) which Bellicum elects to include in the Licensed Field pursuant to the provisions of Section 2.1.2(a). 

1.2 “Affiliate” shall mean any corporation, firm, Limited Liability Company, partnership or other entity that directly
controls or is controlled by or is under common control with a Party to this Agreement. For purposes of this Section 1.2, “control” means ownership, directly or indirectly through one or more Affiliates, of fifty percent (50%) or
more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interests in the case of any other type of legal entity, status as a general partner in any
partnership, or any other arrangement whereby a Party controls or has the right to control the Board of Directors or equivalent governing body of a corporation or other entity. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 2 

 1.3 “Adverse Event” shall mean any untoward medical occurrence in a
patient or subject who is administered a Licensed Product, whether or not considered related to the Licensed Product, including, without limitation, any undesirable sign (including abnormal laboratory findings of clinical concern), symptom or
disease temporally associated with the use of such Licensed Product. 
 1.4 “Antigen” shall mean a molecule
that causes an immune system response. 
 1.5 “ARIAD Data” shall have the meaning set forth in Section
2.1.6. 
 1.6 “ARIAD Dimerizer” shall mean the compound known as AP1903, all analogs and derivatives of
AP1903 and any Dimerizer or salt thereof, where the composition of matter thereof or its use as a divalent ligand is, at any time during the Primary License Term, within the scope of a claim in any patent or patent application within the Licensed
Patent Rights. 
 1.7 “ARIAD Dimerizer Product” shall mean (i) an ARIAD Dimerizer or (ii) a
Licensed Product in which dimerization is effected with an ARIAD Dimerizer. 
 1.8 “ARIAD Indemnitees” shall
have the meaning set forth in Section 8.1.1. 
 1.9 “ARIAD Products” shall mean any product (a) that
comprises or incorporates an ARIAD Dimerizer or Non-ARIAD Dimerizer or (b) that comprises a cell transfected with both (but not limited to) a gene for an Antigen and a gene for an Inducible Costimulatory Molecule where the gene for the
Inducible Costimulatory Molecule is activated using an ARIAD Dimerizer or a Non-ARIAD Dimerizer. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 3 

 1.10 “ARIAD Regulatory Information” shall have the meaning set forth in
Section 2.1.6. 
 1.11 “[***]” shall mean [***]. 

1.12 “[***]-ARIAD MTA Technologies” shall mean technologies resulting from experiments conducted with the materials
provided pursuant to any of the [***] Agreements whether or not the quantities of such materials used in the experiments were manufactured by ARIAD, including without limitation, the technologies known as [***], [***], [***], [***], [***], [***],
and any other technologies disclosed in the patent applications or patents listed in “Licensed Patent Rights Covering [***]-ARIAD MTA Technologies in Schedule A. 

1.13 “[***] Agreement” shall mean each and any of (a) the [***] between [***] and ARIAD, (b) the [***]
between [***] and ARIAD, (c) the [***] between [***] and ARIAD, (d) the [***] between [***] and ARIAD, (e) the [***] between [***] and ARIAD, and (f) the [***] between [***] and ARIAD, each as amended, which collectively cover,
inter alia, the [***]-ARIAD MTA Technologies. 
 1.14 “Bellicum Data” shall have the meaning set forth in
Section 2.2.2. 
 1.15 “Bellicum Indemnitees” shall have the meaning set forth in Section 8.1.2. 

1.16 “Bellicum Information” shall have the meaning set forth in Section 3.1.1. 

1.17 “Bellicum Patent Rights” shall mean all Patent Rights Controlled by Bellicum as of the Original Effective Date or
during the period from the Original Effective Date through the end of the Term, which are necessary or useful for the development, manufacture, use, sale, offer for sale or import of any ARIAD Product or 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 4 

 
Dimerizer, including any ARIAD Dimerizer or Non-ARIAD Dimerizer; provided, however, that Bellicum Patent Rights does not include any Patent Rights claiming (a) the composition of matter
of any Antigen or Inducible Costimulatory Molecule, or (b) the composition of matter of any product (or treatment regime or process using a product) comprising a dendritic cell transfected with both (i) a gene for any Antigen, a peptide or
protein that is an Antigen or an RNA that induces the expression of any Antigen and (ii) a gene for any Inducible Costimulatory Molecule, where such product does not use a Dimerizer to activate any gene that is a part of such product, or
(c) any method of manufacture or use for such Antigen, Inducible Costimulatory Molecule or product described in clause (b) (or treatment regime or process using such product). Bellicum Patent Rights excludes all Patent Rights licensed to
Bellicum or ARIAD by [***] that cover any of the [***]-ARIAD MTA Technologies. 
 1.18 “Bellicum Regulatory
Information” shall have the meaning set forth in Section 2.2.2. 
 1.19 “Bellicum Technology” shall
mean all Technology, whether or not patentable, Controlled by Bellicum as of the Original Effective Date or during the period from the Original Effective Date through the end of the Term, which is necessary or useful to practice any patent or patent
application included in the Bellicum Patent Rights or is necessary or useful for the development, manufacture, use, sale, offer for sale or import of any ARIAD Product or any Dimerizer, including any ARIAD Dimerizer or Non-ARIAD Dimerizer. Bellicum
Technology includes, without limitation, the Bellicum Information described in Section 3.1.1; provided, however, that Bellicum Technology does not include any Technology specifically pertaining to (a) any Antigen or Inducible
Costimulatory Molecule, or (b) any product, or treatment regime or process using any product, comprising a dendritic cell transfected with both (i) a gene for any Antigen, a peptide or protein that is an Antigen or an RNA that induces the
expression of any Antigen and (ii) a gene for any Inducible Costimulatory Molecule, 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 5 

 
where such product does not use a Dimerizer to activate any gene that is a part of such product, or (c) any manufacture or use of such Antigen, Inducible Costimulatory Molecule or product
described in clause (b) (or treatment regime or process using such product). Bellicum Technology excludes all Technology licensed to Bellicum or ARIAD by [***] that covers any of the [***]-ARIAD MTA Technologies. 

1.20 “BLA” shall mean a biologics license application (as defined in Title 21 of the United States Code of Federal
Regulations, as amended from time to time) filed with the FDA seeking Regulatory Approval to market and sell any Licensed Product in the United States for a particular indication within the Licensed Field. 

1.21 “Cell Transplantation Indication” shall mean (i) GvHD or (ii) any other acute or chronic adverse
clinical effect in a human being resulting from transplantation of bone marrow, hematopoietic or stem cells that can be treated by inducing apoptosis of transplanted cells, or (iii) in the case of a bone marrow, hematopoietic or stem cell
product for transplantation that includes cells containing a gene coding for an Inducible Caspase, any disease or condition in a human being that can be treated by such product, where such treatment can lead to an indication in subsection
(i) or (ii). 
 1.22 “Common Stock” shall mean (i) the common stock, par value $0.01 per share, of
Bellicum and (ii) any other securities into which or for which any of the securities described in the foregoing clause (i) may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, consolidation, sale of
assets or other similar transaction. 
 1.23 “Competition” shall mean, with respect to a Licensed Product
sold by Bellicum or an Affiliate or Sublicensee thereof in a given country, that one or more Third Parties are selling any product for the same indication, which product (a) would infringe a Valid Claim of the Licensed Patent Rights Listed in
Part I of Schedule A but  

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 6 

 
for the expiration of those Licensed Patent Rights in that country, (b) contains the same or equivalent (by applicable Regulatory Authority standards) active pharmaceutical ingredient(s) as
contained in such Licensed Product in such country, and (c) sales of such product(s) represent at least [***] percent ([***]%) of the total market share by volume for all sales of such product(s) and the Licensed Product in such country for any
calendar quarter (as measured by reputable published data for such country, e.g. by reference to market share data collected by IMS). 

1.24 “Confidential Information” shall mean with respect to a Party (the “Receiving Party”), all information
which is disclosed by the other Party (the “Disclosing Party”) to the Receiving Party hereunder or to any of its employees, consultants, Affiliates, licensees or sublicensees, except to the extent that the Receiving Party can demonstrate
by written record or other suitable physical evidence that such information, (a) as of the date of disclosure is demonstrably known to the Receiving Party or its Affiliates other than by virtue of a prior confidential disclosure to such Party
or its Affiliates; (b) as of the date of disclosure is, or subsequently becomes, publicly known, through no fault or omission of the Receiving Party; (c) is obtained from a Third Party having a lawful right to make such disclosure free
from any obligation of confidentiality to the Disclosing Party; or (d) is independently developed by or for the Receiving Party without reference to or reliance upon any Confidential Information of the Disclosing Party. 

1.25 “Confidentiality Agreement” shall have the meaning set forth in Section 5.1. 

1.26 “Control” or “Controlled” shall mean with respect to any Patent Rights or Technology, the
possession by a Party of the ability to grant a license or sublicense of such Patent Rights or Technology as provided for herein, without violating the terms of any arrangement or agreement between such Party and any Third Party. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 7 

 1.27 “Convertible Securities” shall mean any stock, notes, warrants, options or
other securities, including without limitation, all Options, entitling the holder to convert, exercise, or exchange such security for an ascertainable number of shares of Common Stock. For the avoidance of doubt, the Notes shall not be deemed to be
Convertible Securities unless and until they are not repaid on the Maturity Date (as defined in the Note), and the Warrants shall not be deemed to be Convertible Securities until they become exercisable. 

1.28 “Dimerizer” shall mean any molecule that is not a [***] Analog and that induces the interaction or proximity of
two or more proteins, modified to contain a dimerizer-binding domain, resulting in the activation of specific cell signaling, gene transcription, or protein secretion events in cultured cells, whole animals or humans. 

1.29 “Drug Approval Application” shall mean any application for Regulatory Approval (including pricing and
reimbursement approvals) required prior to any commercial sale or use of a Licensed Product in any country or jurisdiction in the Territory, including, without limitation, any BLA, NDA, MAA or equivalent application for Regulatory Approval filed
with the FDA or any other Regulatory Authority required prior to any commercial sale or use of a Licensed Product in any country or jurisdiction in the Territory. 

1.30 “Equity Financing” shall mean a bona fide issuance and sale of Common Stock or Convertible Securities other than
upon the grant or exercise of any Option. 
 1.31 “Existing Bellicum Product” shall have the meaning set forth in
Section 2.2.1(a). 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 8 

 1.32 “Expansion Period” shall have the meaning set forth in Section
2.1.2(a). 
 1.33 “First Commercial Sale” shall mean, on a country-by-country basis, the date of the first
arm’s length transaction, transfer or disposition for value to a Third Party of (i) a Licensed Product by or on behalf of Bellicum or any Affiliate of Bellicum or Sublicensee in such country or (ii) of an ARIAD Product by or on behalf
of ARIAD or any Affiliate or sublicensee of ARIAD in such country. 
 1.34 “FDA” shall mean the United States
Food and Drug Administration and any successor agency or authority thereto. 
 1.35 “GvHD” shall mean a
clinical condition involving acute or chronic adverse effects or symptoms resulting from the allogenic transplantation of bone marrow, hematopoietic or stem cells into a human being in which engrafted donor cells attack the patient’s organs and
tissues which can be treated by activating cell signaling leading to apoptosis of the transplanted cells. 
 1.36
“[***]” shall mean the [***]. 
 1.37 “[***]” shall mean the [***]. 

1.38 “Improvement” shall mean any invention or discovery created or otherwise Controlled by ARIAD or Bellicum during
the period from the Original Effective Date through the end of the Term, which constitutes an enhancement or modification of any invention within the Licensed Technology or Licensed Patent Rights, together with the Patent Rights and Technology that
claim or cover such invention or discovery; provided, however, that Improvement does not include (a) any Antigen or Inducible Co-Stimulatory Molecule, (b) any product (or treatment regime or process using a product), comprising (i) a
dendritic cell transfected with both a gene for any Antigen, a peptide or a protein that is an Antigen or an RNA that induces the  

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 9 

 
expression of an Antigen and (ii) a gene for any Inducible Costimulatory Molecule, where such product does not use a Dimerizer to activate any gene that is a part of such product, or
(c) any method of manufacture or use for such Antigen, Inducible Co- Stimulatory Molecule or product described in clause (b) (or treatment regime or process using such product), and, in each case, the Patent Rights and Technology that
claim or cover such invention or discovery. 
 1.39 “IND” shall mean an investigational new drug application (as
defined in Title 21 of the United States Code of Federal Regulations, as amended from time to time) filed or to be filed with the FDA with regard to any Licensed Product. 

1.40 “Indemnitees” and “Indemnifying Party” shall have the meaning set forth in Section 8.2.

 1.41 “Inducible Caspase” shall mean iCASP9 or icp30CASP9 or another molecule that will activate signaling
leading to apoptosis. For purposes of this definition, the following terms shall have the meanings set forth in the following literature references: 
  

	 	•	 	[***] 

  

	 	•	 	[***] 

 1.42 “Inducible Costimulatory Molecule” shall mean iCD40, iTLR
or another molecule that will activate signaling leading to maturation and activation of dendritic cells, including any chimera of the foregoing. For purposes of this definition, the following terms shall have the meanings set forth in the following
literature references: 
  

	 	•	 	[***] 

  

	 	•	 	[***] 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 10 

 1.43 “Licensed Field” shall mean the treatment or prevention of the
progression or occurrence in humans of any Primary Indication and/or any Additional Indication, [***] to the extent permitted under Section 2.1.1 or any non-cancer indication as provided in Section 2.1.2(b), as the case may be. 

1.44 “Licensed Patent Rights” shall mean (a) all Patent Rights Controlled by ARIAD as of the Original Effective
Date or during the Primary License Term, which are necessary or useful for the development, manufacture, use, sale, offer for sale or import of Licensed Products or of Dimerizers used or incorporated in Licensed Products, including without
limitation Patent Rights covering the [***]- ARIAD MTA Technologies and (b) all Patent Rights whether or not controlled by ARIAD that are listed on Schedule A, attached hereto and made a part hereof, regardless of the ownership of such Patent
Rights. The Licensed Patent Rights as of the Effective Date are listed in Schedule A, attached hereto and made a part hereof, which shall be updated, as necessary, from time to time by ARIAD by written notice to Bellicum. 

1.45 “Licensed Product” shall mean: (a) cancer vaccines (whether used prophylactically or therapeutically), the
manufacture, sale, import, administration, activation or other use of which is covered by a claim of any Patent Rights or by Technology, which Patent Rights or Technology are Controlled by Bellicum or its Affiliate (including, without limitation
Patent Rights licensed or assigned to Bellicum that cover any of the [***]-ARIAD MTA Technologies), either (x) containing both (but not limited to) (i) a gene for a [***] Antigen or other Antigen directed to any indication within the
Licensed Field and (ii) one or more genes for Inducible Costimulatory Molecules, (y) containing a dendritic cell transfected with both (but not limited to) (i) a gene for a [***] Antigen or other Antigen directed to any indication
within the Licensed Field and (ii) one or more genes for Inducible Costimulatory Molecules, or (z) containing (i) a peptide or protein that is a [***] Antigen or other Antigen directed to 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 11 

 
any indication within the Licensed Field or an RNA that induces the expression of a [***] Antigen or other Antigen directed to any indication within the Licensed Field and (ii) a dendritic
cell transfected with one or more genes for Inducible Costimulatory Molecule(s) where in any such case ((x), (y) or (z)) the encoded Inducible Costimulatory Molecule(s) are activated upon dimerization using a Dimerizer; (b) a gene or a
cell transfected with such gene coding for an Inducible Caspase, either alone or in combination with other adjuvant genes (such as IL-12 or HSP), where the gene coding for such Inducible Caspase is activated upon dimerization of a Dimerizer;
(c) Dimerizers for use with the products described in clauses (a) or (b) of this Section 1.45; and (d) any treatment regimen or process utilizing any products described in clauses (a), (b) or (c) of this
Section 1.45; provided, however, that in the event the Licensed Field is expanded pursuant to Section 2.1.2(b) to include any non-cancer indication, clause (a) of this Section 1.45 shall include vaccines (as described therein)
directed at such indication as well as cancer vaccines. 
 1.46 “Licensed Technology” shall mean and include all
Technology, whether or not patentable, Controlled by ARIAD as of the Original Effective Date or during the Primary License Term, which (a) is necessary or useful to practice any patent or patent application included in the Licensed Patent
Rights (including without limitation Patent Rights Controlled by ARIAD covering the [***]-ARIAD MTA Technologies) or (b) is necessary or useful to practice any license granted to Bellicum hereunder. The Licensed Technology includes the ARIAD
Regulatory Information and ARIAD know how and trade secrets including but not limited to the following technology for the manufacture of Dimerizers: optimum choice of synthetic route, optimized process steps and parameters, analytic methods using
authentic standards to control chemical and chiral purity through the manufacturing path, background data supporting the chemical and chiral proof of structure of key intermediates, the structural identification of impurities characteristic of this
route, their HPLC characteristics, and the qualification of these impurities for regulatory purposes. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 12 

 1.47 “Losses” shall have the meaning set forth in Section 8.1.1.

 1.48 “MAA” shall mean an application filed with the relevant Regulatory Authorities in Europe seeking
Regulatory Approval to market and sell any Licensed Product in Europe or any country or territory therein for a particular indication within the Licensed Field. 

1.49 “NDA” shall mean a new drug application (as defined in Title 21 of the United States Code of Federal Regulations,
as amended from time to time) filed with the FDA seeking Regulatory Approval to market and sell any Licensed Product in the United States for a particular indication within the Licensed Field. 

1.50 “Net Sales” shall mean the gross invoiced sales price for each Licensed Product sold by Bellicum, its Affiliates
or Sublicensees to Third Parties throughout the Territory, less the following amounts incurred or paid by Bellicum or its Affiliates or Sublicensees with respect to sales of Licensed Products: 

(a) [***]; 
 (b)
[***]; 
 (c) [***]; 

(d) [***]; 
 (e)
[***]; and 
 (f) [***]. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 13 

 “Net Sales” shall not include sales or transfers between Bellicum and its Affiliates or Sublicensees,
unless the Licensed Product is consumed by the Affiliate or Sublicensee. All sales and dispositions of Licensed Product for clinical or pre-clinical studies and “compassionate use” sales shall also be disregarded for purposes of
calculating Net Sales. 
 1.51 “Non-ARIAD Dimerizer” shall mean any Dimerizer other than an ARIAD Dimerizer that is,
at any time during the Primary License Term, within the scope of a claim other than a claim covering the composition of matter thereof or its use as a divalent ligand, but including, without limitation, any manufacture or use claim, in any patent or
patent application within the Licensed Patent Rights. 
 1.52 “Non-ARIAD Dimerizer Product” shall mean
(i) a Non-ARIAD Dimerizer or (ii) a Licensed Product in which dimerization is effected with a Non-ARIAD Dimerizer. 

1.53 “Non-Cancer Expansion Period” shall have the meaning set forth in Section 2.1.2(b). 

1.54 “Non-Cancer Negotiation Period” shall have the meaning set forth in Section 2.1.2(b). 

1.55 “Notes” shall mean the series of [***]. 

1.56 “Option” shall mean options or other securities granted or issued pursuant to any Stock Plan. 

1.57 “Original Effective Date” shall mean July 25, 2006. 

1.58 “Orphan Drug Designation” shall mean the request for designation of AP1903 for the treatment of GvHD as an orphan
drug under 21 C.F.R. §316.20 that has been granted by the FDA under 21 C.F.R. §316.24. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 14 

 1.59 “Patent Rights” shall mean all patents and patent applications,
including, without limitation, certificates of invention and applications for certifications of invention, registered designs and registered design applications, industrial designs and industrial design applications and registrations, reissues,
reexaminations, extensions, substitutions, confirmations, registrations, revalidations, renewals, term restorations, additions, provisionals, continuations, continuations-in-part, divisions, continued prosecution applications, and requests for
continued examination thereof. 
 1.60 “Phase 1 Clinical Trial” shall mean, as to a particular Licensed
Product, a lawful study in humans of the safety and dose ranging of such Licensed Product, which is prospectively designed to generate sufficient data (if successful) to commence a Phase 2 Clinical Trial of such Licensed Product. 

1.61 “Phase 1/2 Clinical Trial” shall have the meaning set forth in Section 4.1.3. 

1.62 “Phase 2 Clinical Trial” shall mean, as to a particular Licensed Product for a particular indication, a
controlled and lawful study in humans of the safety, dose ranging and efficacy of such Licensed Product for such indication, which is prospectively designed to generate sufficient data (if successful) to commence a Phase 3 Clinical Trial of such
Licensed Product for such indication. 
 1.63 “Phase 2/3 Clinical Trial” shall have the meaning set forth in
Section 4.1.3. 
 1.64 “Phase 3 Clinical Trial” shall mean as to a particular Licensed Product for a
particular indication, a controlled and lawful study in humans of the safety and efficacy of such Licensed Product for such indication, which is prospectively designed to demonstrate statistically whether such Licensed Product is safe and effective
for use in such indication in a manner sufficient to file a BLA or NDA for Regulatory Approval to market and sell that Licensed Product in the United States for the indication under investigation in such study. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 15 

 1.65 “Primary Indications” shall mean (a) [***] and (b) any
Cell Transplantation Indication. 
 1.66 “Primary License Term” shall mean, with respect to each Licensed
Product, the period commencing on the Original Effective Date and continuing on a country-by-country, and product-by-product basis until the later of (a) the last to expire Valid Claim covering the composition of matter of the Licensed Product
or any component thereof, or the manufacture or use in the Licensed Field of the Licensed Product or any component thereof, or (b) twelve (12) years from the date of First Commercial Sale in such country. 

1.67 “Qualified Financing” shall mean the last Equity Financing as a result of which Bellicum will have received
cumulative gross proceeds from one or more Equity Financings equal to at least [***] Dollars ($[***]). 
 1.68 “[***]
Analog” shall mean a compound which is an analog or derivative of [***] that induces the formation of a complex with [***] and [***], mutants or other variants thereof, or fusion proteins containing part or all of [***] and [***],
respectively, or their respective mutants or other variants. 
 1.69 “Regulatory Approval” shall mean any and
all approvals (including pricing and reimbursement approvals), product and establishment licenses, registrations or authorizations of any kind of the FDA or any other Regulatory Authority necessary for the development, pre-clinical and/or human
clinical testing, manufacture, quality testing, supply, use, storage, importation, export, transport, marketing and sale of a Licensed Product (or any component thereof) for use in the Licensed Field in any country or other jurisdiction in the
Territory. “Regulatory Approval” shall include, without limitation, any IND, BLA, NDA, MAA or other Drug Approval Application. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 16 

 1.70 “Regulatory Authority” shall mean any applicable supranational,
national, federal, state or local regulatory agency, department, bureau or other governmental entity of any country or jurisdiction (including the FDA in the United States), having responsibility in such country or jurisdiction for any Regulatory
Approvals of any kind in such country or jurisdiction, and any successor agency or authority thereto. 
 1.71
“[***]” shall mean the Board of Trustees of the [***]. 
 1.72 “[***] Agreement” shall have the
meaning set forth in Section 4.1.4. 
 1.73 “[***] IP” shall mean all Licensed Patent Rights and Licensed
Technology licensed to ARIAD under the [***] Agreement. [***] IP does not include [***]. 
 1.74 “Stock Plan”
shall mean Bellicum’s 2006 Stock Option Plan, as may be amended, and any other plan adopted by Bellicum for the issuance of equity securities or options to acquire equity securities to employees, consultants, directors or advisors of
Bellicum. 
 1.75 “Sublicensee” shall mean any Third Party to whom Bellicum grants a sublicense of some or
all of the rights to the Licensed Patent Rights and Licensed Technology granted to Bellicum under this Agreement. 
 1.76
“Technology” shall mean and include any and all unpatented, proprietary ideas, inventions, discoveries, Confidential Information, biologic materials, data, results, formulae, designs, specifications, methods, processes,
formulations, techniques, ideas, know-how, technical information (including, without limitation,  

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 17 

 
structural and functional information), trade secrets, process information, pre-clinical information, clinical information, and any and all proprietary biological, chemical, pharmacological,
toxicological, pre-clinical, clinical, assay, control and manufacturing data and materials. 
 1.77 “Term” shall
have the meaning set forth in Section 9.1. 
 1.78 “Territory” shall mean all countries and jurisdictions of
the world. 
 1.79 “Third Party” shall mean any person or entity other than Bellicum, ARIAD and their
respective Affiliates. 
 1.80 “Valid Claim” shall mean a claim in an issued, unexpired patent or in a pending
patent application that has been pending for [***] since the first substantive office action of the relevant patent office on such patent application within the Licensed Patent Rights (including without limitation Patent Rights covering the
[***]-ARIAD MTA Technologies Controlled by ARIAD) that (a) has not been finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction, (b) has not been revoked, held invalid, or
declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, (c) has not been rendered unenforceable through disclaimer or
otherwise, and (d) is not lost through an interference proceeding. 
 1.81 “Warrants” shall mean
the warrants for Common Stock issued in connection with the Notes. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 18 

	 	2.	GRANT OF RIGHTS 

 2.1 License to Bellicum. 

2.1.1 Grant of License. ARIAD hereby grants to Bellicum an exclusive (even as to ARIAD), royalty-bearing license, including the right
to grant sublicenses in accordance with Section 2.1.4, under the Licensed Patent Rights and Licensed Technology and ARIAD’s interest in any Improvements, subject at all times to the restrictions and obligations under the [***] Agreement
with respect to the [***] IP, (a) to research, develop, test, obtain Regulatory Approval for, make, have made, use, have used, sell, offer for sale, have sold, import, have imported, export and have exported Licensed Products (including,
without limitation, any Dimerizer included or utilized therein) in the Territory, for any and all uses within the Licensed Field during the Term, subject to the terms and conditions of this Agreement, and (b) to make, have made, use,
import and export, in each case solely for research purposes, including pre-clinical IND-enabling toxicology and other pre-clinical studies (but not to conduct clinical trials with respect to or to obtain Regulatory Approval for, sell or
commercialize), Licensed Products (including, without limitation, any Dimerizer included or utilized therein) (i) for any indication other than the Primary Indications until the end of the Expansion Period and, (ii) if Bellicum elects to
add Additional Indications to the Licensed Field during the Expansion Period, for any indication other than the Primary Indications and the Additional Indications until the end of the Non-Cancer Expansion
Period. Bellicum may, pursuant to the license granted under Section 2.1.1(a), include patients with [***] in clinical trials of a Licensed Product intended for use in [***] where the Antigen is PSMA and if Bellicum files an IND to seek
Regulatory Approval of such Licensed Product for [***], then Bellicum may seek Regulatory Approval of such Licensed Product for the treatment or prevention of the progression or occurrence in humans of [***], and, if Bellicum receives Regulatory
Approval of such Licensed Product for the treatment or prevention of the progression or occurrence in humans of [***], then the Licensed Field shall include [***]. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 19 

 2.1.2 Expansion of Licensed Field to Obtain Additional Exclusive Rights. Bellicum may
exercise its rights to expand (or request the expansion of) its exclusive license granted in Section 2.1.1 as follows: 
 (a)
During the period commencing on the [***] and continuing for [***] thereafter (the “Expansion Period”), Bellicum may, at Bellicum’s election, add Additional Indications to the Licensed Field by delivering written notice to
ARIAD which describes each specific cancer indication to be included in the Additional Indications or states that all cancer indications (other than [***]) are to be included in the Additional Indications. 

(b) Within a [***] day period commencing on the later to occur of (i) Bellicum’s exercise of its option to expand the
Licensed Field to include Additional Indications pursuant to Section 2.1.2(a) and (ii) Bellicum’s or its Affiliate’s or Sublicensee’s commencing a [***], or, [***] (the “Non- Cancer Expansion Period”),
Bellicum may, at Bellicum’s election, request that ARIAD agree to expand the Licensed Field to specific non-cancer indications (other than Cell Transplantation Indications) by delivering written notice to ARIAD within such Non- Cancer Expansion
Period which describes the specific products and associated product development plans, capabilities and resources for the specific non-cancer diseases and/or conditions it desires to include within the Licensed Field. Upon receipt of such written
notice, ARIAD shall in good faith consider Bellicum’s request. If ARIAD is willing to so expand the Licensed Field, the Parties will negotiate with respect to a possible amendment to this Agreement setting forth all relevant terms (including
milestones and royalties) pertaining to the expansion for a period of [***] days from the date of ARIAD’s receipt of the written request (the “Non-Cancer Negotiation Period”). If the Parties do not agree upon terms

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 20 

 
and conditions mutually acceptable to both Parties on or before the expiration of such Non-Cancer Negotiation Period despite their respective good faith efforts, then Bellicum shall have no
further rights with respect to such expansion and ARIAD shall have no further obligation to negotiate pursuant to this Section 2.1.2. 

2.1.3 Certain Exclusivity Rights. Notwithstanding anything to the contrary in this Agreement: 

(a) ARIAD will not license (or sublicense) to any Third Party or develop or commercialize itself or together with any Third Party, for
use in the treatment or prevention of (i) the Primary Indication or (ii) any Additional Indication which Bellicum elects to include in the Licensed Field pursuant to the provisions of Section 2.1.2(a) or any non-cancer indication
(other than Cell Transplantation Indications) that is included in the Licensed Field pursuant to the provisions of Section 2.1.2(b), any Dimerizer or other product involving the use of a Dimerizer covered by Bellicum Patent Rights or Bellicum
Technology or any Patent Rights covering the [***]-ARIAD MTA Technologies licensed to ARIAD by [***] as of the Original Effective Date or during the Primary License Term. 

(b) Bellicum will not develop (except as permitted pursuant to the license granted in Section 2.1.1), manufacture, promote or
sell any Dimerizer for any use outside of the Licensed Field as in effect from time to time; provided, however, that, to the extent Bellicum demonstrates to ARIAD’s reasonable satisfaction that off-label use of any Licensed Product outside
the Licensed Field has occurred in the complete absence of any promotion thereof by or on behalf of, or at the request or with the approval of, any of Bellicum, its Affiliates or its or their directors, officers, consultants and clinical
investigators, such off-label use shall not constitute a violation of this provision or this Agreement. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 21 

 2.1.4 Right to Sublicense and Subcontract. Bellicum shall have the right to grant
sublicenses to any Affiliate and/or Sublicensee to all or any portion of its rights under the license granted pursuant to Section 2.1.1; provided, however, that (a) such sublicense under the license granted pursuant to Section 2.1.1
shall be granted in connection with a license to all Patent Rights and Technology Controlled by Bellicum, which are necessary or useful in the manufacture, use or sale of the Licensed Product(s) covered by the sublicense, (b) no sublicense may
include a right to further sublicense any [***] IP unless [***] has provided prior written consent to Bellicum and ARIAD allowing such further sublicense (and, if requested by Bellicum, ARIAD will assist Bellicum in obtaining such consent from
[***]), and all such sublicenses of [***] IP shall be subject and subordinate to, and consistent with, the terms and conditions of the [***] Agreement with respect to sublicenses of [***] IP, (c) ARIAD shall be notified of the grant of a
sublicense to any and all potential sublicenses, (d) any and all sublicenses shall be subject to, and consistent with, the terms and conditions of this Agreement, (e) Bellicum shall remain obligated for the payment to ARIAD of all of its
payment obligations hereunder, including, without limitation, the payment of any royalties described in Section 4 hereof, (f) upon termination of this Agreement, any such sublicense shall be considered a direct license from ARIAD as
provided in Section 9.3 and (g) Bellicum shall provide ARIAD with a copy of each such sublicense agreement (from which Bellicum may redact confidential terms that are not necessary to disclose to ARIAD for purposes of confirming compliance
with this Agreement and the [***] Agreement) within [***] days of execution. In addition, Bellicum shall have the right to subcontract with any Third Party, including [***] (provided that any Third Party manufacturer of AP1903 shall be subject to
approval by ARIAD in its commercially reasonable discretion), to have such Third Party perform work on Bellicum’s behalf pursuant to the license granted pursuant to Section 2.1.1(b) on terms which are subject to, and consistent with, the
terms and conditions of this Agreement. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 22 

 2.1.5 Technology Transfer. ARIAD disclosed to Bellicum after the Original Effective Date,
and shall disclose to Bellicum from time to time during the Primary License Term, all Licensed Patent Rights and Licensed Technology. The matters to be disclosed or delivered to Bellicum pursuant to this Section 2.1.5 are outlined in Schedule
A. Such trade secrets and Technology are disclosed or delivered to Bellicum by ARIAD hereunder on an “as is” basis. ARIAD makes no representation or warranty that such trade secrets and Technology are all that is reasonably necessary to
practice the licenses granted to Bellicum hereunder or as to their fitness for such purpose. 
 2.1.6 ARIAD Regulatory Information.
Subject to applicable laws governing patient confidentiality and to the extent necessary for Bellicum or its Sublicensee(s) to comply with applicable statutes, laws, regulations, ordinances and guidelines governing Regulatory Approval of Licensed
Products, ARIAD shall provide Bellicum or its Sublicensee (i) summaries of, and the right to cross-reference to, any safety data (including Adverse Events) reported to any Regulatory Authority by ARIAD relating to AP1903, (ii) copies of
the clinical investigators’ brochure, protocol and clinical study report in connection with a phase 1 study of AP1903 conducted by ARIAD, and (iii) summaries of relevant data generated by ARIAD in connection with its preclinical
studies of AP1903 (“ARIAD Data”) (collectively, “ARIAD Regulatory Information”). ARIAD Regulatory Information shall be treated as Confidential Information of ARIAD. Bellicum and its Sublicensee(s) shall maintain
such ARIAD Data disclosed to it pursuant to this Section 2.1.6 in confidence and shall not use or disclose it to any Third Party other than (i) Bellicum or its Sublicensee(s), itself or through its agent, may provide a cross-reference to
ARIAD Data reported by ARIAD under any filing to obtain Regulatory Approval for Licensed Products using AP1903 in any country or may disclose ARIAD Data in a written submission to any such Regulatory Authority, in each case solely as required to
obtain Regulatory Approval of 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 23 

 
a Licensed Product in the Licensed Field, but only after obtaining prior written permission from ARIAD to make such disclosure which is conditioned upon Bellicum or its Sublicensee
obtaining written assurances from the Regulatory Authorities to whom the information is being disclosed that such ARIAD Data will be afforded confidential treatment by such Regulatory Authority, and (ii) Bellicum or its Sublicensee, upon prior
written notice to ARIAD, may verbally disclose ARIAD Data in any teleconference or meeting with any Regulatory Authority, in each case solely as required to obtain Regulatory Approval of the Licensed Products in the Licensed Field, but only after
obtaining prior written permission from ARIAD which is conditioned upon affording appropriate ARIAD personnel the opportunity to participate in each such teleconference or meeting. 

2.1.7 Transfer of Orphan Drug Designation. Subject to applicable statutes, laws, regulations, ordinances and guidelines governing the
transfer of the Orphan Drug Designation, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ARIAD hereby transfers, assigns and conveys all its ownership of and any beneficial interest in the Orphan
Drug Designation to Bellicum, effective as of the Effective Date. Within ten (10) business days after the Effective Date, (i) ARIAD and Bellicum shall each submit the required information to the FDA to effect the change of the named
sponsor of the Orphan Drug Designation from ARIAD to Bellicum in accordance with the applicable statutes, laws, regulations, ordinances and guidelines, and (ii) ARIAD shall transfer a complete copy of the Orphan Drug Designation, including any
amendments or supplements thereto, and correspondence regarding the Orphan Drug Designation to Bellicum. ARIAD shall cooperate reasonably with Bellicum, as requested by Bellicum and at Bellicum’s expense, in Bellicum’s efforts to maintain
the Orphan Drug Designation. 
 2.1.8 Reservation of Rights. As between the Parties, ARIAD shall retain ownership of or license
rights to all right, title and interest in and to the Licensed 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 24 

 
Patent Rights and Licensed Technology, and no other license, either express or implied or by implication or estoppel, is granted hereunder with respect to any Technology or Patent Rights of ARIAD
or its licensors except as expressly stated in this Section 2.1 and ARIAD reserves all rights in and to the same. Bellicum acknowledges that [***] and [***] and the inventors identified in the [***] Agreement each retain the rights to,
respectively: (i) practice the [***] IP solely for non-commercial research purposes; (ii) publish any information included in the [***] IP; and (iii) provide tangible materials included in the [***] IP to academic or not-for-profit
research institutions under the terms of a material transfer agreement, subject to the restriction in the [***] Agreement that no rights shall be granted by [***] or [***] to any inventions or technology incorporating or utilizing such materials for
any commercial purpose. Bellicum acknowledges that the [***] IP is subject to 35 U.S.C. §§ 200-204, including an obligation that Licensed Products that would be “Licensed Products” under the [***] Agreement sold or produced in
the United States be “manufactured substantially in the United States”. Bellicum acknowledges that the [***] IP is subject to certain obligations to [***] as set forth in the [***] Agreement, a complete copy of which obligations to [***]
ARIAD has provided to Bellicum. 
 2.1.9 [***] Agreement. [***], [***] and [***], as applicable, are intended Third Party
beneficiaries of this Section and Sections 2.1.8, 4.2, 4.3, 5.4, 5.5, 7.3.1, 8.3 and 11.1 of this Agreement, and such parties have the right to bring any suit at law or equity for any matter governed by or subject to such provisions. If the [***]
Agreement is terminated, then from and after the effective date of such termination, the license granted by ARIAD to Bellicum under the [***] IP shall be deemed a direct license from [***] to Bellicum and all obligations of Bellicum under this
Agreement with regard to such license under the [***] IP, and all obligations of ARIAD under the [***] Agreement with regard to Licensed Products (as defined herein) developed, made, used or sold by Bellicum or any Affiliate or Sublicensee of
Bellicum that would be “Licensed Products” under the [***] Agreement including the payment of 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 25 

 
royalties to [***], shall be deemed obligations of Bellicum to [***]. As long as Bellicum has not materially breached any material obligation or condition that would entitle ARIAD to terminate
this Agreement, ARIAD will not voluntarily terminate or willfully breach the [***] Agreement. In addition to specific provisions in this Agreement relating to the [***] Agreement, the provisions of Articles 8, 9 and 10 of the [***] Agreement, with
Bellicum substituted for AGTI in such provisions, are expressly included in this Agreement for the benefit or [***], [***] and [***]. To the extent the provisions of Articles 8, 9 and 10 of the [***] Agreement cover the same subject matter as other
provisions in this Agreement relating to the [***] Agreement, the provisions imposing the greatest obligation on Bellicum shall apply. 

2.2 License to ARIAD. 

2.2.1 Grant of License. 

(a) Bellicum hereby grants to ARIAD a non-exclusive, royalty-free (subject only to Section 2.2.1(b)) license, including the right
to grant sublicenses, under the Bellicum Patent Rights and Bellicum Technology, and Bellicum’s interest in any Improvements, to develop, make, have made, use, have used, sell, offer for sale, have sold, import, have imported, export and have
exported ARIAD Products (including products comprising or utilizing AP1903) for any and all uses outside of the Licensed Field, subject to the terms and conditions of this Agreement. In no event will ARIAD practice any Bellicum Patent Rights or
Bellicum Technology, or Bellicum’s interest in any Improvements (excluding any Improvements licensed to Bellicum and ARIAD by [***] that cover any of the [***]-ARIAD MTA Technologies), for any use within the Licensed Field or to sell, offer for
sale, have sold, import, have imported, export and have exported any ARIAD Product (including any product comprising or utilizing AP1903) for any use outside of the Licensed Field, if such ARIAD Product is the same (for regulatory purposes) as
any Licensed Product listed on Schedule B 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 26 

 
pursuant to Section 3.2.1 prior to ARIAD’s commencement of the development thereof and that is being developed or commercialized to ARIAD’s knowledge by Bellicum or any of its
Affiliates or Sublicensees for any use within the Licensed Field (an “Existing Bellicum Product”). In the event that Bellicum has not filed an IND for a particular Licensed Product within [***] after such Licensed Product is listed
on Schedule B, then the foregoing prohibition shall not apply to such Licensed Product. Notwithstanding the foregoing, ARIAD shall be free to develop, make, have made, use, have used, sell, offer for sale, have sold, import, have imported,
export and have exported, any Dimerizer for any purpose without restriction, except that ARIAD shall not sell, offer for sale, have sold, import, have imported, export or have exported any Dimerizer covered by Bellicum Patent Rights that is
specifically labeled by ARIAD for use with an Existing Bellicum Product. 
 (b) If any Bellicum Patent Rights or Bellicum Technology
licensed to Bellicum by any Third Party would require payment to such Third Party upon ARIAD’s practice thereof pursuant to the license granted under this Section 2.2.1, then Bellicum shall so notify ARIAD in writing promptly after
obtaining the license. ARIAD may, by written notice to Bellicum provided at any time prior to the First Commercial Sale of any ARIAD Product utilizing the subject matter of the Bellicum Patent Rights or Bellicum Technology licensed to Bellicum by
the Third Party, (i) elect to accept the license to such Bellicum Patent Rights or Bellicum Technology, in which case, ARIAD shall be responsible for making any payment to such Third Party resulting from ARIAD’s practice of such Bellicum
Patent Rights or Bellicum Technology pursuant to the license granted under this Section 2.2.1 and shall provide Bellicum written notice confirming that it has made such payments (and, if it fails to make any such payment in accordance with the
terms of the agreement with such Third Party, the license to such Bellicum Patent Rights or Bellicum Technology under this Section 2.2.1 shall terminate), or (ii) elect to decline the license to such Bellicum Patent Rights or Bellicum
Technology 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 27 

 
(and shall be deemed to decline the license to such Bellicum Patent Rights or Bellicum Technology if it does not provide Bellicum written notice of its election as set forth above), in which case
such Bellicum Patent Rights or Bellicum Technology shall be excluded from the license granted to ARIAD under this Section 2.2.1. 

2.2.2 Bellicum Regulatory Information. To facilitate the development of ARIAD Products by ARIAD or its sublicensee(s) pursuant to the
license granted under this Section 2.2, and subject to applicable laws governing patient confidentiality and to the extent necessary for ARIAD or its sublicensee(s) to comply with applicable statutes, laws, regulations, ordinances and
guidelines governing Regulatory Approval of ARIAD Products, Bellicum shall provide, and shall require its Sublicensees to provide, to ARIAD or its sublicensee (i) the right to cross-reference to any safety data (including Adverse Events)
reported to the FDA by Bellicum under any IND relating to a Licensed Product using AP1903, (ii) copies of all investigator safety letters provided by Bellicum to its clinical investigators in connection with clinical studies of Licensed
Products using AP1903 and (iii) summaries of relevant data generated by Bellicum in connection with its preclinical studies of a Licensed Product using AP1903 (“Bellicum Data”) (collectively, “Bellicum Regulatory
Information”). Bellicum Regulatory Information should be treated as Confidential Information of Bellicum. ARIAD and its sublicensee(s) shall maintain such Bellicum Data disclosed to it pursuant to this Section 2.2.2 in confidence and
shall not use or disclose it to any Third Party other than (i) ARIAD or its sublicensee(s), themselves or through their agents, may provide a cross-reference to Bellicum Data reported to the FDA by Bellicum under any IND or corresponding
foreign country filing to obtain Regulatory Approval for ARIAD Products using AP1903 in any country or may disclose Bellicum Data in a written submission to any such Regulatory Authority, in each case solely as required to obtain Regulatory Approval
of a ARIAD Product using AP1903 outside the Licensed Field, but only after obtaining prior written permission from Bellicum to make such 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 28 

 
disclosure which is conditioned upon ARIAD or its sublicensee obtaining written assurances from the Regulatory Authorities to whom the information is being disclosed that such Bellicum Data will
be afforded confidential treatment by such Regulatory Authority, and (ii) ARIAD or its sublicensee, upon prior written notice to Bellicum, may verbally disclose Bellicum Data in any teleconference or meeting with any Regulatory Authority, in
each case solely as required to obtain Regulatory Approval of the ARIAD Products using AP1903 pursuant to the license granted in Section 2.2, but only after obtaining prior written permission from Bellicum which is conditioned upon affording
appropriate Bellicum personnel the opportunity to participate in each such teleconference or meeting. 
 2.2.3 Reservation of
Rights. As between the Parties, Bellicum shall retain ownership of or license rights to all right, title and interest in and to the Bellicum Patent Rights and Bellicum Technology, and no other license, either express or implied or by implication or
estoppel, is granted hereunder with respect to any Technology or Patent Rights of Bellicum or its licensors except as expressly stated in this Section 2.2 and Bellicum reserves all rights in and to the same. 

3. DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS. 

3.1 Commercialization. 

3.1.1 Responsibility. From and after the Original Effective Date, Bellicum shall have full control and authority over the development
and commercialization of Licensed Products in the Licensed Field in the Territory, including without limitation, (a) all pre-clinical development activities (including any pharmaceutical development work on formulations or process development
relating to any Licensed Product), (b) all activities related to human clinical trials (including all clinical studies), (c) all activities relating to manufacture and supply of all Licensed

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 29 

 
Products (including all required process development and scale up work with respect thereto), (d) all marketing, promotion, sales, distribution, import and export activities relating to any
Licensed Product, and (e) all activities relating to any regulatory filings, registrations, applications and Regulatory Approvals relating to any of the foregoing (including any INDs or foreign equivalents, any manufacturing facility validation
and/or licensure, any Drug Approval Applications and any other Regulatory Approvals). Bellicum shall own all data, results and all other information arising from any such activities of Bellicum with respect to Licensed Products in the Licensed Field
in the Territory under this Agreement, including without limitation, all regulatory filings, registrations, applications and Regulatory Approvals relating to Licensed Products (including any INDs or foreign equivalents, any Drug Approval
Applications and any other Regulatory Approvals) (collectively, “Bellicum Information”), and all of the foregoing Bellicum Information shall be considered Confidential Information and Technology solely owned by Bellicum. Bellicum
Information which is necessary or useful for the development, manufacture, use, sale, offer for sale or import of any Dimerizer, including any ARIAD Dimerizer or Non-ARIAD Dimerizer, or any ARIAD Product, shall be included in Bellicum Technology and
subject to the license granted to ARIAD in Section 2.2.1. All activities relating to development and commercialization of Licensed Products under this Agreement shall be undertaken at Bellicum’s sole cost and expense, except as otherwise
expressly provided in this Agreement. 
 3.2 Diligence. Bellicum will exercise commercially reasonable efforts and diligence in
developing and commercializing at least one Licensed Product that is a cancer vaccine described in clause (a) of Section 1.45 and one Licensed Product that is a gene or a cell transfected with such gene coding for an Inducible Caspase
described in clause (b) of Section 1.45 and in undertaking investigations and actions required to obtain Regulatory Approvals necessary to market such Licensed Products in the Licensed Field in the Territory, taking into account the
competitiveness of the 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 30 

 
marketplace, the proprietary position of the Licensed Product, the relative potential safety and efficacy of the Licensed Product, the cost of goods and availability of capacity to manufacture
and supply the Licensed Product at commercial scale, the profitability of the applicable Licensed Product, and other relevant factors including, without limitation, technical, legal, scientific or medical factors. 

3.3 Updates and Reports. 

3.3.1 Updates and Reports. Bellicum shall update Schedule B each time Bellicum or any Sublicensee determines to manufacture (or have
manufactured) GLP or GMP Quality Licensed Product for use in GLP toxicology studies for any potential Licensed Product and shall furnish such updated Schedule B to ARIAD. Bellicum shall provide ARIAD with written reports no less frequently than
[***] during the Term summarizing Bellicum’s efforts to develop and commercialize Licensed Products hereunder. Such reports shall include, at a minimum, information sufficient to enable [***] to satisfy its reporting requirements to the United
States Government, and shall contain a tabulation and key results of clinical trials, clinical plans, and summaries of the results of preclinical and clinical studies relating to Licensed Products for the then preceding half-year. Bellicum shall
provide ARIAD with at least [***] prior written notice of the intended filing, prior to any public disclosure of such filing, by Bellicum or, to the extent Bellicum is aware, a Sublicensee with the FDA or any other Regulatory Authority of any IND or
equivalent application with regard to any Licensed Product or any Drug Approval Application or the intended commencement by Bellicum of any clinical trial of any Licensed Product and will notify ARIAD of any such filing or commencement of a clinical
trial within [***] after such filing is made or such clinical trial is commenced. In addition, Bellicum shall provide ARIAD with prompt written notice of the occurrence of the First Commercial Sale of any Licensed Product in any country. In addition
to such reports, Bellicum agrees (i) upon request by ARIAD, to provide ARIAD with copies of all documents submitted to, 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 31 

 
or received from, Regulatory Authorities, relating to Licensed Products, including without limitation, INDs and their foreign equivalent, and correspondence to and from Regulatory Authorities,
and (ii) to provide ARIAD with Adverse Event information and product complaint information relating to Licensed Products as compiled and prepared by Bellicum in the normal course of business in connection with the development, commercialization
or sale of any Licensed Product, within time frames consistent with reporting obligations under applicable laws and regulations. All reports, updates, Adverse Event, product complaint and other information provided by one party to the other Party
under this Agreement (including under this Section 3), shall be considered Confidential Information of the Disclosing Party, subject to the terms of Section 5 hereof. 

3.4 Manufacturing. Bellicum shall have the right to manufacture or have manufactured such quantities of any Dimerizer as it may require
in order to develop and commercialize any Licensed Product pursuant to the terms of this Agreement. Bellicum will notify ARIAD in writing of its intent to manufacture (or have manufactured by a Third Party) any Dimerizer at least [***] prior to
commencement of manufacture by itself or through a Third Party. Upon ARIAD’s request at any time, the Parties will negotiate in good faith a supply agreement under which ARIAD will provide [***] rolling [***] forecasts of its anticipated need
for such Dimerizer (of which an agreed number of months will be binding) provided that, under such supply agreement, either (a) Bellicum will use commercially reasonable efforts to supply all quantities of Dimerizer ordered by ARIAD and will
supply such Dimerizer to ARIAD and ARIAD’s licensees on at a price equal to fully burdened manufacturing costs plus [***] percent ([***]%); or (b) if a Third Party manufactures such Dimerizer for Bellicum, then Bellicum shall
(i) procure for ARIAD and its Affiliates and licensees the right to purchase such Dimerizers from the Third Party on terms no less favorable than those granted to Bellicum, giving ARIAD and its Affiliates and licensees equal priority with

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 32 

 
respect to quantity or lead time for delivery of such Dimerizers as given to Bellicum, its Affiliates and its Sublicensees, and (ii) grant to such Third Party all licenses to Patent Rights
and Technology Controlled by Bellicum (without Bellicum incurring additional expense or obligations to Third Party licensors of Bellicum) as may be required in order for the Third Party to supply ARIAD and ARIAD’s licensees with such
Dimerizers. In addition, the supply agreement will provide that, if Bellicum or its Third Party manufacturer fails to supply Dimerizer as required thereby, Bellicum or its Third Party manufacturer will transfer to ARIAD or its designee all
technology necessary to manufacture such Dimerizer and will grant all necessary licenses to ARIAD or its designee on a royalty fee basis. 

3.5 Compliance With Law. Each Party shall comply with all applicable laws, rules, regulations and guidelines, including without
limitation, rules and guidelines of all institutions at which any work relevant to this Agreement or Licensed Products is conducted and rules and guidelines of relevant professional societies, including without limitation the American Society of
Gene Therapy. 
 4. PAYMENTS AND ROYALTIES 

4.1 Payment of Royalties; Royalty Rates; Minimum Royalties 

4.1.1 Initial Payment. In consideration of (i) the conversion of Bellicum’s license for [***] from a non-exclusive license to
an exclusive license, and (ii) the inclusion of Cell Transplantation Indications as Primary Indications and the consequent grant to Bellicum of an exclusive license for Cell Transplantation Indications, Bellicum agrees to pay to ARIAD the
non-refundable amount of two hundred fifty thousand dollars ($250,000) within [***]. 
 4.1.2 Royalty Payments. In consideration of
(i) the grant of the license by ARIAD under this Agreement, and (ii) the Licensed Technology and Orphan 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 33 

 
Drug Designation provided and/or transferred hereunder, and subject to the other terms of this Agreement (including the remainder of this Section 4), Bellicum shall pay to ARIAD royalty on
annual Net Sales for such Licensed Product at the percentage rates as follows: 
 (a) subject to Section 4.1.2(b) and (c) below,
commencing on the date of the First Commercial Sale of each Licensed Product in each country in the Territory and continuing until expiration of the Primary License Term with respect to such Licensed Product: 

 

					
	Annual Net Sales	  	ARIAD Dimerizer
Products	 	Non-ARIAD
Dimerizer Products
	 [***]MM
	  	[***]%	 	[***]%
	 >$[***]MM
	  	[***]%	 	[***]%

 (b) if either (x) the only remaining Valid Claim with respect to such Licensed Product in a country is a
claim in Patent Rights covering the [***]-MTA Technologies and there is Competition or (y) all Valid Claims covering the composition of matter of such Licensed Product or any component thereof, or the use in the Licensed Field of such Licensed
Product or any component thereof, in such country have expired but the Primary License Term with regard to such Licensed Product in such country has not expired and there is no Competition, then the following royalty rates shall instead apply until
the end of the Primary License Term with regard to such Licensed Product in such country: 
  

					
	Annual Net Sales	  	ARIAD Dimerizer
Products	 	Non-ARIAD
Dimerizer Products
	 [***]MM
	  	[***]%	 	[***]%
	 >$[***]MM
	  	[***]%	 	[***]%

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 34 

 
(c) If all Valid Claims covering the composition of matter of such Licensed Product or any component thereof, or the use in the Licensed Field of such Licensed Product or any component thereof,
in such country have expired but the Primary License Term with regard to such Licensed Product has not expired and there is Competition, then in consideration of the Licensed Technology and Orphan Drug Designation provided and/or transferred
hereunder, the following royalty rates shall instead apply until the end of the Primary License Term with regard to such Licensed Product in such country: 
  

					
	Annual Net Sales	  	ARIAD Dimerizer
Products	 	Non-ARIAD
Dimerizer Products
	 [***]MM
	  	[***] %	 	[***] %
	 >$[***]MM
	  	[***] %	 	[***] %

 Following expiration of the Primary License Term with regard to a Licensed Product in a country, Bellicum
shall have a fully paid up, perpetual, irrevocable license under Section 2.1.1 with regard to such Licensed Product in such country. 

4.1.3 Milestone Payments. Bellicum shall make the following milestone payments to ARIAD within [***] after the occurrence of the
following events: 
  

			
	Event	  	Payment
	 [***]
	  	
	 [***]
	  	$[***]
	 [***]
	  	$[***]
	 [***]
	  	$[***]

 In the event of a [***], the milestone payable upon the occurrence of [***] shall be payable by Bellicum
(x) upon commencement of [***] or (y) upon commencement of [***]; provided that the foregoing shall not apply to any [***] of a Licensed Product commenced prior to the Effective Date. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 35 

 In the event of a [***], the milestone payable upon occurrence of commencement of the [***] shall
be payable by Bellicum upon commencement of [***] and the milestone payable upon occurrence of commencement of [***] shall be payable by Bellicum upon the later of (i) commencement of [***], or (ii) the date (which may during or after such
[***]) when [***]. 
 4.1.4 Royalty Payments to Certain Third Parties. Any royalty payments owed and payable with respect to the
Licensed Products to [***] University pursuant to that certain [***], by and between the [***] and ARIAD Gene Therapeutics, Inc., as amended from time to time (the “[***] Agreement”), shall be the sole responsibility and obligation
of ARIAD. All other royalty or other payments owed and payable with respect to the Licensed Products, including without limitation any royalty or other payments due to [***], will be the sole responsibility and obligation of Bellicum. 

4.1.5 Acknowledgement. Bellicum recognizes and acknowledges that each of the following, separately and together, has substantial
economic benefit to Bellicum: (i) ARIAD’s expertise concerning the discovery and understanding of Dimerizers and dimerization technology; (ii) the licenses granted to Bellicum hereunder with respect to Licensed Technology that is not
within the claims of any Licensed Patent Rights; (iii) the licenses granted to Bellicum under Licensed Patent Rights; (iv) the Orphan Drug Designation transferred to Bellicum hereunder; and (v) the exclusivity, if any, which may be
afforded to Bellicum by each of the foregoing. The Parties agree that the royalty rates set forth in Section 4.1.2 reflect a fair and reasonable blended allocation of the values provided by ARIAD to Bellicum, regardless of whether any
particular Licensed Product utilizes any ARIAD Dimerizer or is covered by Licensed Patent Rights. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 36 

 4.2 Payment Terms. 

4.2.1 Payment of Royalties. Unless otherwise expressly provided, Bellicum shall make any license or royalty payments owed to ARIAD
hereunder in arrears, within [***] from the end of each quarter in which such payment accrues. For purposes of determining when a sale of any Licensed Product occurs under this Agreement, the sale shall be deemed to occur on the earlier of
(a) [***] or (b) on the date of [***]. Each royalty payment shall be accompanied by a report for each country in the Territory in which sales of Licensed Products occurred in the calendar quarter covered by such statement, specifying: the
gross sales (if available) and Net Sales in each country’s currency; the applicable royalty rate under this Agreement; the royalties payable, including an accounting of deductions taken in the calculation of Net Sales; the applicable exchange
rate to convert from each country’s currency to United States Dollars under this Section 4.2, if any; and the royalties payable in United States Dollars. 

4.2.2 Overdue Payments. Subject to the other terms of this Agreement, any payments not paid within the time period set forth in this
Section 4 shall bear interest at a rate of [***] percent ([***]%) per [***] from the due date until paid in full, provided that in no event shall said annual rate exceed the maximum interest rate permitted by law in regard to such payments.
Such payment when made shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not negate or waive the right of ARIAD to any other remedy, legal or equitable, to which it may be entitled because of
the delinquency of the payment. 
 4.2.3 Accounting. All payments hereunder shall be made by Bellicum in the United States in United
States dollars. Conversion of foreign currency to United States dollars shall be made at the conversion rate existing in the United States (as reported in [***]) on the last business day of the quarter immediately preceding the applicable calendar
quarter. If [***] ceases to be published, then the rate of exchange to be used shall be that reported in such other business publication of national circulation in the United States as the Parties reasonably agree. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 37 

 4.2.4 Tax Withholding; Restrictions on Payment. All payments hereunder shall be made free
and clear of any taxes, duties, levies, fees or charges, except for withholding taxes (to the extent applicable). Bellicum shall make any applicable withholding payments due on behalf of ARIAD and shall provide ARIAD with such written documentation
regarding any such payment as available to Bellicum relating to an application by ARIAD for a foreign tax credit for such payment with the United States Internal Revenue Service. 

4.3 Records Retention; Review. 

4.3.1 Royalties. Commencing as of the date of First Commercial Sale of the first Licensed Product hereunder, Bellicum and its
Affiliates and Sublicensees shall keep for at least [***] from the end of the calendar year to which they pertain complete and accurate records of sales by Bellicum or its Affiliates and Sublicensees, as the case may be, of each Licensed Product, in
sufficient detail to allow the accuracy of the payments hereunder to be confirmed. 
 4.3.2 Review. Subject to the other terms of
this Section 4.3.2, at the request of ARIAD, which shall not be made more frequently than [***] during the Term, upon at least [***] prior written notice from ARIAD, and at the expense of ARIAD (except as otherwise provided herein), Bellicum
shall permit an independent certified public accountant reasonably selected by ARIAD and reasonably acceptable to Bellicum to inspect (during regular business hours) the relevant records required to be maintained by Bellicum under this
Section 4.3 (provided no records may be reviewed more than once under this Section 4.3.2). Results of any such review shall be binding on both Parties absent manifest error. ARIAD agrees to treat the results of any such accountant’s
review of records under this Section 4.3 as Confidential Information of 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 38 

 
Bellicum subject to the terms of Section 5. If any review reveals a deficiency in the calculation and/or payment of royalties by Bellicum, then (a) Bellicum shall promptly pay ARIAD the
amount remaining to be paid, and (b) if such underpayment is by [***] percent ([***]%) or more, Bellicum shall pay the reasonable out-of- pocket costs and expenses incurred by ARIAD in connection with the review. If any review reveals an
overpayment of royalties by Bellicum, ARIAD shall promptly remit such overpaid amounts to Bellicum. 
 4.3.3 Other Parties. Bellicum
shall include in any agreement with its Affiliates or Sublicensees terms requiring such party to retain records as required in this Section 4.3 and to permit ARIAD to inspect such records as required by this Section 4.3. 

4.4 Initial Issuance of Common Stock. The Parties hereby acknowledge that in connection with the 2006 Agreement and pursuant to the
Stock Purchase Agreement, dated July 25, 2006, between the Parties, Bellicum issued to ARIAD and ARIAD received 206,111 shares of Common Stock, which 206,111 shares of Common Stock constituted, after giving effect to such issuance, [***]
percent ([***]%) of Bellicum’s Shares of Common Stock on a Fully Diluted Basis as of July 25, 2006. 
 5. TREATMENT OF
CONFIDENTIAL INFORMATION 
 5.1 Confidential Obligations. The Mutual Non-Disclosure Agreement between the Parties dated
October 16, 2004 (the “Confidentiality Agreement”) shall apply to information provided under this Agreement. Each Party shall take such action, and shall cause its Affiliates or Sublicensees to take such action, to preserve the
confidentiality of each other’s Confidential Information as it would customarily take to preserve the confidentiality of its own Confidential Information, using, in all such circumstances, not less than reasonable care to prevent the
Confidential Information of 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 39 

 
the other Party from being copied, used or disclosed to any Third Party without the other Party’s prior written consent except for those Third Parties to whom disclosure of the Confidential
Information is permitted pursuant to the terms of the Confidentiality Agreement. To the extent of any conflict between the provisions of this Article 5 and the Confidentiality Agreement, the provisions of this Article 5 shall control and pertain to
all information provided under this Agreement and the Confidentiality Agreement, retroactive to October 16, 2004. 
 5.2 Limited
Disclosure and Use. ARIAD and Bellicum each agree that any disclosure of the other Party’s Confidential Information to any officer, employee, consultant or agent of the other Party or any of its Affiliates or Sublicensees shall be made only
if and to the extent necessary to carry out its rights and responsibilities under this Agreement, shall be limited to the maximum extent possible consistent with such rights and responsibilities and shall only be made to the extent any such persons
are bound by written confidentiality obligations to maintain the confidentiality thereof and not to use such Confidential Information except as expressly permitted by this Agreement. ARIAD and Bellicum each further agree not to disclose or transfer
the other Party’s Confidential Information to any Third Parties under any circumstance without the prior written approval from the other Party (such approval not to be unreasonably withheld), except as otherwise required by law, and except as
otherwise expressly permitted by this Agreement. Each Party may disclose the Confidential Information of the other Party to any investors, prospective investors, lenders and other potential financing sources and Third Parties conducting due
diligence in connection with any financing or acquisition transaction who are obligated to keep such information confidential. Each Party, upon the request of the other Party, will return all the Confidential Information disclosed or transferred to
it by the other Party pursuant to this Agreement, including all copies and extracts of documents and all manifestations in whatever form, within [***] of such request or, if earlier, the termination or expiration

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 40 

 
of this Agreement; provided however, that a Party may retain (a) any Confidential Information of the other Party relating to any license which expressly survives such termination and
(b) one (1) copy of all other Confidential Information in inactive archives solely for the purpose of establishing the contents thereof. 

5.3 Publicity. Neither Party may publicly disclose the existence or terms or any other matter of fact regarding this Agreement without
the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that (a) either party may issue a press release upon execution hereof, (b) either Party may make such a
disclosure (i) to the extent required by law or by the requirements of any nationally recognized securities exchange, quotation system or over-the-counter market on which such Party has its securities listed or traded, and (ii) to any
investors, prospective investors, lenders and other potential financing sources who are obligated to keep such information confidential, provided that in the event that such disclosure is required under clause (b)(i) of this Section 5.3, the
disclosing Party shall provide the other Party with notice beforehand and, to the extent reasonably practical, coordinate with the other Party with respect to the wording and timing of any such disclosure, and (c) ARIAD may disclose the filing
by Bellicum or a Sublicensee with the FDA or any other Regulatory Authority of any IND, NDA, BLA or equivalent application or the commencement by Bellicum or a Sublicensee of any clinical trial, provided that ARIAD may only disclose such filing or
commencement by a Sublicensee (x) if (i) Bellicum or the Sublicensee makes prior public disclosure of such filing or commencement and (ii) ARIAD provides Bellicum with notice beforehand and, to the extent reasonably practical,
coordinates with Bellicum with respect to the wording and timing of any such disclosure or (y) if the Sublicensee consents. If Bellicum or the Sublicensee does not intend to make prior public disclosure of such filing or commencement, Bellicum
will so notify ARAIAD with the notice thereof pursuant to Section 3.2.1 and will use good faith efforts to obtain 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 41 

 
the consent of the Sublicensee for ARIAD to make such disclosure. Once any press release or any other written statement is approved for disclosure by both Parties, either Party may make
subsequent public disclosure of the contents of such statement without the further approval of the other Party. 
 5.4 Use of Name.
Neither Party shall employ or use the name of the other Party or the name of [***], [***], [***] or [***] in any promotional materials or advertising without the prior express written permission of the other party. 

5.5 [***]. Notwithstanding anything to the contrary in this Agreement, ARIAD may disclose the terms of this Agreement and
Bellicum’s Confidential Information (including the terms of any Bellicum sublicense) to [***] as reasonable and necessary required to fulfill its obligations under the [***] Agreement. 

6. PROVISIONS CONCERNING THE FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS 

6.1 Patent Filing, Prosecution, Maintenance and Enforcement. ARIAD shall have the sole right, but not the obligation, to prepare, file,
prosecute, obtain and maintain, and a first right to enforce, any Licensed Patent Rights (excluding all Patent Rights licensed to Bellicum by [***] that cover any of the [***]-ARIAD MTA Technologies). In the event that ARIAD elects not to enforce
any of the Licensed Patent Rights, if the alleged infringement is in the Licensed Field with a product that that comprises a cell transfected with both (but not limited to) a gene for an Antigen and one or more genes for Inducible Costimulatory
Molecule(s) where the gene or genes for the Inducible Costimulatory Molecule(s) are activated using an ARIAD Dimerizer or a Non-ARIAD Dimerizer, Bellicum may do so at its sole expense; provided that, if the Licensed Patent Right alleged to be
infringed is a patent other than a Licensed Patent Right covering any of the [***]-ARIAD MTA Technologies, Bellicum may do so only with the advance written consent of ARIAD, which may be granted or withheld in

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 42 

 
ARIAD’s sole discretion. Bellicum may recover, collect and keep any damages collected as a result of such enforcement by Bellicum. Bellicum shall have the sole right, but not the obligation,
to prepare, file, prosecute, obtain, maintain and enforce any Bellicum Patent Rights, and as between Bellicum and ARIAD, Bellicum shall have the sole right to prepare, file, prosecute, obtain and maintain any Patent Rights licensed to Bellicum by
[***] that cover any of the [***]-ARIAD MTA Technologies in accordance with the terms and conditions agreed upon between Bellicum and [***]. Subject to any rights granted, at any time, by Bellicum to its Affiliates and/or Sublicensees, in the event
that Bellicum elects not to enforce any of the Bellicum Patent Rights, ARIAD may do so only at its own expense and only with the advance written consent of Bellicum, which may be granted or withheld in Bellicum’s sole discretion. ARIAD may
recover, collect and keep any damages collected as a result of such enforcement by ARIAD. To the extent Bellicum assumes enforcement of Licensed Patent Rights or ARIAD assumes enforcement of Bellicum Patent Rights under this Section 6, and
later elects not to enforce such rights, such Party will notify the other Party in writing promptly upon such election not to so enforce, and in any event, at least [***] prior to the deadline to submit any filing related thereto. 

7. REPRESENTATIONS AND WARRANTIES 

7.1 ARIAD Representations. ARIAD represents and warrants to Bellicum that: 

(a) the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized
by all appropriate ARIAD corporate action and will not require the consent or approval of ARIAD’s stockholders; 
 (b) this
Agreement is a legal and valid obligation binding upon ARIAD and enforceable in accordance with its terms, and the execution, delivery and performance of this Agreement by the Parties does not conflict with any agreement, instrument or understanding
to which ARIAD is a party or by which it is bound; 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 43 

 (c) ARIAD has the full right and legal capacity to grant the rights granted to Bellicum
hereunder without violating the rights of any Third Party; 
 (d) ARIAD has provided a true and complete copy of the [***] Agreement
and each [***] Agreement to Bellicum, and ARIAD is not in material default of the [***] Agreement or any [***] Agreement; and 
 (e)
No royalty or other payment is due under any agreement between ARIAD and a Third Party, as a result of the license granted by ARIAD herein or the practice of the rights granted to Bellicum hereunder, other than any remuneration which may be due
pursuant to the [***] Agreement and the [***] Agreements. 
 7.2 Bellicum Representations. Bellicum represents and warrants to ARIAD
that: 
 (a) the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly
authorized by all appropriate Bellicum corporate action and will not require the consent or approval of Bellicum’s stockholders; 

(b) this Agreement is a legal and valid obligation binding upon Bellicum and enforceable in accordance with its terms, and the
execution, delivery and performance of this Agreement by the Parties does not conflict with any agreement, instrument or understanding to which Bellicum is a party of or by which it is bound; 

(c) Bellicum has the full right and legal capacity to grant the rights granted to ARIAD hereunder without violating the rights of any
Third Party; and 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 44 

 (d) No royalty or other payment is due under any agreement between Bellicum and a Third
Party, as a result of the license granted by Bellicum herein or the practice of the rights granted to ARIAD hereunder; and 
 (e) To
Bellicum’s knowledge, after due investigation, [***] is the owner of all of the Patent Rights listed in Schedule A under “Part II: For [***]-ARIAD MTA Technologies”, except for rights to the patents and patent applications entitled
“induced activation in dendritic cells” in said Part II of Schedule A, which were partially released to the inventors and licensed to Bellicum by the inventors by license agreement dated as of [***]. As of the Effective Date, Bellicum
(i) has not filed any patent application, (ii) has no internal patent disclosures or similar documents, and (iii) has no license from [***], except for license agreements dated as of [***] and [***], that in each case relates to any
product or other discovery or invention conceived or reduced to practice using any proprietary materials provided under any [***] Agreement, including without limitation, [***] and any other Dimerizer or [***] Analog, regardless of whether the
quantities of such proprietary materials actually used were manufactured by ARIAD, Bellicum or [***]. 
 7.3 No Warranties.

 7.3.1 Nothing in this Agreement is or shall be construed as: 

(a) a warranty or representation by either Party as to the validity or scope of any patent application or patent licensed hereunder;

 (b) a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted pursuant to
this Agreement is or will be free from infringement of patents, copyrights, and other rights of third parties; 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 45 

 (c) a warranty or representation by ARIAD that any information, trade secrets or
Technology provided by ARIAD to Bellicum under any license granted pursuant to this Agreement is sufficient to practice the Licensed Patent Rights granted hereunder. 

(d) any warranty or representation regarding (i) an obligation of ARIAD or [***] to bring or prosecute actions or suits against
Third Parties for infringement; (ii) granting by implication, estoppel or otherwise any licenses or rights under patents or other rights of [***] or [***] or other persons other than the [***] IP, regardless of whether such patents or other
rights are dominant or subordinate to any Licensed Patent Right. 
 7.3.2 EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER
PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR OF NON-INFRINGEMENT OF ANY PATENT, COPYRIGHT,
TRADEMARK, OR OTHER RIGHTS OF THIRD PARTIES, OR ANY OTHER IMPLIED WARRANTIES. 
 8. INDEMNIFICATION 

8.1 Indemnification. 

8.1.1 Bellicum Indemnity. Bellicum shall indemnify, defend and hold harmless ARIAD, [***], [***], and their respective Affiliates,
directors, officers, employees, stockholders and agents, the inventors identified in the [***] License Agreement, and each of their respective successors, heirs and assigns, its Affiliates and their respective directors, officers, employees,
stockholders and agents, and their respective successors, heirs and assigns (the “ARIAD Indemnitees”) from and against 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 46 

 
any liability, damage, loss or expense (including reasonable attorneys’ fees and expenses of litigation) (collectively, “Losses”) incurred by or imposed upon such ARIAD
Indemnitees, or any of them, in connection with any Third Party claims, suits, actions, demands or judgments, including, without limitation, personal injury and product liability matters, to the extent arising out of (a) the development,
testing, production, manufacture, supply, promotion, import, sale or use by any person of any Licensed Product (or any component thereof) manufactured or sold by Bellicum or any Affiliate or Sublicensee under this Agreement, or (b) gross
negligence or willful misconduct on the part of Bellicum or any of its Affiliates or Sublicensees, except to the extent that such Losses are attributable to the breach by ARIAD of any of its representations, warranties or covenants set forth in this
Agreement or the gross negligence or willful misconduct of an ARIAD Indemnitee. 
 8.1.2 ARIAD Indemnity. Subject to
Section 8.1.1 above, ARIAD shall indemnify, defend and hold harmless Bellicum, its Affiliates and Sublicensees and their respective directors, officers, employees, and agents, and their respective successors, heirs and assigns (the
“Bellicum Indemnitees”), from and against any Losses incurred by or imposed upon such Bellicum Indemnitees, or any of them, in connection with any Third Party claims, suits, actions, demands or judgments, including, without
limitation, personal injury and product liability matters, to the extent arising out of (a) the development, testing, production, manufacture, supply, promotion, import, sale or use by any person of any ARIAD Product (or any component thereof)
manufactured or sold by ARIAD or any Affiliate or ARIAD sublicensee under this Agreement, or (b) gross negligence or willful misconduct on the part of ARIAD or any of its Affiliates or sublicensees, except to the extent that such Losses are
attributable to the breach by Bellicum of any of its representations, warranties or covenants set forth in this Agreement or the gross negligence or willful misconduct of a Bellicum Indemnitee. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 47 

 8.2 Indemnification Procedures. In the event that any ARIAD Indemnitee or Bellicum
Indemnitee (each, an “Indemnitee”) is seeking indemnification under Section 8.1 above from a Party (the “Indemnifying Party”), the Indemnitee shall notify the Indemnifying Party of such claim with respect to
such Indemnitee as soon as reasonably practicable after the Indemnitee receives notice of the claim, and the Indemnitee shall permit the Indemnifying Party to assume direction and control of the defense of the claim (including the right to settle
the claim solely for monetary consideration) and shall cooperate as reasonably requested (at the expense of the Indemnifying Party) in the defense of the claim. The indemnification obligations under Article 8 shall not apply to any harm suffered as
a direct result of any delay in notice to the Indemnifying Party hereunder or to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement is effected without the consent of the Indemnifying Party, which consent
shall not be withheld or delayed unreasonably. The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnifying Party and its legal representatives in the investigation of any claim, demand, action or other proceeding
covered by Section 8.1. 
 8.3 Limitation of Liability. Except for liability to a Third Party under Section 8.1, NEITHER PARTY
NOR ITS AFFILIATES OR LICENSORS SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY. 

9. TERM AND TERMINATION 

9.1 Term; Expiration. The term of this Agreement shall commence upon the Effective Date and shall expire upon the expiration of the last
Primary License Term, unless terminated as set forth herein (the “Term”). 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 48 

 9.2 Termination Rights for Breach. 

9.2.1 Termination for Breach. Subject to the other terms of this Agreement, this Agreement and the rights and options granted herein
may be terminated by either Party upon any material breach by the other Party of any material obligation or condition, effective thirty (30) days after giving written notice to the breaching Party of such termination in the case of a payment
breach and ninety (90) days after giving written notice to the breaching Party of such termination in the case of any other breach, which notice shall describe such breach in reasonable detail. The foregoing notwithstanding, if such default or
breach is cured or remedied or shown to be non-existent within the aforesaid thirty (30) or ninety (90) day period, the notice shall be automatically withdrawn and of no effect. 

9.2.2 Voluntary Termination. Bellicum shall have the right to terminate this Agreement at any time after two (2) years from the
Effective Date in the event that Bellicum determines not to develop or commercialize any Licensed Product. 
 9.2.3 Termination for
Bankruptcy. In the event that either Party files for protection under bankruptcy laws, makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over its property, files a petition under any
bankruptcy or insolvency act or has any such petition filed against it which is not discharged within sixty (60) days of the filing thereof, then the other Party may terminate this Agreement effective immediately upon written notice to such
Party. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 49 

 9.3 Effects of Termination. Upon any termination of this Agreement by ARIAD or Bellicum
under Section 9.2.1 or by Bellicum pursuant to Section 9.2.2, as of the effective date of such termination all relevant licenses and sublicenses granted by ARIAD to Bellicum shall terminate automatically. Upon any termination of this
Agreement by ARIAD or Bellicum under Section 9.2.1 or by Bellicum pursuant to Section 9.2.2, subject to applicable statutes, laws, regulations, ordinances and guidelines governing the transfer of the Orphan Drug Designation and any similar
designation in any jurisdiction of orphan drug status for AP1903, Bellicum will transfer, assign and convey all its ownership of and any beneficial interest in the Orphan Drug Designation and any similar designation in any jurisdiction of orphan
drug status for AP1903 to ARIAD, effective as of the date of termination, and within ten (10) days of such termination, ARIAD and Bellicum shall each submit the required information to the FDA and any other relevant Regulatory Authority to
effect the change of the named sponsor of the Orphan Drug Designation and any similar designation in any jurisdiction of orphan drug status for AP1903 from Bellicum to ARIAD in accordance with the applicable statutes, laws, regulations, ordinances
and guidelines, and Bellicum shall transfer a complete copy of the Orphan Drug Designation and any similar designation in any jurisdiction of orphan drug status for AP1903, including any amendments or supplements thereto, and correspondence relating
thereto, to ARIAD. No termination of this Agreement shall affect ARIAD’s rights pursuant to the Investor Rights Agreement, dated as of July 25, 2006, as amended, except as stated therein. Notwithstanding the foregoing, and subject at all
times to the provisions of the [***] Agreement with respect to the [***] IP to the extent a license under such [***] IP is granted to Bellicum under this Agreement, (a) no such termination of this Agreement shall be construed as a termination
of any valid sublicense of any Sublicensee hereunder, and thereafter each such Sublicensee shall be considered a direct licensee of ARIAD, provided that (i) such Sublicensee is then in full compliance with all terms and conditions of its
sublicense, (ii) all accrued payments obligations of such Sublicensee to 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 50 

 
ARIAD have been paid, and (iii) such Sublicensee agrees in writing to assume all applicable obligations of Bellicum under this Agreement arising thereafter to the extent of the scope of the
sublicense, and (b) Bellicum and its Affiliates and Sublicensees shall have the right, for six (6) months or such longer time period (if any) on which the Parties mutually agree in writing, to sell or otherwise dispose of all Licensed
Products then on hand, with royalties to be paid to ARIAD on all Net Sales of such Licensed Products as provided for in this Agreement. 

9.4 Remedies. Except as otherwise expressly set forth in this Agreement, the termination provisions of this Article 9 are in addition
to any other relief and remedies available to either Party at law. 
 9.5 Surviving Provisions. Notwithstanding any provision herein
to the contrary, the rights and obligations of the Parties set forth in Sections 1, 2.1.8, 2.1.9, 2.2.1, 2.2.2, 2.2.3, 4.1.2 (last sentence and with respect to events occurring before termination or sales after termination permitted by
Section 9.3), 4.1.4, 4.3.1 (for the period stated therein), 4.3.2, 4.3.3, 5, 6, 7, 8, 9.3, 9.4, 9.5, 10 and 11, as well as any rights or obligations otherwise accrued hereunder (including any accrued payment obligations), shall survive the
expiration or termination of the Term. Without limiting the generality of the foregoing, Bellicum shall have no obligation to make any milestone or royalty payment to ARIAD that has not accrued prior to the effective date of any termination of this
Agreement, but shall remain liable for all such payment obligations accruing prior to the effective date of such termination. 
 10.
DISPUTES 
 10.1 Negotiation. The Parties recognize that a bona fide dispute as to certain matters may from time to time arise
during the Term that relates to either Party’s rights and/or obligations hereunder. In the event of the occurrence of such a dispute, either Party may, by written notice to the other Party, have such dispute

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 51 

 
referred to their respective senior officials designated below or their successors, for attempted resolution by good faith negotiations within [***] after such notice is received. Said designated
senior officials are as follows: 
 For Bellicum: Chief Executive Officer 

For ARIAD: Chief Executive Officer 
 In the
event the designated senior officials are not able to resolve such dispute within the [***] period, either Party may invoke the provisions of Section 10.2. 

10.2 Arbitration. Subject to Section 10.1, any dispute, controversy or claim initiated by either Party arising out of, resulting
from or relating to this Agreement, or the performance by either Party of its obligations under this Agreement (other than bona fide Third Party actions or proceedings filed or instituted in an action or proceeding by a Third Party against a Party),
whether before or after termination of this Agreement, shall be finally resolved by binding arbitration. Whenever a Party shall decide to institute arbitration proceedings, it shall give written notice to that effect to the other Party. Any such
arbitration shall be conducted under the Commercial Arbitration Rules of the American Arbitration Association by a panel of three arbitrators appointed in accordance with such rules. Any such arbitration shall be held in Boston, Massachusetts. The
method and manner of discovery in any such arbitration proceeding shall be governed by the laws of the State of New York. The arbitrators shall have the authority to grant injunctions and/or specific performance and to allocate between the parties
the costs of arbitration in such equitable manner as they determine. Judgment upon the award so rendered may be entered in any court having jurisdiction or application may be made to such court for judicial acceptance of any award and an order of
enforcement, as the case may be. In no event shall a demand for arbitration be made after the date when institution of a legal or equitable proceeding based upon such 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 52 

 
claim, dispute or other matter in question would be barred by the applicable statute of limitations. Notwithstanding the foregoing, either Party shall have the right, without waiving any right or
remedy available to such Party under this Agreement or otherwise, to seek and obtain from any court of competent jurisdiction any interim or provisional relief that is necessary or desirable to protect the rights or property of such Party, pending
the selection of the arbitrators hereunder or pending the arbitrators’ determination of any dispute, controversy or claim hereunder. 
  

	 	11.	MISCELLANEOUS 

 11.1 Insurance. 

11.1.1 To the extent and for so long as any [***] IP is licensed to Bellicum under Section 2.1.1 and as required by the [***]
Agreement, Bellicum shall comply with the terms of this Section 11.1.1. Bellicum shall comply, through insurance written by reputable and financially secure insurance carriers, with all statutory workers’ compensation and employers’
liability requirements covering any and all employees with respect to its activities performed under this Agreement. In addition to the foregoing, Bellicum shall maintain Comprehensive General Liability Insurance, including Products Liability
Insurance, covering Bellicum’s indemnification obligations hereunder, with reputable and financially secure insurance carrier(s) to cover the activities of Bellicum, its Affiliates and Sublicensees. Such insurance shall provide minimum limits
of liability considered to be standard for Bellicum’s industry prior to human clinical trials. Commencing with human clinical trials of a Licensed Products, Bellicum shall maintain such insurance with minimum limits of liability of [***]
dollars ($[***]) per occurrence and [***] dollars ($[***]) in aggregate and shall include ARIAD and [***], [***], [***], [***] and their respective trustees, directors, officers, employees, students, and agents as additional insureds. Such insurance
shall be written to cover claims incurred, discovered, manifested, or made during and after the Term. At 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 53 

 
ARIAD’s request, Bellicum shall furnish a Certificate of Insurance evidencing primary coverage and requiring [***] prior written notice of cancellation or material change to ARIAD. Bellicum
shall advise ARIAD, in writing, that it maintains excess liability coverage (following form) over primary insurance for at least the minimum limits set forth above. All such insurance of Bellicum shall be primary coverage; insurance of the above
additional insureds shall be excess and noncontributory. ARIAD acknowledges that the insurance specified in this Section 11.1.1 may be or become unavailable or unavailable on commercially practicable terms. In such event, ARIAD agrees to
discuss with Bellicum commercially reasonable alternatives. Each Party shall carry appropriate insurance covering such Party’s indemnification obligations under this Agreement, through insurance written by reputable and financially secure
insurance carriers. 
 11.2 Notification. All notices, requests and other communications hereunder shall be in writing, shall be
addressed to the receiving party’s address set forth below or to such other address as a party may designate by notice hereunder, and shall be either (i) delivered by hand, (ii) made by facsimile transmission (to be followed with
written fax confirmation), (iii) sent by private courier service providing evidence of receipt, or (iv) sent by registered or certified mail, return receipt requested, postage prepaid. The addresses and other contact information for the
parties are as follows: 
  

			
	 If to ARIAD:
		 ARIAD Pharmaceuticals, Inc.
 26 Landsdowne
Street
 Cambridge, MA 02139
 Attn: Chief Executive
Officer

		
	 With a copy to:
		 Mintz, Levin, Cohn, Ferris, Glovsky and

Popeo, P.C.
 One Financial Center

Boston, MA 02111
 Attn: Jeffrey M. Wiesen, Esq.

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 54 

			
	If to Bellicum:		 Bellicum Pharmaceuticals, Inc.
 6400 Fannin
St., Suite 2300
 Houston, TX 77030
 Attn: Chief Executive
Officer

		
	With a copy to:		 Cooley LLP
 4401 Eastgate Mall

San Diego, CA 92121
 Attn: L. Kay Chandler, Esq.

 All notices, requests and other communications hereunder shall be deemed to have been given either (i) if
by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if made by telecopy or facsimile transmission, at the time that receipt thereof has been acknowledged by the recipient,
(iii) if sent by private courier, on the day such notice is delivered to the recipient, or (iv) if sent by registered or certified mail, on the fifth (5th) business day following the day such mailing is made. 

11.3 Language. This Agreement has been prepared in the English language and the English language shall control its interpretation. 

11.4 Governing Law. This Agreement will be construed, interpreted and applied in accordance with the laws of the State of New York
(excluding its body of law controlling conflicts of law). 
 11.5 Limitations. Except as expressly set forth in this Agreement,
neither Party grants to the other Party any right or license to any of its intellectual property. 
 11.6 Entire Agreement. This
Agreement, together with the Confidentiality Agreement, constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all prior representations, understandings and agreements between the Parties with
respect to the subject matter 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 55 

 
hereof. ARIAD and Bellicum agree that the 2006 Agreement is amended and restated in its entirety as set forth in this Agreement as of the Effective Date and that the 2006 Agreement was in effect
from the Original Effective Date until the Effective Date. No modification shall be effective unless in writing with specific reference to this Agreement and signed by the Parties. 

11.7 Waiver. The terms or conditions of this Agreement may be waived only by a written instrument executed by the Party waiving
compliance. The failure of either Party at any time or times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by either Party of any condition or term shall be deemed
as a continuing waiver of such condition or term or of another condition or term. 
 11.8 Headings. Section and subsection headings
are inserted for convenience of reference only and do not form part of this Agreement. 
 11.9 Assignment. Neither this Agreement nor
any right or obligation hereunder may be assigned, delegated or otherwise transferred, in whole or part, by either Party without the prior express written consent of the other; provided, however, that either Party may, without the written consent of
the other, assign this Agreement and its rights and delegate its obligations or sublicense its rights hereunder to its Affiliates, or in connection with the transfer or sale of all or substantially all of such Party’s assets or business related
to this Agreement, or in the event of its merger, consolidation, change in control or similar transaction. In the event of such transaction, however, intellectual property rights of the acquiring party in such transaction (if other than one of the
Parties to this Agreement) shall not be included in the technology licensed hereunder. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section 11.9 shall be
void. The terms and conditions of this Agreement shall be binding upon and inure to the benefit of the permitted successors and assigns of the parties. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 56 

 11.10 Force Majeure. Neither Party shall be liable for failure of or delay in performing
obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters or any causes beyond the reasonable control of such Party. In event of such force majeure, the
Party affected thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 

11.11 Construction. The Parties hereto acknowledge and agree that: (i) each Party and its counsel reviewed and negotiated the
terms and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement;
and (iii) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement. 

11.12 Severability. If any provision(s) of this Agreement are or become invalid, are ruled illegal by any court of competent
jurisdiction or are deemed unenforceable under then current applicable law from time to time in effect during the Term hereof, it is the intention of the Parties that the remainder of this Agreement shall not be affected thereby provided that a
Party’s rights under this Agreement are not materially affected. The Parties hereto covenant and agree to renegotiate any such term, covenant or application thereof in good faith in order to provide a reasonably acceptable alternative to the
term, covenant or condition of this Agreement or the application thereof that is invalid, illegal or unenforceable, it being the intent of the Parties that the basic purposes of this Agreement are to be effectuated. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 57 

 11.13 Status. Nothing in this Agreement is intended or shall be deemed to constitute a
partner, agency, employer-employee, or joint venture relationship between the Parties. 
 11.14 Section 365(n). All licenses
granted under this Agreement are deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined in Section 101 of such Code. The Parties agree that Bellicum may
fully exercise all of its rights and elections under the U.S. Bankruptcy Code, regardless of whether either Party files for bankruptcy in the United States or other jurisdiction. The Parties further agree that, in the event Bellicum elects to retain
its rights as a licensee under such Code, Bellicum shall be entitled to complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to the Bellicum not
later than: 
 (a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects
to perform its obligations under the Agreement, or 
 (b) if not delivered under Section 11.14(a) above, upon the rejection of
this Agreement by or on behalf of Bellicum, upon written request. 
 11.15 Export Compliance. Each Party, and its Affiliates and
sublicensees shall comply with all United States laws and regulations controlling the export of certain commodities and technical data, including without limitation all Export Administration Regulations of the United States Department of Commerce.
Among other things, these laws and regulations prohibit or require a license for the export of certain types of commodities and technical data to specified countries. Bellicum hereby gives written assurance that it will comply with, and will cause
its Affiliates and Sublicensees to comply with, all United States export control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its Affiliates or Sublicensees, and that it will
indemnify, defend, and hold ARIAD harmless (in accordance with Section 8) for the consequences of any such violation. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 58 

 11.16 Further Assurances. Each Party agrees to execute, acknowledge and deliver such
further instructions, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

11.17 Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 
 [Signature page follows] 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 59 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representative in two (2) originals. 
  

							
	Bellicum Pharmaceuticals, Inc.		ARIAD Pharmaceuticals, Inc.
				
	By:		/s/ Thomas J. Farrell		By:		/s/ Harvey J. Berger, M.D.
			Thomas J. Farrell				Harvey J. Berger, M.D.
	Title:		Chief Executive Officer		Title:		Chairman and Chief Executive Officer

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 60 

 Schedule A—Licensed Patent Rights 

[ 

									
	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	
	 [***]
	 		 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]

  

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

									
	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	
	 [***]
	 	[***]	 	[***]	 	[***]	 	
	 [***]
	 	[***]	 	[***]	 	[***]	 	
	 [***]
	 	[***]	 	[***]	 	[***]	 	
	 [***]
	 	[***]	 	[***]	 	[***]	 	
	 [***]
	 		 	[***]	 	[***]	 	
	 [***]
	 	[***]	 	[***]	 	[***]	 	
	 [***]
	 	[***]	 	[***]	 	[***]	 	
	 [***]
	 	[***]	 	[***]	 	[***]	 	
	 [***]
	 	[***]	 	[***]	 	[***]	 	
	 [***]
	 	[***]	 	[***]	 	[***]	 	
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 		 	[***]	 	[***]	 	

 ] 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 62 

 Schedule B 

Licensed Products 
  

	1.	BPX-101 (formerly BP-GMAX-CD1) 

  

	2.	CaspaCIDe Donor Lymphocyte Infusion 

	

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 63

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]